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Abstract  
Skeletal muscle dysfunction and increased rate of fatigue is observed in a number 
of disorders. An increase in systemic and/or local pro-inflammatory cytokines has 
been proposed to modulate the ability of skeletal muscle to generate force, alter 
mitochondrial bioenergetics and induce reactive oxygen species (ROS) generation 
in muscle. Evidence suggests cytokines such as Tumour necrosis factor-α (TNF-α) 
play a major role in modulating the function of muscle cells. Muscle contraction 
and fatigue is a multidimensional concept which can be defined through both 
physical and psychological concepts, thus systemic changes in cytokine levels may 
alter both central and peripheral fatigue. Increased levels of dietary polyphenols 
have been associated with a reduction in systemic inflammation and may therefore 
alleviate muscle dysfunction.  
The aim of this work was to use cell-based studies to validate TNF-α induced 
cytokine production and examine the potential effects of targeted polyphenol 
interventions on cytokine release by skeletal muscle cells. Moreover, the aim of this 
study was to investigate in a human clinical population the role of cytokines in 
subjective fatigue and peripheral function of skeletal muscle. The human study 
focussed on patients with chronic fatigue syndrome (CFS), a condition associated 
with enhanced and chronic perceived fatigue. Patients with CFS report symptoms 
of post exertion malaise and general widespread fatigue in the outer limbs. The 
cellular mechanisms associated with perceived muscle weakness in CFS are poorly 
characterised. The hypothesis of this thesis was that altered circulating levels of 
cytokines and chemokines may play a major role in the pathogenesis of CFS. 
A cell model of increased cytokine release through TNF-α exposure of muscle cells 
was validated. C2C12 myotubes treated with 25ng/ml TNF-α released increased 
levels of IL-6, CCL2, CCL5 and CXCL1. Pre-treatment with polyphenol 
compounds followed by TNF-α exposure showed that resveratrol attenuated TNF-
induced release of IL-6, CCL2, CCL5 and CXCL1 cytokines from C2C12 
myotubes. These data suggest that resveratrol may inhibit the actions of TNF-α, 
thus can potentially modulate local environment and potentially affecting muscle 
function. These findings are clinically relevant and have widespread implications 
for the understanding of diverse scientific areas, including the potential effect of 
polyphenol compounds on muscle function as well as inflammatory human muscle 
diseases in which cytokines may alter both central and peripheral muscle fatigue.  
This study showed that maximum voluntary contractions (MVC) were significantly 
reduced in patients with CFS compared with Healthy Controls (HCs). No difference 
was seen in electrically stimulated muscle tetanic forces or fatigue or single muscle 
fibre force measurements between groups. There was no difference in circulating 
cytokine levels or cytokine gene expression within the muscle in CFS compared 
with HCs although there was a suggestion of an increase in IP-10 and CCL2. 
Muscle mitochondrial respiratory function and ROS generation were not 
significantly different between patients with CFS and HCs although mitochondria 
in muscles of patients with CFS showed a blunted response to substrates compared 
with HCs. Overall these data suggest that patients with CFS do not show grossly 
altered muscle ROS generation, mitochondrial function or altered systemic levels 
of cytokines. Further investigations are required to determine the cause of reduced 
MVC and elevated perception of fatigue in patients with CFS and to examine the 
effect of stratification of these data from patients with CFS.  
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CHAPTER One 
Introduction  
1.1 Skeletal muscle  
 
Skeletal muscle is a diverse and plastic tissue displaying a highly organised and 
complex structure, which is matched to its principle function of force generation 
and locomotion. It is the most abundant tissue in the human body, supporting 
multiple biological functions; including the maintenance of core body temperature 
through the production of heat, as well as providing storage to macromolecules 
amino acids and carbohydrates. (Marieb and Hoehn, 2009). Muscle has the ability 
to exert numerous endocrine effects though the production and release of a wide-
range of small peptides and proteins.   
 
1.1.1 Skeletal muscle structure 
 
Skeletal muscle is typically characterised as a striated and multi-nucleated tissue; 
which is attached to the skeleton by tendons and works under voluntary control 
from the peripheral nervous system. Skeletal muscle is the largest tissue in the 
human body making up 40% of the total body weight in men and 30% in women 
and is the largest supply of protein in body containing 50 – 75% % of the total body 
store (Janssen et al., 2000). Skeletal muscle mass is maintained through a fine 
balance between protein synthesis and degradation (Kandarian and Jackman, 2006). 
The continual turnover of muscle accounts for 30-50% of all protein turnover in the 
body. Factors such as mobility, physical activity and nutritional status play affect 
these processes (Henriksson, 1995, Gerdhem et al., 2003, Baxter-Jones et al., 2008, 
Mazis et al., 2009).  
Skeletal muscle is characterised by a precise arrangement of muscle cells (also 
referred to as muscle fibres or myofibres) which is highly organised and conserved 
(Figure 1.1). The size and number of fibres is the main determinant for whole 
muscle size and function. Muscle fibres are bound together to form bundles termed 
fascicles; which collectively make up a whole muscle. Each fascicle is encapsulated 
by layer of connective tissue called a perimysium. The perimysium is an extension 
of the connective tissue which surrounds the entire muscle, termed the epimysium. 
Neuronal innervation is essential for skeletal muscle function and contraction. Each 
individual muscle fibre is innervated by a single branch from a motor neurone.  
 Figure 1.1 Schematic representation of the structure of skeletal muscle. A 
representation of the hierarchical organisation of skeletal muscle. Adapted from 
Lightfoot, 2011.  
 
A single muscle cell is elongated and cylindrical in shape, multinucleated and in a 
post mitotic phase. Each fibre is surrounded by a layer of connective tissue called 
an endomysium as well as a plasma membrane called a sarcolemma. Muscle fibres 
appear striated by a highly organised internal arrangement of units called myofibrils 
embedded within the cytoplasm of the cell. The striated appearance of muscle is a 
result of alternating dark and light areas caused by the arrangement of contractile 
proteins (actin/myosin) units which comprise the sarcomere. Myofibrils are divided 
into segments called sarcomeres which contain thick and thin filaments which 
collectively work together to generate force. Thick filaments consist of myosin 
whilst thin filaments consist mainly of actin, tropomyosin and troponin. The most 
prominent striations are the A and I bands and the Z lines. A bands are made up of 
a combination of thick and thin filaments whilst I bands consist of thin filaments 
only. Z discs mark the borders which link and separate individual sarcomeres. 
Within the middle of the A band is a region when the thin myosin filaments do not 
cross the thick actin filaments. This line is known as the H zone. The M line is 
situated within the H zone (Figure 1.2) (Mougios, 2006).  
 
1.1.1.2 Skeletal muscle - fibre type  
Human skeletal muscle consists of a heterogeneous collection of muscle fibre types. 
These can be broadly classified as oxidative (type I), fast oxidative (Type IIα) and 
fast glycolytic (IIβ and IIx) muscle fibres (Table 1.1). Each fibre type has its own 
unique properties which enables whole muscles to perform a magnitude of different 
contractile functions (Essen et al., 1975). Different muscles are made up of different 
compositions of fibres. Type I fibres are also known as slow twitch fibres. They are 
very resistant to fatigue and are capable of producing repeated low-level 
contractions. These fibres are type I myofibres are rich in mitochondria and able to 
produce large amounts of ATP through oxidative phosphorylation. Type IIα fibres 
are known as fast/oxidative/glycolytic, they produce fast, strong muscle 
contractions, although they are more prone to fatigue than type I fibres. These fibres 
contain a large number of mitochondria and manufacture ATP at a fast rate by 
utilising both aerobic and anaerobic metabolism. Type IIβ fibres are known as fast 
glycolytic fibres. They contain few mitochondria, producing ATP at a slow rate by 
anaerobic metabolism which is broken down very quickly. These fibres are able to 
produce short, fast bursts of power and rapid fatigue (Macintosh et al., 2006). 
Muscles are adaptive to changing demands; they can by alter their size or fibre type 
composition i.e. Type IIβ fibres can turn into type IIα fibres by resistance training. 
This is beneficial due to an increase in the muscle’s ability to utilise ATP and 
fatigue more slowly. The impairments and disabilities seen in some patient groups 
suffering from deconditioning because of prolonged inactivity, limb 
immobilization, or muscle denervation may be partly the result of changes in fibre 
type composition. 
  
  Type I Fibres Type IIα Fibres 
Type IIβ/IIX 
Fibres 
Motor unit 
type 
Slow/Oxidative Fast/Ox&Gly Fast/Glycolytic 
Twitch Speed Slow Fast Fast 
Twitch force Small Medium Large 
Resistance to 
fatigue 
High Fairly high Low 
Oxidative 
capacity 
High Higher Moderate 
 
Table 1.1 Human skeletal muscle fibre type properties.  
 
1.1.2 Muscle contraction 
 
The contraction of skeletal muscle and force generation is a highly complex and 
specialised process, which focusses around two central components, actin and 
myosin filaments. As previously mentioned actin and myosin are the major 
contractile proteins involved in force production and constitute a large proportion 
of the thin and thick filaments respectively (Figure 1.2). The lengths of filaments 
do not alter during contraction, however, the intersection between them increases. 
This results in the shortening of the sarcomeres in proportion to the whole muscle. 
The basic mechanism thorough which a muscle fibre generates force was first 
proposed in 1954 as the sliding-filament model (Huxley and Niedergerke, 1954).  
The contraction of skeletal muscle is initiated by the propagation of a neural 
impulse from the central nervous system to a motor neuron which innervates a 
number of muscle fibres. The neural impulse is propagated down an axon toward 
the neuromuscular junction. A neural impulse of sufficient magnitude to raise the 
membrane potential of the surrounding sarcolemma will cause the activation and 
opening of Na⁺/K⁺ channels. The influx of Na⁺ across the fibre causes 
depolarisation and propagates an action potential. The outer plasma membrane of 
muscle fibres, the sarcolemma contains transverse tubules (T-tubules) which run 
perpendicular to the myofibril surface. These allow the action potential to transmit 
from the motor end plate across the sarcolemma resulting in depolarisation of the 
sarcoplasmic reticulum (SR). Depolarisation of the SR initiates the release of Ca²⁺ 
though voltage-gated calcium channels into the cytosol. Calcium ions bind to 
troponin located on the thin actin filaments of the myofibrils. At rest, tropomyosin 
acts as a blocker between the myosin binding sites on the thin actin filaments. The 
binding of Ca²⁺ to troponin causes tropomyosin to alter its configuration (via 
allosteric modification) freeing up the myosin binding sites. The myosin heads are 
then free to bind to the binding sites on the thin actin filaments forming a cross 
bridge. ATP bound to the myosin head is utilised to produce ADP and inorganic 
phosphate (Pi) as the actin and myosin filaments slide past each other. This draws 
the Z-bands towards each other thus shortening the sarcomere and the I-band. The 
actin and myosin filaments therefore remain the same length throughout the 
contraction. The process of muscular contraction through the re-binding of myosin 
to its binding site can be repeated given there is a constant supply ATP and Ca²⁺ is 
still bound to the thin actin filaments through the presence of a neural impulse. 
When calcium ceases to be bind to troponin on the thin filament, tropomyosin is 
modified back to its previous state thus blocking the binding sites of myosin again. 
Myosin is unable to bind to the thin actin filament, and the contractions cease 
(Mougios, 2006). 
 
Figure 1.2 A longitudinal electron micrograph of several myofibrils (top) and a 
schematic representation of the overlapping arrangement between thick (myosin) 
and thin (actin) filaments responsible for the characteristic striated appearance. 
Taken from (Macintosh et al., 2006).  
1.2 The pathophysiology of fatigue 
 
Fatigue is a common aspect of life, which affects the majority of individuals to 
varying degrees. The word “fatigue” can be used to describe the real or perceived 
reduction in physical or mental capability and performance (Macintosh et al., 2006). 
It can therefore be divided into either physiological and psychological fatigue or a 
combination of the two. The presence of fatigue can be the consequence of altered 
central or peripheral functioning in the body (Davis and Walsh, 2010). Despite 
extensive research having been undertaken, the exact aetiology of fatigue is often 
unclear. This is due, at least in-part, to the difficulty in making objective 
measurements in relation to everyday activity. Some of the more common causes 
of fatigue within the general population include inadequate sleep, physical and 
mental exertion, poor diet/nutritional deficiency, anaemia and altered thyroid 
function (Hublin et al., 1996, Hardy et al., 1997, Huskisson et al., 2007, Bager, 
2014).  
The extent to which fatigue impacts upon a healthy individual is generally of little 
significance and may be resolved through rest or cessation of fatigue-inducing 
activity. However, for a growing number of individuals, fatigue is becoming a more 
frequent problem. According to international studies, the prevalence of fatigue-
related complaints ranged from 10-30% of patients visiting their general 
practitioners and within the wider population, the proportion of individuals 
reporting symptoms of fatigue rose to between 30-50% (Cullen et al., 2002, van't 
Leven et al., 2010). The overall incidence of all fatigue diagnoses made in the UK 
between 1990 and 2001 decreased by 44% taking the previous number of diagnoses 
from 87 per 100,000 patients to 49 (Gallagher et al., 2004). Other forms of fatigue 
related disease such as CFS and fibromyalgia have increased in their incidence 
(Table 1.2).  
The occurrence of fatigue in the general population remains relatively unknown. At 
present the concept of “fatigue” holds no clear or widely accepted definition within 
scientific literature. This is largely due to the vast number of problems which arise 
when trying to study such a multidimensional concept.  This is largely a result of 
the varying use of definitions and diagnosis for patients. Most studies investigating 
fatigue and chronic fatigue are also based on small and pre-selected samples of 
patients giving rise to sample bias. The majority of analyses undertaken on muscle, 
in the context of muscle fatigue, are carried out within a laboratory setting. 
Fatigue can affect individuals of all ages, race and sex. Numerous reports have 
suggested specific age groups may have an increased susceptibility to fatigue, 
however data between studies is inconclusive. The main consensus indicates fatigue 
is low in the childhood population below 11 years of age (Farmer et al., 2004). 
Despite being lower than adult figures, the prevalence of fatigue is still high 
amongst the adolescent population according to various epidemiological studies. 
Female adolescents were reportedly more affected by fatigue with a 3:1 gender ratio 
of fatigued girls to boys (ter Wolbeek et al., 2006).  
Fatigue can present itself in people, with no defined somatic disease has been 
established. Prevalence rates may vary as a result of differing views of fatigue 
between health professionals (Hamilton et al., 2010). Symptoms of fatigue recorded 
can range between tiredness, weakness or exhaustion. As prevalence and severity 
increases, the importance of acknowledging fatigue as a serious ailment increases. 
Knowledge behind the mechanisms of fatigue and potential therapies to reduce it 
need to improve. This cannot be accomplished without first outlining a clear 
definition of fatigue. Individual research groups define fatigue relative to the setting 
in which it is being used to avoid confusion. This has led to inconsistencies and 
comparability issues with other papers. The work detailed in this thesis, focuses on 
muscle fatigue which is defined as an inability to maintain prescribed muscle force 
output and define it according. 
 
1.2.1 Psychological fatigue 
 
Psychological (mental) fatigue is a subjective concept. Common symptoms include 
somnolence, lethargy, reduced alertness, depression and impaired cognitive 
functioning. The majority of which cannot be objectively assessed in a clinical 
setting. Currently no quantifiable measures have been defined for psychological 
fatigue. Differentiating between psychological fatigue and other morbidities such 
as stress and depression can be difficult. As well as being an entity in itself, 
psychological fatigue is also an attributing factor for voluntary physical actions and 
can increase voluntary muscular fatigue (Marcora et al., 2009).  
 1.2.2 Muscle fatigue 
 
Despite being extensively investigated; the cause of muscle fatigue is still relatively 
unclear in many situations. Muscular fatigue is generally a consequence of 
increased muscular activity; however, muscle fatigue can also be reported when 
little muscular activity has been undertaken. This may be triggered by 
psychological factors associated with perceived effort and the emotional response 
to activity (Marcora et al., 2009). The most common general description of 
muscular fatigue in scientific literature is the reversible decline of performance 
during activity” (Allen et al., 2008). A decrease in physical performance due to a 
failure to maintain the requested or expected power output may be due to a rise in 
real or perceived difficulty. In this thesis, muscular fatigue will be focused on the 
following definition; “failure to maintain the required or expected force” (Edwards, 
1981). Muscular fatigue is a tangible concept and may be recognised more 
objectively through biological markers (Finsterer, 2012). This may be driven by the 
peripheral or central nervous system. Muscular fatigue is a reversible sensation. The 
rate of fatigue depends on the muscles employed and the fibre type composition of 
the muscle, the relative intensity of the exercise, and the type of muscle contraction 
whether it be intermittent or continuous (Macintosh et al., 2006). The fatigue profile 
of a muscle during exercise is influenced by the following factors; muscle fibre 
composition, neuromuscular characteristics, energy metabolite stores, buffering 
capacity, ionic regulation, capillarisation, and mitochondrial density (Costill et al., 
1976, Amann and Calbet, 2008, McKenna et al., 2008). Figure 1.3 shows the 
decline in force of the quadriceps during sustained contraction as the muscle 
fatigues. The exact cause of skeletal muscle fatigue if often unknown and/or cannot 
be determined. This is due to the complexity of muscle contraction and the potential 
involvement of multiple sites of failure.  
  
 Figure 1.3 Loss of force during uninterrupted maximum voluntary contractions 
(MVC) of the quadriceps from two individuals. Subjects were asked to hold a MVC 
for 1 min. Force is expressed as a percentage of the initial value. (Adapted from 
Jones et al, 2009). 
 
1.2.2.1 Mechanisms underlying skeletal muscle fatigue 
 
Muscle contraction is a complex process under the voluntary control of the brain 
(Section 1.1). Figure 1.4 illustrates the chain of command leading to muscle 
contraction and force generation. A break in the chain at any point will reduce or 
prevent force production culminating in muscle fatigue. At the point marked on 
Figure 1.4 “electrical stimulation”, failures prior to this point suggests centrally 
driven fatigue whilst failures after this point are described as peripheral driven 
fatigue. In general fatigue is not caused by one single entity but rather it is the 
consequence of multiple factor occurring independently at numerous locations 
simultaneously in both the central and peripheral nervous system (Enoka and Stuart, 
1992). 
 
 Figure 1.4 Schematic representation of the chain of command in muscle 
contraction leading from motivation, to the generation of force by cross bridges. 
Adapted from (Jones et al., 2004).  
In this thesis, fatigue is defined by the most common general definition of muscular 
fatigue in scientific literature as “failure to maintain the required or expected force”. 
Mechanisms behind a decrease in maximal contractile force include the 
unavailability of metabolic substrates, the accumulation of toxic products, impaired 
neuromuscular transmission, compromised calcium uptake and release and 
dysfunction in the actin-myosin cross-bridges (Allen et al., 2008). A failure of 
appropriate energy supply to muscles is a fundamental cause of fatigue and 
metabolic changes associated with energy supply have been associated with muscle 
fatigue including a reduction in pH (6-8), an increased concentration of inorganic 
phosphate (Pi), and modified levels of Reactive Oxygen Species (ROS) and 
cytokine molecules (Reid, 2001, Westerblad et al., 2002, Debold et al., 2008, Visser 
et al., 2002, Davis and Bailey, 1997). 
 Figure 1.5 Practical scheme illustrating the contributing factors of muscle fatigue. 
Adapted from (Edwards, 1978).  
 
 
1.3 Cytokines  
 
Cytokines make up a large and diverse family of polypeptides, protein and 
glycoprotein molecules within the body. The term cytokine is derived from the 
Greek word cyto meaning cell and kinos meaning movement thus implying their 
role as cell signalling molecules which travel throughout the body (Murphy, 2011). 
Cytokines are small intracellular signalling molecules which have the ability to 
mediate a wide range of aspects of cell function throughout the body including 
eliciting cellular proliferation/differentiation.  
The term cytokine encompasses interferons, the interleukins, the chemokine family, 
mesenchymal growth factors, the tumor necrosis factor family and adipokines. 
Cytokines were originally, thought to act only within the innate immune system 
acting to defend the host and aid recovery by eliciting flu-like symptoms. However, 
it is now clear that cytokines mediate an array of diverse effects in normal 
physiology and disease (Kelso, 1998, Dinarello, 2007).  
Cytokines are produced by multiple cell types both within and outside of the 
immune system in response to various stimuli. Cytokines producing immune cells 
include monocytes, macrophages, B and T lymphocytes and NK (natural killer) 
cells (Cooper et al., 2001). Non-immune cells which have been identified as 
cytokine producing cells include adipose, endothelial, fibroblast and muscle cells 
(Sironi et al., 1989, Pedersen, 2011, Apte, 1995, Hotamisligil et al., 1993). The 
majority of cytokines are produced from monocytes, macrophages and 
lymphocytes, in addition to microglia and astrocytes.  
 
1.3.1 Impact of cytokines on skeletal muscle  
 
Cytokines are known mediators of muscle function and physiology (Spate and 
Schulze, 2004). Low levels of both pro-inflammatory cytokines and anti-
inflammatory cytokines are essential for muscle repair and maintenance (Arnold et 
al., 2007). Determining a physiological level at which cytokines may potentially be 
detrimental to muscular health is yet to be defined. The overall effect of cytokine 
levels is dependent on the type of cytokine produced, the source of the cytokine 
(local vs systemic), the availability of the cytokine to bind receptors, the expression 
of appropriate receptors, the length of exposure (chronic vs acute) and the response 
of the target cell. Raised levels of circulating cytokines are common in conditions 
including chronic obstructive pulmonary disease (COPD), chronic heart failure, 
cancer and sepsis (Tisdale, 1999, Bolton, 2000, Gan et al., 2004). Muscular 
abnormalities have been reported in the advanced stages of these conditions 
including altered muscle morphology, atrophy, and metabolism (Drexler et al., 
1992, Anker et al., 1997). 
A widely studied area of altered cytokine profiles is the effect on muscle mass. 
Cytokines have a profound role in the loss of muscle mass in many disease states 
(Fearon et al., 2006, Anker and Coats, 1998, Wagner, 2008) through activation of 
the ubiquitin proteasome pathway skeletal muscle and muscle atrophy (Li et al., 
1998). Muscle atrophy is a debilitating consequence of several disease including 
advanced cancer, sepsis and diabetes. Muscle atrophy results from an imbalance 
between the rates of protein synthesis and degradation. Elevated levels of 
circulating pro-inflammatory cytokines activate muscle atrophy through elevated 
production of free radicals and activation of proteolysis through the ubiquitin 
proteasome pathway (Strassmann et al., 1992, Acharyya et al., 2004, Lang et al., 
2007). This is characterised by a reduction in protein synthesis and an increase in 
protein degradation. This subsequently leads to weight loss, muscle wasting and a 
reduction in muscle function as commonly reported in these patients (Lightfoot et 
al., 2009, Remels et al., 2013). Loss of muscle mass can lead to muscle weakness 
and potentially precipitate to impaired mobility. Loss of fibres and fibre atrophy is 
also accompanied by a depletion in mitochondrial oxidative enzymes leading to 
uncoupling of oxidative phosphorylation and reduced aerobic capacity. Reports 
have demonstrated a reduction in muscle mass and function is associated with 
increased morbidity and mortality rates (Evans, 2010). 
Cytokines have been identified as potential modulators of contractile activity and 
force production independently of signalling pathways in which fibre morphology 
is altered (fibre atrophy and loss of fibres). Research has identified TNF-α’s actions 
through binding to the TNFR1 receptor causes an increase in cytosolic antioxidant 
activity which can lead to a depression in force production. Increased oxidant levels 
have been shown to depress force through a reduction in myofibrillar function (Reid 
and Moylan, 2011). 
 
1.3.1.1 TNF-α 
 
Tumour necrosis factor–α (TNF-α) is one of the most widely researched cytokines 
in the context of muscle physiology. TNF-α is involved in regulating numerous 
diverse bodily functions including inflammation, autoimmunity, septic shock cell 
growth modulation, viral replication, and tumour genesis (Aggarwal et al., 2012). 
TNF-α plays a major role in a range of myo-pathologies, through its contribution to 
growth stimulation and inhibition as well as playing a major role in the immune 
response. Originally named cachectin due its first identified role as a stimulant of 
cachexia (Beutler et al., 1985), TNF-α is an acute phase pro-inflammatory protein 
secreted by macrophages in response to a wide range of immunological stimuli; 
these include other cytokines, bacteria (lipopolysaccharides), viruses and parasites 
(Janeway et al., 2001). The TNF-α gene is encoded on chromosome 6 in humans 
(Nedwin et al., 1985). TNF-α is primarily produced as a trans-membrane protein 
from which the soluble homotrimeric form of TNF-α is produced through 
proteolytic cleavage (Wajant et al., 2003).  TNF-α functions as a trimer when bound 
to its receptor. Despite having the ability to bind to approximately 25 different 
receptors in the body (Idriss and Naismith, 2000), TNF-α has been shown to largely 
signal through two distinct cell surface receptors, termed TNFR-1 and TNFR-2 
(Smith et al., 1994). TNFR-1 is the most prevalent receptor in the body, present in 
nearly all cells in the body and extensively throughout the lymphoid system and 
skeletal muscle (Loetscher et al., 1990). Consequently, the majority of biological 
functions of TNF occur via is TNFR-1 (Chen and Goeddel, 2002). TNFR-1 can be 
fully activated by both the membrane-bound and soluble trimeric forms of TNF. 
TNFR2 is not as widely expressed to the same extent as TNFR1. TNFR2 is mainly 
found in immune cells including certain populations of lymphocytes, including T-
regulatory cells (Ware et al., 1991), endothelial cells, microglia, neuron subtypes, 
oligodendrocytes cardiac myocytes, and human mesenchymal stem cells (Faustman 
and Davis, 2013). TNFR2 can be activated by the membrane-bound form of the 
TNF homotrimer. 
 
TNF-α is proposed to be a mediator of contractile dysfunction which can occur 
dependently or independently of changes in protein turnover and muscle mass TNF-
α induced muscle atrophy can occur through the impairment of muscle cell 
differentiation and can therefore result in muscle weakness (Langen et al., 2002).  
This commonly leads to a reduction in the capability of an individual to carry out 
everyday tasks. Experimental evidence shows that muscle-derived oxidants are 
essential mediators of TNF/TNFR1-induced muscle weakness/impaired muscle 
contraction. Intervention studies have revealed, the presence of ROS scavengers 
such as the SS-31 peptide reduce oxidant levels which in turn reduces contractile 
dysfunction and/or muscle atrophy. (Murrant and Reid, 2001, Reid, 2001, Li et al., 
2005, Hardin et al., 2008, Reid and Moylan, 2011). Muscle weakness and impaired 
contractile function is also proposed to be a downstream consequence of muscle 
atrophy (Li et al., 2005). However, there is a growing body of evidence associating 
the actions of inflammatory molecules such as cytokines with impaired muscle 
function, fatigue and weakness separately to muscle atrophy through increased 
production and signalling of reactive oxygen species (ROS) (Reid and Moylan, 
2011). Altered levels of pro and anti-inflammatory cytokines can impact upon both 
voluntary force production suggesting a potential effect on the central pathways 
leading to muscle contraction (McNicol et al., 2010). Given the identification of a 
wide range of cytokines directly expressed and secreted from skeletal muscle, the 
effect of both local and systemic levels of circulating cytokines need to be 
considered when assessing the relationship between muscle function and cytokines 
(Wessely et al., 1997). 
TNF-α is the most widely studied pro-inflammatory cytokine associated with 
muscle physiology. Increased levels of pro-inflammatory cytokine TNF-α have 
been associated with muscle atrophy and wasting in human and animal studies 
(Reid et al., 2002). Direct administration of TNF-α to mice was shown to increase 
muscle atrophy and reduce force contraction (Hardin et al., 2008). 
 
1.3.1.2 IL-6 
 
IL-6 is one of the most widely studied cytokines in inflammatory/autoimmune 
disease (Jones et al., 2011). Il-6 is elevated in a large number of inflammatory states 
and is a recognised target for therapeutic interventions e.g. the use of tocilizumab 
in Rheumatoid Arthritis (Maini et al., 2006). IL-6 is predominantly regarded as a 
pro-inflammatory cytokine although it has also been associated with anti-
inflammatory activities and regeneration (Starkie et al., 2003). Reports show a 
significant increase in circulating levels of IL-6 following periods of acute exercise; 
a process which occurs independently of induced muscle cell damage (Ostrowski 
et al., 1998). Evidence suggests that this surge in IL-6 following exercise may play 
an anti-inflammatory role, as it can promote the inhibition of TNF-α production 
(Pedersen et al., 2003). IL-6 exerts its effects through the receptor complex IL-6 
binding type I transmembrane glycoprotein termed IL-6R (Scheller et al., 2011). 
The effect of elevated “pro-inflammatory” cytokines such as IL-6 on skeletal 
muscle have generally been viewed as adverse however this is dependent on the 
time of exposure i.e acute vs chronic. IL-6 has been directly and indirectly 
associated with deleterious effects such as muscle catabolism and sarcopenia 
(Haddad et al., 2005), however, this is dependent on receptor binding and 
local/systemic levels. The presence of IL-6 within circulation is complex given the 
different effects locally or systemically and depending of the time of exposure.  
 
1.3.1.3 CCL and CXCL family 
 
Within the chemokine family are two major subtypes, otherwise known as the CC 
and CXC chemokines. CC and CXCL chemokines are typically small peptides, with 
the primary function of initiating inter-cellular chemotaxis. The relationship 
between circulating levels of CCL and CXCL chemokines and muscle physiology 
is poorly understood.  
1.3.1.4 CCL2/MCP-1 
 
CCL2, also referred to as monocyte chemoattractant protein-1 (MCP-1), is a 
member of the CC chemokine family. These small peptides are potent chemotactic 
factors for monocytes. CCL2 is produced by a number of different cell types, either 
constitutively or through stimuli such as oxidative stress, cytokines, or growth 
factors (Deshmane et al., 2009). CCL2 has been reported to play an integral role in 
muscle regeneration following injury (Warren et al., 2005).  Further evidence 
showing cultured myoblasts (C2C12) exposed to CCL2 exhibit increased myoblast 
proliferative responses supports the role of CCL2 in muscle repair (Yahiaoui et al., 
2008).  
 
1.3.1.5 CCL5/RANTES 
 
CCL5, also known as RANTES (regulated on activation, normal T cell expressed 
and secreted) acts as a potent chemoattractant for many cell types. CCL5 was 
originally identified as a T cell-specific chemokine, however it is now known to 
be expressed by a number of other cell types including epithelial cells, platelets, 
monocytes, NK cells and eosinophils (Crawford et al., 2011). CCL5 plays an 
important role in homing and migration of effector and memory T cells during 
acute infections. There is little evidence published on the role of CCL5 in the 
functioning and physiology of muscle. Reports have suggested a potential effect 
of CCL5 in the suppression of muscle regeneration (Kohno et al., 2011).  
 
1.3.1.6 CXCL1/KC 
 
The chemokine, keratinocyte chemoattractant (KC), also known as CXCL1 is a 
potent neutrophil chemoattractant. Keratinocytes, vascular endothelial cells, 
monocytes, and macrophages produce CXCL1 in potentially high levels in response 
to a variety of endogenous stimuli, including platelet-derived growth factor, colony 
stimulating factor-1, TNF-α and microbial stimuli (Shea-Donohue et al., 2008). 
Relatively little is known about the regulation of CXCL1/KC expression or its role 
in inflammation. Whether elevated levels of CXCL1 play a role in the induction 
protective or pathologic response pathways is yet to be fully 
elucidated. CXCL1/KC has been observed to be strongly upregulated in a variety 
of in vitro and in vivo systems (Lira et al., 1994, Roche et al., 2007).  
 
1.3.2 Muscle derived cytokines (myokines) 
 
Muscle acts as a secretory organ producing an array of peptides including cytokines. 
IL-6 was the first myokine to be identified by (Ostrowski et al., 1998). The group 
demonstrated the ability of muscle to produce and secrete peptides/proteins into 
circulation and the endocrine effects of these molecules. The authors termed these 
secreted molecules “myokines” (Pedersen et al., 1998).  
Muscle cells have the ability to synthesise the cytokines (myokines) IL-6, 
CCL5/RANTES, MCP-1/CCL2, KC/CXCL1 and secrete them into the surrounding 
milieu (Lightfoot et al., 2015). Skeletal muscle is now a recognised source of an 
array of cytokines in the body (Peake et al., 2015). Research has shown that resting 
healthy human muscles express cytokines in a fibre type specific manner 
(Plomgaard et al., 2005). The extent to which myokine production can impact upon 
circulating cytokine levels and muscle physiology is not yet fully understood. The 
impact of myokines may potentially be greater locally given the higher 
concentration at which they are present. The most widely characterised myokine is 
IL-6. Levels of IL-6 in the blood have been shown to increase in response to muscle 
contraction (Ostrowski et al., 1998).  
Skeletal muscle constitutes a large proportion of the total body weight and protein 
content. An increase in myokine release has the potential to result in a major change 
in the overall concentration of systemic cytokines. Assessment of local production 
and systemic cytokine levels would aid researchers in determining the impact of 
myokines on circulating cytokine levels.   
1.3.3 Cytokine induced NFκB activation  
 
Nuclear factor kappa B (Nf-κB) is a complex of transcription factors (Li and Verma, 
2002) ubiquitously expressed throughout the body in almost all cell types and 
tissues. The Nf-κB complex encompasses 5 related transcription factor subunits; 
p50, p52, RelA (p65), c-Rel and RelB (Moynagh, 2005, Hayden and Ghosh, 2011). 
A range of stimuli can activate NF-κB, including ROS (Reactive Oxygen Species), 
viral and bacterial antigens and cytokines including TNF-α (Ashall et al., 2009). 
NF-κB family members play an important role as a major regulator of inflammatory 
responses within innate and adaptive immunity (Vallabhapurapu and Karin, 2009, 
Hayden and Ghosh, 2008). Research initially focussed on NF-κB activation in the 
immune system however research interest has grown in other types including 
muscle. The activation of NF-κB in muscle has been associated with age-related 
sarcopenia, muscle weakness, muscle atrophy in diseases including heart disease, 
AIDS and cancer and inflammatory myopathies (Reid, 2001, Reid and Moylan, 
2011, Jackman et al., 2013, Huang et al., 2014, Guttridge et al., 2000). NF-κB 
activation has been strongly linked to the effects exerted by TNF-α upon skeletal 
muscle dysfunction and wasting. The actions of TNF-α in stimulating muscle 
atrophy through a loss of muscle protein, reduction in fibre diameter and contractile 
dysfunction are dependent on Nf-κB activation and are mediated by ROS 
generation and the activation of redox-sensitive transcription factors (Jackson et al., 
2002, Reid and Moylan, 2011, Morgan and Liu, 2011).  
 
 
  
  
1.4 Reactive oxygen species produced by skeletal muscle  
 
1.4.1 Reactive oxygen and nitrogen species  
 
Free radicals are molecules containing one or more unpaired electrons which have 
the capability to exist independently (Radak, 2000). Molecules with unpaired 
electron are very unstable and reactive. The most widely studied include hydroxyl, 
superoxide, nitric oxide (NO) and peroxyl radical. The term reactive oxygen species 
(ROS) is a general term which encompasses both free radical (species which 
contain one or more unpaired electrons) and non-free radical species of molecular 
oxygen derived molecules. These include peroxynitrite, hypochlorous acid, 
hydrogen peroxide (H2O2), singlet oxygen, and ozone (O3) which are not free 
radicals but are highly reactive oxidising agents and can easily lead to free radical 
reactions in living organisms (Halliwell, 2006). These molecules are highly reactive 
and are capable of oxidising many biological targets including protein, lipid and 
DNA. Similarly, the term RNS collectively describes free radical and non-free 
radical species in which nitrogen is at the reactive centre. Excessive levels of RONS 
as a result of increased production and/or a reduction in antioxidant defence systems 
and can lead to oxidative damage and cellular death. This can subsequently lead to 
impaired physiological functioning and contribute to the pathology of many chronic 
diseases (Zelko et al., 2002).  
1.4.2 Skeletal muscle produces reactive oxygen species  
 
It is now widely recognised that skeletal muscle is a constant source of ROS and 
RNS (collectively termed RONS) both at rest and during contractions (Barbieri and 
Sestili, 2012). Some of the first major studies to report ROS accumulation and 
potential effects of RONS in contracting muscle were published in the late 1970s 
and 1980s. Early studies were restricted by limitations in analytical techniques of 
RONS detection and focused on the quantification of oxidative damage as a marker 
of RONS levels. Since these early findings, research has advanced significantly in 
confirming the continual production of RONS from skeletal muscle cells and the 
importance of RONS in skeletal muscle maintenance and functioning. Skeletal 
muscle is known to produce a range of RONS. More recently, research has focused 
on identifying the multiple sources of RONS, factors affecting their production and 
the role RONS plays in skeletal muscle physiology and function. RONS are 
produced from a number of sub-cellular locations in muscle. 
 
RONS have been identified as essential components of normal muscle physiology 
and function (Westerblad and Allen, 2011) which play multiple regulatory roles 
including mediating cell signalling pathways, the regulation of gene expression 
through the activation of redox sensitive pathways and the modulation of force 
production. These molecules are produced during basal metabolic conditions and 
are required at low concentrations for many metabolic processes however 
production can be modulated in response to increased contractile activity, 
inactivity, foreign pathogens and inflammatory molecules including cytokines. 
Evidence has shown a link between excess free radical production and the 
pathogenesis of diseases.  RONS production by skeletal muscle is proposed to 
contribute to disuse muscle atrophy (Powers et al., 2012).  
 
RONS are produced from numerous sub-cellular compartments within skeletal 
muscle cells including mitochondrion, sarcoplasmic reticulum, transverse tubules, 
sarcolemma and the cytosol (Jackson, 2011). Original reports first identified 
mitochondria as the predominant site of cellular RONS production in skeletal 
muscle (Davies et al., 1982, Koren et al., 1983). RONS are produced during 
mitochondrial respiration and the formation of ATP. The final stage of this process 
is oxidative phosphorylation in which molecular oxygen is reduced to water. 
Secondary products of this process are intermediate ROS which can, in turn, be 
reduced to more reactive free radical species. More recent studies have identified 
alternative sources to be the major contributors of RONS. A number of different 
sources which contribute to RONS production within skeletal muscle have been 
identified. Non-mitochondrial sources of RONS include nicotinamide adenine 
dinucleotide phosphate (NADPH) oxidases (NOXs), xanthine oxidase, NADPH is 
the major source of RONS (superoxide) in skeletal muscle (Powers et al., 2010, 
Powers et al., 2011). These sources produce a number of different RONS either at 
rest and/or during contraction. The primary RONS produced by skeletal muscle are 
superoxide and NO during rest as well as during contraction (McArdle and Jackson, 
2000).  
 
The superoxide anion is an oxygen centred radical, produced through the one 
electron reduction of molecular oxygen (O2). Production can occur at multiple 
locations within the muscle fibre, including the mitochondrion, sarcoplasmic 
reticulum, transverse tubules, sarcolemma and the cytosol. Superoxide is a 
comparatively stable ROS and has a relatively long half-life (Valko et al., 2007). 
Superoxide does not readily react with protein, lips or DNA molecules causing 
oxidative damage and is generally converted to secondary ROS such as 
hydroperoxyl radicals (HOO-) or hydrogen peroxide H2O2 by reacting with 
additional molecules, such as MnSOD/CuZnSOD and extracellular SOD. 
Superoxide conversion can occur directly or through catalysed enzyme or metal 
linked superoxide dismutase reactions (McCord and Fridovich, 1969).  
 
Nitric oxide (NO) is a primary radical species in which a nitrogen is the central 
element. Production arises from the action of nitric oxide synthase (NOS) enzymes 
in converting L-arginine to citrulline. The reaction utilises NADPH as a co-factor 
(Droge, 2002). There are three isoforms of NOS in humans; these are neuronal 
(nNOS), endothelial (eNOS) and inducible (iNOS). All three are present in skeletal 
muscle. nNOS and eNOS are constitutively expressed however iNOS is only 
expressed intermittently (Hussain et al., 1997). nNOS is localised to the plasma 
membrane of skeletal muscle fibres. eNOS expression was originally thought to be 
specific to endothelial cells however it is also expressed in the mitochondria of 
skeletal muscle cells response though HSP90. The majority of iNOS activity occurs 
under inflammatory conditions in skeletal muscle (Powers and Jackson, 2008). NO 
readily diffuses over cells, through the cytoplasm and plasma membranes and is 
generally unreactive to most biological materials however it does react readily with 
radical species as well as oxygen and water. NO readily reacts with oxygen to 
produce nitric dioxide (NO2) as well as superoxide to produce peroxynitrite 
(ONNO-) (Halliwell, 1989).  
 
  
1.4.3 Detecting and quantifying RONS  
 
RONS (particularly free radical species of RONS) are highly reactive species and 
subsequently have very short half-lives. This makes accurate detection and 
quantification challenging. RONS have previously only been assessed indirectly in 
skeletal muscle through end products formed through RONS reacting with proteins, 
lipids and DNA (such as protein carbonyls, malondialdehyde (MDA) and 8-
hydroxy-2’deoxyguaosine respectively). Recent developments in the technology 
used to detect RONS has enables researchers to not only identify free radical species 
produced by skeletal muscle but quantify production in real time. Detecting and 
quantifying RONS in skeletal muscle has been attempted through a number of 
techniques (Murrant and Reid, 2001). These methods including spectrophotometry, 
fluorescence, chemiluminescence and electron spin resonance have been developed 
to assess individual RONS or total levels (He et al., 2014, Dikalov and Harrison, 
2014). In vivo measurements are preferable over in vitro analysis due to the risk of 
artificially heightened ROS generation during tissue processing and 
homogenisation (Palomero et al., 2008). 
1.4.4 Regulation of RONS in skeletal muscle  
 
RONS play an important role in regulating cell signalling pathways associated with 
skeletal muscle physiology and the adaptive response of muscle to physical 
inactivity or activity. The presence of RONS is necessary for the activation of redox 
sensitive transcription factors associated with regulation of cell signalling pathways 
associated with skeletal muscle physiology. Excess RONS can be detrimental, 
causing oxidative damage which may potentially be implicated in the process of 
ageing (Liochev, 2013) and the cause of many diseases including atherosclerosis, 
cancer, neural diseases and diabetes (Pham-Huy et al., 2008, Uttara et al., 2009). 
As a result of the importance in regulating RONS levels within skeletal muscle 
cells, the body has developed a number of systems in place which maintain redox 
homeostasis. Muscle fibres contain a network of defence mechanisms which aim to 
reduce elevated levels of RONS; these include the antioxidant defence systems and 
synthesis of heat shock proteins (HSPs) which aim to protect cells and aid recovery 
(Jackson, 2005). Within the current context antioxidants are broadly defined as any 
substance that delays or prevents the oxidation of a substrate (Valko et al., 2007).  
Antioxidant defence systems aim to reduce excessive free RONS thus preventing 
oxidative damage. These systems can be grouped into enzymatic and non-
enzymatic systems. Enzymatic regulators within skeletal muscle which directly aid 
the scavenging of oxidants includes the superoxide dismutase (CuZnSOD, 
MnSOD), catalase, thioredoxin reductases, glutathione peroxidases (GPX), 
peroxiredoxins and glutaredoxins (Halliwell, 2006). The activity level of these 
enzyme is associated with muscle fibre type. Expression of these enzymes is highest 
in type one oxidative fibres. Physical activity has been shown to increase the 
activity of these enzymes (Powers et al., 1994).  
1.4.4.1 Superoxide dismutase  
 
The superoxide dismutases (SODs) are part of the main regulatory antioxidant 
enzymes defence systems in the body. SODs catalyse the conversion of superoxide 
to hydrogen peroxide through the one electron dismutation (Jackson and McArdle, 
2011). SOD is present in two isoforms within skeletal muscle; each is characterised 
by the metal ion it is bound to (Zelko et al., 2002). The copper-zinc isoform 
(CuZnSOD or SOD1) is primarily located within the cytosol and the intermembrane 
space of mitochondria. The manganese isoform (MnSOD or SOD2) is expressed in 
the mitochondrial matrix of skeletal muscle (Powers and Jackson, 2008). Muscles 
with a higher proportion of type 1 fibres reportedly have higher levels of SOD 
activity in their muscles (Radák, 2000). An additional isoform of SOD known as 
SOD 3 which is CuZn bound exists in within the extracellular fluid of numerous 
cells and tissues and the interstitial regions of tissue (Mates and Sanchez-Jimenez, 
1999). SOD activity was first within the human plasma, lymph, ascites, and 
cerebrospinal fluids. SOD3 accounts for the majority of SOD activity in the tissues 
it is expressed in (Marklund et al., 1982).  
1.4.4.2 Catalase  
Catalase is another major endogenous antioxidant enzyme. Catalase is a heme 
enzyme (Requires Fe3+ at the enzymes active site) which catalyses the breakdown 
of hydrogen peroxide (H2O2) species to water (H2O) and oxygen (O2) (Zamocky 
and Koller, 1999). Catalase is predominantly found in the cytosolic compartment 
of the muscle fibres. Catalase activity alters in response to H2O2 production (Mates 
and Sanchez-Jimenez, 1999). An increase in catalase protein expression would be 
indicative of muscle adaptations to raised H2O2 production. 
1.4.4.3 Glutathione peroxidase 
 
Glutathione peroxidase (GPX) is the final major antioxidant enzyme within skeletal 
muscle. It is a homotetramer which contains the element selenium at its active site 
in the form of selenocysteine. GPX catalyses the reduction of H2O2 to water and 
organic hydroperoxides to alcohols. The reduced form of glutathione (GSH) is 
utilised by GPX as an electron donor, resulting in the formation of oxidised 
glutathione disulphide (GSSG). Glutathione reductase acts to regenerate GSH 
(Brigelius-Flohe, 1999). There are five isoforms of GPX (GPX1-GPX5) in humans. 
Each isoform occupies a different cellular location.  
 
GPX 1  Thyroid, liver, kidney, and pituitary gland 
GPX 2 Thyroid, pituitary gland, central nervous system, brown adipose tissue 
GPX 3  Skin, placenta and central nervous system 
GPX 4 Expressed in all tissues. 
GPX 5 Epididymis  
 
Table 1.2: Expression of glutathione peroxidase (GPX) 1-5 in different tissues.  
(Brigelius-Flohe, 1999, Arthur, 2000) 
 
  
1.4.4.4 Peroxiredoxins 
Peroxiredoxins (PRXs) are an additional group of enzymes which contribute to 
cellular antioxidant defence in maintaining RONS homeostasis and preventing 
excess levels of RONS (Wood et al., 2003). PRXs are capable of reducing 
hydroperoxide. Six isoforms of PRX (PRX I – VI) are expressed in skeletal muscle. 
PRX I, II and VI are located in the cytosol, PRX III is in the mitochondria and PRX 
IV is present in the extracellular space (Powers and Jackson, 2008). PRX V is 
expressed in numerous cellular areas including the peroxisome, cytosol, 
mitochondria and nuclei (Rhee et al., 2005).  
 
1.4.4.5 Non enzymatic antioxidants 
 
An additional system of defence exists within the body; this includes non-enzymatic 
antioxidant systems including glutathione, uric acid, bilirubin and Coenzyme Q10 
which are endogenously produced within the body. Glutathione is the most 
abundant non enzymatic anti-oxidant in the body and aids in the protection of cells 
from damage. Glutathione exists in both an oxidised (GSSG) and reduced (GSH) 
state. The reduced state (GSH) can scavenge free radicals providing direct 
protection from reactive oxygen species (ROS). The balance between GSH and 
GSSG maintains the redox environment of the cell. Alternatively, exogenous 
antioxidants can be obtained through dietary intake in the form of polyphenols, 
polyphenolic acids, carotenoids, and vitamins C and E (Roberts et al., 2007, 
Krinsky, 1998, Pandey and Rizvi, 2009).  
 
  
1.4.5 RONS mediated cytokine release  
 
Increased generation of RONS by muscle occurs in response to cytokines such as 
TNF-α (Langen et al., 2002). However, elevated RONS can also act as a stimulant 
for the production of pro-inflammatory cytokines. RONS activate numerous diverse 
downstream signalling pathways including mitogen-activated protein kinases 
(MAPKs). This can lead to the activation of transcription factors which modulate 
various stages of the inflammatory cascade including the production of IL-6, CCL2, 
CCL5, CXCL1 (Kosmidou et al., 2002, Lightfoot et al., 2015).  
1.4.6 ROS and skeletal muscle function  
 
RONS are continuously generated by skeletal muscle and low-to-moderate levels 
of oxidants are essential in the physiology of skeletal muscle as they are implicated 
in the control of gene expression, regulation of cell signalling pathways, and 
modulation-optimization of skeletal muscle force production (Powers et al., 2011). 
An excessive increase in RONS production coupled with a decline in antioxidant 
defence systems may lead to oxidative damage in skeletal muscle cells and 
potentially physiological dysfunction.  
Production of RONS is augmented in skeletal muscle in response to numerous 
factors including altered inflammatory environment, local cytokine levels as well 
as contractile function (Jackson, 2005). Intense physical activity increases the 
productions of ROS (Powers and Jackson, 2008, Lamb and Westerblad, 2011). 
Endogenous ROS scavenging pathways, such as glutathione peroxidase (GPX) and 
superoxide dismutase (SOD) activities are substantially up-regulated by exercise 
training as well as inflammation. Increased production and accumulation of RONS 
in skeletal muscle cells has been implicated in the mechanisms responsible for 
muscle fatigue  (Allen et al., 2008). RONS have been implicated in process of 
oxidative damage of cellular proteins, DNA, and lipids and have thus been 
associated with muscle damage and muscle wasting observed in high intensity 
dynamic exercise, disuse, and various pathological conditions (Pellegrino et al., 
2011).  
Physical inactivity is also associated with increased ROS production in skeletal 
muscle (Powers et al., 2005, Zhang et al., 2007). The role of RONS has been 
assessed in models of muscle disuse in which physical activity is greatly reduced 
and limbs are immobilised. Muscle disuse is characterised by muscle atrophy and 
reduced force generation. Evidence suggests an increase in radical species and a 
reduction in cellular defence systems (a reduction in the activity of antioxidant 
enzymes including catalase and GPX and HSPs) resulting increased oxidative 
damage contributes to the atrophy (Lawler et al., 2003, Pellegrino et al., 2011, 
Lawler et al., 2006). 
 
1.5 Modulation of cytokine levels through polyphenols  
1.5.1 Polyphenols and phenolic Acids 
Polyphenols are a collection of naturally occurring organic chemicals which are 
found predominantly in plants. Polyphenols are found in a large number of foods 
and drinks including vegetables, fruits, red wine, and tea (Manach et al., 2004). The 
term polyphenol denotes the presence of multiple phenolic rings. A phenolic ring 
is a 6-carbon benzene ring with an attached hydroxyl (OH) group, also referred to 
as the hydroxyl functional group (Pandey and Rizvi, 2009). Researchers have 
identified thousands of different natural polyphenols; which are categorised 
according to the presence of phenolic structural units per molecule and are divided 
into several groups. The ability of polyphenols to interact with other compounds as 
well as their antioxidant capability and bioavailability are all derived from their 
intricate chemical structure (Scalbert and Williamson, 2000). Polyphenols are 
associated with anti-oxidant and anti-inflammatory effects within the body 
(Rahman et al., 2006). Increased consumption of dietary polyphenols has been 
linked with a number of health benefits including reduced risk of cardiovascular 
disease, cancer and many inflammatory based diseases (Arts et al, 2005, Riboli et 
al, 2003).  
Polyphenols were first identified as exogenous antioxidants which could work 
within the body to scavenge free radicals; however, the antioxidant properties of 
these molecules are now thought to be elicited through secondary mechanisms of 
antioxidant prevention by the activation of signalling pathways associated with 
internal redox defence mechanisms. The exact mechanisms by which polyphenols 
exert their biological effect are still not fully understood. The common action 
associated with antioxidant activity is hydrogen donation however it is now thought 
that the cellular effects associated with polyphenol consumption must be via an 
alternative mechanism.   
The absorption of polyphenols and their bioavailability is affected by numerous 
factors during digestion, modifications by intestinal enzymes, ability to be 
transported through the gut lining, and metabolism to phenolic acids by the colonic 
microflora (Manach et al., 2004). Upon ingestion and during the process of 
digestion and absorption, polyphenols are often altered considerably. The 
metabolism of these substances naturally results in structural changes and a change 
in antioxidant potential.  
 
1.5.2 Resveratrol  
 
Resveratrol (trans-3,4',5-trihydroxystilbene) is a non-flavonoid polyphenolic 
compound with natural antioxidant properties. It is one of the most widely studied 
phenolic acids and has been associated with numerous health benefits including 
anti-inflammatory and anti-cancerous activities (King et al., 2006, Baur and 
Sinclair, 2006).  Commonly found in raw foods such as red grapes, peanuts, cocoa, 
resveratrol is transferred during processing to the subsequent by-products; red wine, 
chocolate, peanut butter etc. Resveratrol is part of the stilbene subclass of non-
flavonoid polyphenolics. It is a phytoalexin produced by higher plants in response 
to environmental stresses such as infection, nutrient deprivation and UV radiation. 
Two isomeric forms of resveratrol exist naturally. A free form in cis or trans 
configuration as well as a β-glucoconjugated form (Gulcin et al, 2010).  
 
Resveratrol was first identified through epidemiological studies; a strong inverse 
relationship between diets high in resveratrol such as the Mediterranean Diet are 
associated with a significantly reduced risk of diseases such as cardiovascular 
disease, metabolic syndrome and cancer (Keys et al., 1986). Wine consumption was 
also inversely related to coronary disease associated mortality despite a high intake 
of saturate fat. This was first described by St Leger et al as the “French Paradox”. 
This led many researchers to investigate the properties of resveratrol further. The 
majority of results shows beneficial effects and identified key pathways and targets 
of Resveratrol. In vivo studies have been less conclusive. The concentration of 
resveratrol used in in vitro studies was considerably higher than levels recorded 
plasma levels. Resveratrol has a low bioavailability and would therefore enter the 
systemic blood stream at considerably lower concentrations than those used in most 
resveratrol cell culture models. Due to the high number of hydroxyl groups on 
polyphenol compounds, polyphenols including resveratrol are broken down rapidly 
in the body to smaller metabolites and do not enter circulation.  
 
 
Figure 1.6 Basic structure of resveratrol.  
 
1.5.3 Curcumin  
 
Curcumin (diferferuloylmethane) is a natural diphenylheptanoid polyphenol found 
within the tropical spice Turmeric (Curcuma Ionga rhizomes) commonly cultivated 
in Southeast Asia. Curcumin is the primary active constituent responsible for 
Turmeric’s vibrant yellow colour. Curcumin was first isolated almost two centuries 
ago, and its structure as diferuloylmethane was determined in 1910.     
Curcumin has been shown to suppress the release of cytokines IL1β, IL8, TNFα, 
monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory 
protein-1α (MIP-1α) from PMA (para-Methoxyamphetamine) or LPS 
(lipopolysaccharide) stimulated peripheral blood monocytes (Abe et al., 1999). 
Similar studies have reported a reduction in the release of cytokines IL-1β and 
PMA-induced IL-6 expression from MH7A cells (a human synovial fibroblast cell 
line) and RA-FLS, (fibroblast-like synoviocytes (FLS) derived from patients with 
rheumatoid arthritis (RA). Evidence suggests the mechanism through which 
curcumin may be mediating cytokine secretion maybe through the inhibition of 
transcriptional factor NF-kB (Singh and Aggarwal, 1995) (Kloesch et al., 2013). 
 
Figure 1.7 Basic structure of curcumin.  
 
1.5.4 EGCG 
 
Epigallocatechin-3-gallate (EGCG), the most abundant catechin component in 
green tea. It is the major polyphenolic constituent found in green tea (Bettuzzi et 
al., 2006; Demeule et al., 2002). More than 50% of the mass of this catechin 
combination is composed of EGCG and a vast body of scientific research suggests 
that EGCG (and other catechins) is responsible for the majority of the potential 
health benefits attributed to green tea consumption (Nagle et al., 2006). Further 
research has identified potent antioxidant, chemopreventive and anti-tumour 
activity from EGCG (Tipoe et al, 2007). The effect of EGCG exposure on cytokine 
release has been investigated in a number of cell lines (with the exception of skeletal 
muscle) providing mixed results. 
 
Treatment of corneal epithelial cells (HCEpiC) with EGCG reduced IL-1β induced 
cytokine release of Il-6, IL-8, GM-CSF and MCP-1 in a dose dependent manner (3-
30µM) (Cavet et al, 2011).  Primary white blood cells (WBC) stimulated with the 
T-cell mitogen concanavalin A followed by EGCG treatment showed reduced gene 
expression of TNF-α, however there was no effect on the expression pattern of IL-
6 and IL-1β (Sehm et al, 2005). EGCG inhibited PMA (phorbol 12-myristate 13-
acetate) induced TNF-α, IL-6 and IL-8 expression and production in human mast 
cell line (HMC-1) (Shin et al, 2007).  
 
 
Figure 1.8 Basic structure of EGCG.  
 
 
  
1.6 Chronic Fatigue Syndrome as a complex model of fatigue 
1.6.1 The pathophysiology of chronic fatigue syndrome   
 
Chronic fatigue syndrome (CFS) as it has been known in the UK since the 1950s, 
is a clinically accepted condition now referred to in Britain (Hutchinson et al., 
2002). Historically, the earliest mention of CFS dates back to the 19th century under 
the names neurasthenia, neauromyasthenia, and Beard’s disease, in which patients 
described symptoms of extreme fatigue, headache, and irritability (Beard, 1989). 
CFS also referred to as or Myalgic Encephalopathy (ME), Myalgic 
Encephalomyelitis (ME), Iceland disease, Effort Syndrome, post-viral fatigue 
syndrome (PVFS) and chronic fatigue immune dysfunction syndrome (CFIDS) 
(White and Burtch, 1954, Lindan, 1956, Stokes et al., 1988, Defreitas et al., 1991) 
is a severely debilitating disease characterised by extreme and disabling fatigue. 
Worldwide prevalence of CFS is unknown due to inconsistencies in 
epidemiological data on CFS. This may be a consequence of the changing case-
deﬁnitions and titles for the condition between different populations. Two US 
community-based surveys, found the prevalence of 0.23% and 0.42% (Jason et al., 
1999, Reyes et al., 2003), whereas a British primary care study, using the same 
case-deﬁnition, found a prevalence of 2.6% (Wessely et al., 1997). This is contrary 
to two more recent US and UK studies which found prevalence at 0.4–1% and 0.2-
0.5% respectively (Devanur et al, 2006, (Nacul et al., 2011). Prevalence in the UK 
and United States has been estimated over 240,000 and 800,000 patients 
respectively. Figures are often inconsistent, due to a lack of understanding of the 
disease and imprecise diagnosis methodology. Despite minor changes in diagnostic 
criteria, the incidence of patients entering NHS patients care for CFS is rising 
(Buchwald et al., 1995). Table 1.3 reveals completed triaged referrals from the 
Royal Liverpool and Broadgreen University Hospital Trust CFS Services. These 
figures support previous evidence of an increase in referrals of CFS. This is likely 
to reflect the changing attitude of medical staff towards fatigue and CFS and 
perception within the public.    
CFS affects both male and female individuals of all ages. Evidence suggests that 
CFS is more prevalent in adults and females (Jason et al., 1999); (Reyes et al., 
2003). Research from Reyes and Colleagues (2003) revealed that the mean age of 
sufferers with CFS within their study cohort of 3528 individuals was 47 years. 
Eighty percent of individuals within the cohort were women. There are 
discrepancies in the literature regarding a specific age group most affect or pre-
disposed to the disease. Adults suffering from general fatigue are believed to hold 
the same risk of developing CFS as adults (Farmer et al., 2004).  The Centres for 
Disease Control and Prevention (CDC) in America has reported the highest 
incidence of CFS in individuals aged between 40 – 50 years (CDC, 2013). A study 
by Dowsett et al (1990) reported the majority of individuals within their cohort  
(75%) developed CFS earlier on in life between adolescence and their mid-forties 
of which the ratio of women to men was 3:1 (Dowsett et al., 1990). CFS is also 
found in children and young adults. Incidence rates across adolescents (aged 11-15 
years) have been reported as high as 0.5% (Rimes et al., 2007). 
 
YEAR NUMBER OF CASES 
2011 268 
2012 328 
2013 384 
2014 442 
2015 536 
 
Table 1.3 Completed triaged referrals from the Royal Liverpool and Broadgreen 
University Hospital Trust CFS Services. Part completed referrals returned to GPs 
not included. Provided by C. Foster - Service Manager, Chronic Fatigue Services. 
Unpublished data. (2016).  
 
The pathophysiological cause of this disease is yet to be fully defined. There is a 
lack of evidence within current literature to confirm any specific biological 
abnormalities which may underlie CFS. This is not to say that there are no objective 
abnormalities. This has been demonstrated when comparing CFS individuals with 
healthy subjects and/or patients with other chronic illness where fatigue is a caused. 
CFS is a medical syndrome and will therefore have numerous causal factors (Afari 
and Buchwald, 2003). This makes identifying the disease very difficult. CFS has 
been linked with other diseases such as fibromyalgia, depression/anxiety, infectious 
mononucleosis, lyme disease and sleep disorders (Griffith and Zarrouf, 2008, 
Patrick et al., 2015, Bourke, 2015, Ferre, 2016). There are a broad range of 
symptoms associated with CFS. The main symptom of CFS is severe 
fatigue/exhaustion which can be triggered by minimal/ no activity.  Additional 
symptoms commonly associated with CFS include general malaise/flu-like 
symptoms, muscular and joint pain, sleep disturbances, headaches, gastric 
disturbances and cognitive impairments such as short term memory loss, poor 
concentration and mental confusion. Further reports have described symptoms 
including intolerance to noise and light, sensory overload, difficulties with balance, 
dizziness, disordered temperature control, restless legs and muscle twitching.  
 At present, there is no treatment for CFS. Current therapies offered to CFS 
sufferers by the National Health Service (NHS) in England include cognitive 
behavioural therapy (CBT) and graded exercise therapy (GET). Both have been 
shown to improve both primary and secondary outcomes of CFS (White et al., 
2011). 
 
1.6.2 Diagnosing chronic fatigue syndrome 
 
The characteristics of populations with CFS differ greatly depending on the 
diagnostic criteria utilised and the procedure by which cases are determined. A 
number of terms and case definitions have been produced for CFS (Table 1.3). The 
creation of the term Chronic Fatigue Syndrome originated from Holmes et al (1988) 
which thus led to the formation of the Holmes Case Criteria (Holmes et al., 1988). 
There have been numerous case definitions since then. A recent review of case 
definitions identified 20 different case definitions in published studies of which 13 
had been assessed in 1 or more validation studies (Brurberg et al., 2014). There are 
currently 5 major different case definitions available to define CFS. The diagnostic 
case definition for CFS produced by the American Centre for Disease Control and 
Prevention (CDC) in 1994 (Fukuda et al., 1994) has been identified as the most 
widely used around the world (Brurberg et al., 2014). Guidelines within the UK 
were produced by the National Institute for Care and Excellence (NICE) in 2007.  
For an individual to be diagnosed with CFS, they must have had persistent/recurrent 
fatigue for at least six months as well as four of the following symptoms; difficulty 
sleeping or insomnia, muscle or joint pain without inflammation, headaches, painful 
lymph nodes that are not enlarged, sore throat, poor mental function (difficulty in 
thinking), symptoms getting worse after physical or mental exertion, feeling unwell 
or having flu-like symptoms, dizziness or nausea or heart palpitations (without heart 
disease).    
Diagnosing CFS is often a case of excluding other causes of fatigue such as an 
underlying illness e.g. multiple sclerosis, hypothyroidism or depression. Diagnosis 
is subject to the physicians own views which can be highly confounding (Bayliss 
et al., 2014). The issue of diagnosis is often a controversial topic between sufferers 
and physicians.  
 
 
Diagnostic Criteria 
 
Case Definition and Author Syndrome Title 
 
American Centre for 
Disease Control (CDC) 
 
Holmes case definition 
(Holmes et al., 1988) 
 
Fukuda case definition (Fukuda 
et al., 1994) 
 
Chronic Fatigue 
Syndrome (CFS) 
The Oxford criteria The Oxford criteria 
Chronic Fatigue 
Syndrome 
 
Post inflectional viral 
syndrome (PIFS) 
 
Nice Guidelines 
 
 
Chronic fatigue 
syndrome/myalgic 
encephalomyelitis (or 
encephalopathy): diagnosis and 
management in adults and 
children (Turnbull et al., 2007) 
Chronic Fatigue 
Syndrome/Myalgic 
encephalomyelitis (or 
encephalopathy) 
 
 
Canadian Clinical Case 
Definition 
 
 
(Carruthers et al., 2003, 
Carruthers, 2007) 
Myalgic 
encephalomyelitis/ 
Chronic Fatigue 
Syndrome 
 
 
Table 1.4 The main diagnostic criteria, case definitions and syndrome titles for 
CFS.  
 
  
1.6.3 Aetiologies of chronic fatigue syndrome  
 
The primary cause of CFS remains elusive. Many theories for the pathophysiology 
of CFS have been proposed. Previous assumptions, based loosely on the presence 
of symptoms, suggested an acute viral infection or a psychiatric disorder. Recent 
investigators have postulated that CFS is now more likely to be of a complex and 
multifactorial aetiology. Reports suggest there may be elements which predispose 
an individual to develop CFS, it is unclear why some individuals go to suffer from 
CFS and some do not. Numerous factors including endocrine, neuroendocrine, 
psychosocial, and potentially immunological have all been associated with 
facilitating the physiological response of CFS and the course/duration of the illness. 
Despite the demonstration of abnormalities across these and other domains, such 
findings remain largely isolated observations, with the interactions and 
relationships among them unexplored. However, the potential link behind these 
symptoms and the cause of CFS remains unknown. 
Alternative terms for CFS such as Post Viral Syndrome (PVS) and ME have been 
created based on from terminology describing the suspected cause of the disease. 
For example, PVS arose from the high incidence of CSF/ME sufferers reporting a 
previous viral infection prior to the onset of the disease. Lyme disease, the Human 
Herpes Virus family including the Epstein-Bar virus (Glandular fever) (Manian, 
1994). Myalgic Encephalitis (ME) is a neurological disease characterised by 
inflammation of the brain and spinal cord. Despite being technically incorrect, the 
term myalgic encephalopathy is the most widely used alongside CFS. 
Patterns of risk factors associated with CFS have been hard to determine from 
current literature, due to differences within sample populations and recruitment. 
Associations have been made between lifestyles choices and risk of CFS suggesting 
a higher use of anti-depressants, sleeping-pills, painkillers and antibiotics within 
this population (Jones et al., 2003). Research has suggested, early onset of severe 
and inexplicable fatigue during adolescent and even childhood may be a predictor 
of CFS in later life (Huibers et al., 2004). The use of different diagnostic criteria 
between studies has led to the formation of heterogeneous CFS populations and 
contributed to the high output of contradictory findings. This has made determining 
the pathology of the disease troublesome. The Fukuda case definition report 
suggested the understanding that a heterogeneous group was being identified using 
its methodology and the potential need for sub-grouping within CFS, (Fukuda et 
al., 1994). This has been re-iterated in a recent review (Jason et al., 2005).  
There is a growing body of research which suggest that infections and 
immunological dysfunction including perturbed cytokine levels may be a key 
contributing factor in the development and/or maintenance of CFS and its related 
symptoms, with the possibility of an interacting genetic and psychosocial factors. 
The current study will focus on immunological disturbances focussing on cytokine 
dysregulation and the muscle fatigue in patients with CFS.   
 
1.6.4 Treatment of chronic fatigue syndrome  
 
To date, there is no cure or direct treatment for CFS. Some of the symptoms 
associated with the disease such as myalgia or sleep disturbances, can be alleviated 
through painkillers or sleeping medication respectively. The NHS offers two forms 
of treatment which aim to alleviate the symptoms associated with CFS; Cognitive 
behavioural therapy (CBT) and graded exercise therapy. Recommendations are 
based on the 2007 NICE guidelines for the diagnosis and management of CFS. CBT 
aims to help patients cope with the mental stress of the condition of suffering with 
CFS. Many patients with CFS suffer from anxiety, stress and depression as a 
consequence of the disease. Additionally, CBT aims to change the way in which 
you approach daily talks in life and pace yourself. The use of CBT does not suggest 
that CFS is a psychological condition. CBT is used in a wide range of patient groups 
including severely fatigued cancer survivor in which it has been shown as an 
effective treatment (Gielissen et al., 2006). The main outcome measures of CBT 
include improved functional status and a reduction in fatigue scores (Deale et al., 
1997, Prins et al., 2001). The mechanisms through which CBT influences CFS and 
other conditions are unclear (Wiborg et al., 2010). Graded exercise therapy is a 
controlled exercise programme. It uses a combination of aerobic exercises which 
raise an individual’s heart rate. The therapy aims to gradually increase how long an 
individual can carry out a physical activity. There are some conflicting data 
regarding the use of GET. There is evidence which suggest GET can worsen CFS 
in a cohort of patients (Lapp, 1997) whilst other reports propose physical 
deconditioning is not contributing factor in the is a progression/maintenance of CFS 
and therefore GET is ineffective. The overall consensus is GET is an effective 
treatment for CSF/ME and has a positive effect on patient physical functioning, 
fatigue, self-perceived general health and sleep quality (Larun et al., 2015). 
Additional therapy which is not included in the NHS treatment programme for CFS 
includes pacing. Pacing is a process in which people are encouraged to make 
gradual increases in both mental and physical activity levels depending on stage, 
severity and variability of their illness. Pacing encourages patients to maintain a 
constant level of activity without causing over exertion (and a relapse). It is a 
flexible approach which is tailored specifically to an individual’s needs. This 
process is fully supported by the ME Association charity (Shepherd, 2015) 
Muscular and join pain is a widespread problem amongst patients with CFS 
(Krzeczkowska et al., 2015). Painkillers may be taken to relieve the patients from 
muscular aches and pains they may be experiencing. Self-medicating amongst 
patients is high. A case-control study reported >90% of Patients with CFS to have 
consumed at least one drug or supplement in the two weeks prior to the screening. 
The average intake of drugs/supplements was 5.8 per person (Boneva et al., 2009). 
Further research has reported patients with CFS were significantly more likely to 
use antidepressants, sedatives, muscle relaxants, and anti-acids, antihistamines and 
cold/sinus medications than were HCs. 
When left untreated, the estimated number of patients with CFS who make a 
recovery is <10% (Nisenbaum et al., 2003). The likeliness of a patient recovering 
is thought to be greater when the duration of illness is less than 15 months prior to 
treatment (van der Werf et al., 2002).  
 
1.6.5 Impaired muscle function in patients with chronic fatigue syndrome 
 
There has been a large amount of interest in the objective determination of muscle 
function in patients with CFS given the obvious symptoms of muscle weakness and 
fatigue, post-exertional malaise and a general feeling of weak muscles in the limbs 
of these patients (Friedberg et al., 2000). The sensation of fatigue which CFS 
patients describe has still not been clearly defined. In this study, fatigue is defined 
objectively as “failure to maintain the required or expected force”. Additional 
symptoms of muscle pain (fibromyalgia), “restless, muscle twitching legs” also 
feature highly in the list of ailments commonly reported in CFS (Fukuda et al., 
1994). This may suggest an abnormality within the muscles which is contributing 
to impaired physical functioning. 
Patients with CFS commonly self-report high scores of impaired muscle function 
and perceived effort and exertion during physical activity (Fulcher and White, 
2000). CFS report symptoms of extreme periods of physical fatigue/exhaustion both 
post exercise (Edwards et al., 1977) as well as post mental stimuli and an inability 
to perform physical tasks previously performs with ease (Marcora et al., 2009). 
Muscle function has been extensively investigated in these patients however results 
are still not full conclusive. Studies examining involuntary and voluntary force 
production have produced mixed results. Maximal voluntary force measurements 
alone have been assessed in a collection of studies. Evidence supporting the 
hypothesis of normal maximal isometric strength in unfatigued muscle of patients 
with CFS has been reported by (Lloyd et al., 1991, Gibson et al., 1993, Stokes et 
al., 1988) From these reports, a reduction was identified (which did not reach 
significance) in maximum voluntary force generation in some patients with CFS 
(Kent-Braun et al., 1993). A significant reduction in MVC was identified by 
(Schillings et al., 2004). Twitch interpolation on top of maximal isometric force 
measurements indicated submaximal effort in a minority of subjects suggesting 
suboptimal effort or impaired central motor drive given the increase in force (Stokes 
et al., 1988, Lloyd et al., 1991, Gibson et al., 1993). mechanisms responsible for the 
patients with CFS inability to perform maximal voluntary contractions (Schillings 
et al., 2004) may be due to insufficient central or peripheral activation from the 
nerve. Patients with CFS generally reported high levels of fatigue and post-
exertional fatigue following low intensity activities. To date, general everyday 
activity and sub-maximal contractile function has not been assessed in patients with 
CFS.  
The effect of repeated contractile function (muscle fatigue) on force production has 
also been assessed in patients with CFS. Further analysis from (Kent-Braun et al., 
1993) revealed, following a four minute fatiguing protocol of sustained maximal 
contraction, the reduction in central activation was significantly greater in CFS 
subjects than HCs. These results are supported by additional studies assessing 
central activation in CFS (Schillings et al., 2004). Despite no difference in markers 
of contractile muscle function, the perception of exertion, effort and fatigue was 
greater in patients with CFS (Gibson et al., 1993). Recovery of maximal isometric 
strength was significantly impaired after endurance sequence testing in the patients 
in comparison with control subjects. Strength, force decline and recovery 
measurements following repeated maximal isometric contractions in Patients with 
CFS revealed no significant contractile abnormality in these patients (Lloyd et al., 
1988). To date there have been no investigations into muscle fatigue following 
repeated involuntary submaximal isometric contractions (in the absence of volition) 
which would aid researchers in confirming whether reduced central activation was 
present in CFS. As previously mentioned in Section 1.3.2.3, physical activity and 
muscle function occurs through a combination of signalling pathways in the central 
and peripheral nervous system. Skeletal muscle contraction in under voluntary 
control and is reliant on a motivation factor.  
 
1.6.6 Muscle physiology in chronic fatigue syndrome 
 
Several studies have investigated whether patients with CFS have altered muscle 
physiology which may potentially be as a result of the disease or a contributing 
factor in the disease pathology. Early light and electron microscope studies 
examining muscle biopsies from patients with CFS have revealed there are no major 
abnormalities in muscle physiology with regards to fibre type content, fibre size 
(markers of fibre atrophy/hypertrophy (Edwards et al., 1993).  
Patients with a severe form of CFS are often forced to bed rest and unable to weight 
bear for relatively long periods of time. A reduction in physical activity and 
mechanical loading commonly results in a number of morphological changes within 
the muscle with the end results of increased muscle atrophy and a muscle weakness 
(Chambers et al., 2009). Muscle unloading reduces electromyographic activity and 
causes muscle atrophy and significant decreases in capillarisation and oxidative 
enzymes activity (Bogdanis, 2012). A reduction in protein synthesis combined with 
acceleration in protein degradation leads to a reduction in muscle mass (Thomason 
and Booth, 1989). Behan et al demonstrated atrophy of type II fibres in muscle 
biopsies taken from patients with CFS (Behan et al., 1991). These findings have not 
been uniformly reported from all studies (Lane et al., 1998).  
The overlap with symptoms associated with the common-cold/flu and other viral 
infections lead many researchers to hypothesis there may be the presence of a 
persistent infection in the muscles. Previous reports suggested the presence of 
enteroviral RNA within 21% of the muscles of patients with CFS in their study (in 
20 out of 96 patients) (Archard et al., 1988), and the persistence of enteroviral 
antigen in the serum of 51% of patients with CFS (44 of 87 patients) (Yousef et al., 
1988). A more recent investigation by polymerase chain reaction of enteroviral 
infection in CSF/ME patients revealed no quantifiable amounts of enteroviral RNA 
(McArdle et al., 1996). 
 
1.6.7 Cytokine dysregulation in patients with chronic fatigue syndrome 
 
Perturbed circulatory cytokine levels (plasma or serum) have been proposed to be 
an important component in the pathophysiology of CFS. Numerous symptoms 
commonly reported in patients with CFS are linked to the flu-like symptoms and 
inflammatory processes (e.g. swollen and tender lymph nodes, sore throat, myalgia, 
and arthralgia). This has led many researchers to hypothesise that cytokine 
dysregulation (e.g. increased levels of pro-inflammatory cytokines and/or 
decreased anti-inflammatory cytokines) may be a key contributing factor in the 
pathophysiology of the illness (Lorusso et al., 2009). Alternatively, cytokine 
dysregulation may be a consequence of the illness and thus a product of the CFS 
symptom complex. Thus, disease duration may play an important role in the 
analysis of cytokine levels in patients with CFS because for this reason (Hornig et 
al., 2015). At present there is no clear consensus as to the presence and degree to 
which altered cytokine profiles are present in patients with CFS, despite several 
investigations into circulating cytokine levels. There are an array of behavioural 
and symptomatic similarities CFS and symptoms of the common cold/flu. The 
collection of symptoms common experience during the common cold/flu have 
described as “sickness behaviour” by (Morris et al., 2013). These observations have 
directed researchers to hypothesise the role of immunological dysfunction (i.e. – 
altered cytokine profiles) in causing/maintaining the disease. Potential sites/sources 
of dysregulated cytokine production may be immune and non-immune cell types 
including macrophages and/or skeletal muscle cells which may in turn affect local 
and/or systemic cytokine levels.. Studies investigating altered cytokine profiles in 
patients with CFS reveal mixed results. There are reports which suggest alterations 
in systemic cytokine expression in CFS and an equal number which do not.  
Potential reasoning may be the sensitive nature of these signalling molecules which 
is subject to change in response to factors such as physical activity, time of day, 
stress and diet (Krueger et al., 2001, Esposito et al., 2004, Mozaffarian et al., 2004). 
Sample processing and detection methods can also have a large impact on the level 
of these molecules detected (Zhou et al., 2010). Cytokines circulate at very low 
levels and therefore high sensitivity methods are required for reliable detection. 
Making comparison between studies utilising different assays is very difficult 
(Banks, 2000). CFS may potentially be associated with subtler alterations of 
cytokine networks rather than individual cytokines. Cytokine levels in adolescent 
patients with CFS have not been as extensively investigated. A recent study 
published by Wyller et al investigating adolescents (ages 12-18 years) with CFS 
found no difference in cytokine levels between CFS and HCs (Wyller et al., 2015). 
 
1.6.8 Elevated levels of RONS and oxidative stress in muscle of patients with 
chronic fatigue syndrome 
 
Excess production of ROS from skeletal muscle cells, combined with insufficient 
antioxidant capacity, results in an accumulation of these species and oxidative 
stress. Substantial oxidative stress can lead to cellular damage, impaired 
physiological functioning and cell death. In more recent years, there has been a 
change in the focus of CFS research towards subtler metabolic changes such as 
mitochondrial function and subsequently perturbed ROS homeostasis in an attempt 
to explain the symptoms present in patients with CFS. Markers of oxidative damage 
and altered levels of antioxidant enzymes have been assessed between patients with 
CFS and HCs in muscle and blood samples. Evidence which suggests ROS are 
elevated in patients with CFS (Pall, 2000, Pall, 2003) includes the assessment of 
markers of oxidative stress including oxidative damage to lipids (malondialdehyde 
(MDA), isoprostane and thiobarbuturic), proteins (protein carbonyls) and DNA (8-
hydroxyguanosine).  Increased blood markers of oxidative stress and decreased 
antioxidant defences have been reported in patients with CFS. Lower plasma 
concentrations of Vitamin E (known to have antioxidant properties) and low-
density lipoproteins (LDL), higher LDL thiobarbituric acid reactive substances 
(TBARS). These levels were shown to correlate with  symptoms of musculoskeletal 
health reported by Patients with CFS (Vecchiet et al., 2003). Increased oxidative 
damage to DNA and lipids and increased activity of the antioxidant enzymes 
catalase, glutathione peroxidase, and transferase, and increases in total glutathione 
plasma levels were reported in muscle of patients with CFS (Fulle et al., 2000). 
These data suggests oxidative damage in muscle from patients with CFS is not due 
to the decline in antioxidant enzymes given the significantly higher levels in CFS 
patients reported above but an increase in the generation of ROS. Additionally, 
evidence has reported patients with CFS have significantly increased levels of 
isoprostanes and oxidised low-density lipoproteins in the muscle. CFS symptoms 
(total symptom score, joint pain, and post-exertional malaise) were found to 
correlate with isoprostane levels (Kennedy et al., 2005). Reports also reveals higher 
levels of MDA (malondialdehyde) in patients with CFS than age and sex match 
HCs (Richards et al., 2000). Further experimental evidence shows urinary excretion 
of 8-hydroxy-deoxyguanosine (8-OhdG), a marker of oxidative damage to DNA 
was higher in patients with CFS and depression (Maes et al., 2009). No difference 
was reported between patients with CFS and HCs.  
One study has investigated oxidative stress in skeletal muscle of patients with CFS. 
Data revealed increased levels of 8-hydroxyguanosine and MDA as well as 
increased levels of antioxidant enzymes catalase, GPX and increases in total 
glutathione plasma levels (Fulle et al., 2000). These data suggest an increase in 
oxidative stress in patients with CFS although the study only contained six patients 
with CFS vs. age and sex matched controls.  
Despite a relatively large number of studies investigating oxidative stress in CFS, 
there is very little/no existence of any overlapping data and so comparable markers 
between studies investigating elevated ROS and oxidative stress in patients with 
CFS. In addition there have not been any direct measures of ROS production from 
in situ permeabilised muscle fibres. 
1.6.9 Altered muscle mitochondrial function in patients with chronic fatigue 
syndrome 
 
Fatigability and post-exertion malaise remain fundamentally at the centre of CFS 
(Fukuda et al., 1994). These symptoms are associated with energy metabolism and 
so potentially mitochondrial function. There are numerous similarities between 
CFS and disorders involving mitochondrial dysfunction as shown in Table 1.6. 
Muscle impairments such as muscle weakness, cramps and pain are all present in 
mitochondrial dysfunction and CFS. Mitochondrial dysfunction has been 
associated with irregular immuno-inflammatory pathway signalling resulting in 
elevated activation of the NF-κB and perturbed cytokine profiles. Increased levels 
of pro-inflammatory cytokines, such as interleukin-1 and tumour necrosis factor-α 
may alter mitochondrial respiration, the activities of the electron transport chain and 
mitochondrial membrane potential, increase mitochondrial membrane 
permeability, interfere with ATP production and cause mitochondrial shutdown 
(Lopez-Armada et al., 2006, Lopez-Armada et al., 2013, Doll et al., 2015). 
 
Mitochondrial function has been investigated in muscle cells and white blood cells 
in CFS patients (Booth et al., 2012). Within muscle, data suggests abnormalities in 
mitochondrial function the form of reduced ATP production, impaired oxidative 
phosphorylation, mitochondrial degeneration and elevated ROS production in CFS 
(McCully et al., 1996, Booth et al., 2012). Evidence has suggested the presence of 
structural abnormalities in muscle mitochondria of patients with CFS including the 
fusion and branching of mitochondrial cristae (Behan et al., 1991, Plioplys and 
Plioplys, 1995) which may impact on functional capacity. These differences in 
mitochondrial function between CFS patients and HCs are yet to be fully 
established or confirmed in studies with larger sample sizes. Such deficiencies may 
contribute to the sensation of overwhelming fatigue and post-exertional malaise 
which these patients suffer from. Evidence in this area is limited and requires further 
investigation. Excessive levels of RONS causes oxidative and nitrosative damage 
which can potentially lead to cellular damage (Zelko et al., 2002). This can in turn 
cause impaired electron transport chain functioning resulting in a reduction in the 
production of ATP (Tiwari et al., 2002). Reduced ATP synthesis causes a 
deficiency in oxidative phosphorylation and can subsequently lead to mitochondrial 
dysfunction (Kirkinezos and Moraes, 2001). Impaired oxidative phosphorylation 
alone can lead to increase production of RONS thus creating a cycle self-
propagating dysfunction (Wei et al., 1998). 
The quality and study design of a large proportion of the investigations on CFS and 
oxidative stress are relatively weak containing few objective markers of ROS 
production, oxidative damage and mitochondrial function. There is lack of primary 
evidence to support a large number of conclusions (Maes et al., 2007). 
  
Organ System Symptoms in Mitochondrial 
Disorders  
Symptoms in CFS  
Muscle  Weakness  
 Cramps 
 Pain (Fibromyalgia) 
 Hypotonia 
Yes 
Yes 
Yes 
Brain  Migraine 
 Dementia 
 Neuropsychiatric disorders 
Yes 
Neurocognitive 
disorders  
Depression 
 
Nervous 
System  
 Neuropathic pain and 
weakness 
 Neuropathic gastrointestinal 
problems (gastroesophageal 
reflux, constipation)  
 Fainting, absent or excessive 
sweating, aberrant 
temperature regulation 
 
Yes 
 
Yes 
 
 
 
 
Yes 
Heart   Cardiomyopathy  
Liver  Hypoglycaemia 
 Gluconeogenic defects 
 Non-alcoholic liver disease 
 Liver failure  
 
 
General/ 
Systemic  
 Fatigue 
 Exercise Intolerance 
 Respiratory  
Yes 
Yes 
 
Table 1.5 Signs, symptoms, and diseases associated with mitochondrial 
dysfunction. Adapted from (Cohen and Gold, 2001, Morris and Maes, 2014). 
  
1.7 Summary  
 
In summary, perturbed levels of cytokines such as TNF-α are known to influence 
of muscle function and physiology. An increase in systemic pro-inflammatory 
cytokines can modulate the ability of skeletal muscle to generate force, alter 
mitochondrial bioenergetics and induce reactive oxygen species (ROS) generation 
in muscle. Cytokines are produced by a number of cells including skeletal muscle 
and research suggests a potential role of antioxidants such as naturally occurring 
dietary polyphenols in the modulation of cytokine production. Patients with CFS 
suffering from perceived increases in fatigue may have altered muscle function 
which may be, at least in part, the consequence of altered levels of systemic 
cytokines and/or altered mitochondrial function and oxidative stress. Reports to 
date are inconclusive regarding the role of altered cytokine levels in patients with 
CFS, the production of cytokines by muscle, muscle mitochondrial function and/or 
oxidative stress in muscle.  
  
1.8 Hypothesis  
 
We hypothesise that: 
 Treatment of C2C12 myotubes with TNF-α will result in the release of pro-
inflammatory cytokines and this can be altered by pre-treatment of 
myotubes with polyphenols. 
 Patients with CFS show evidence of fatigue and impaired muscle force 
generation. 
 Altered muscle function seen in patients with CFS is associated with 
modified levels of cytokines either systemically or locally to muscle.  
 Altered muscle function and altered cytokine levels in patients with CFS 
will be associated with altered mitochondrial ROS generation and 
respiratory function.  
1.9 Aims  
 
The main aims of this thesis were to: 
 Establish a comprehensive, non-damaging model of TNF-α treatment of 
C2C12 myotubes and determine the effect of pre-treatment of C2C12 
myotubes with resveratrol, curcumin or EGCG on TNF-α induced 
cytokine release. 
 Use Chronic Fatigue Syndrome as a potential model of fatigue and 
determine muscle function and fatigue (central and peripheral) in a 
patient cohort reporting increased fatigue by questionnaire analysis, 
compared with matched Healthy Controls (HCs). 
 Investigate plasma cytokine levels and cytokine gene expression in 
skeletal muscle of patients with CFS and compared with matched HCs. 
 Assess mitochondrial content and respiratory function in situ in 
permeabilised muscle fibre bundles isolated from skeletal muscle of 
patients with CFS and HCs and characterise mitochondrial ROS 
production in muscle from patients with CFS compared with HCs in situ 
in permeabilised muscle fibre bundles 
 Assess markers of oxidative damage in skeletal muscle of patients with 
CFS compare with HCs.  
  
 
 
 
 
Chapter Two 
Methods  
Chapter 2: Methods 
 2.1 Cell culture techniques  
 
2 .1.1 Tissue culture material  
 
Plasticware was obtained from Sarstedt, Germany and Fisher Scientific UK. Ltd, 
Loughborough, UK. All cell culture procedures were carried out in aseptic 
conditions in a laminar flow hood with sterilised plasticware, reagents and media.   
 Dulbeco’s Modified Eagles Medium DMEM (Sigma Aldrich, Dorset, UK) 
 L-Glutamine (Lonza, UK) 
 Penicillin/Streptomycin (Sigma Aldrich, Dorset, UK) 
 Fetal calf serum (FCS) (Life Technologies, UK) 
 Horse Serum (Sigma Aldrich, Dorset, UK) 
 
2.1.2 Cell culture lines 
 
C2C12 cells were derived from an existing mouse myoblast cell line. These cells 
were originally obtained from the thigh muscle of a healthy wild type C3H mouse 
(Yaffe and Saxel, 1977).  
2.1.3 Basic culture techniques of muscle cells 
 
Cell growth media consisted of 10% Fetal Bovine Serum (FBS) (v/v) in Dulbecco’s 
Modified Eagle’s medium (DMEM) containing 0.45% (w/v) glucose supplemented 
with 2mM L-glutamine (Sigma Aldrich, Dorset, UK), 50 i.u penicillin and 50μg/ml 
streptomycin (Sigma Aldrich, Dorset, UK). C2C12 myoblasts were grown in 
T25cm2 or T75cm² flasks at 5% CO2 saturation at 37°C in a humidified 
environment and media was replaced daily. Upon reaching 60-70% confluence, 
cells were passaged. Cells were washed with Dulbecco’s Phosphate Buffered Saline 
(PBS) without Calcium and Magnesium and sub-cultured using 0.25% (w/v) 
trypsin, 0.025% (w/v) EDTA in Dulbecco’s PBS into 9.5cm² 6 well plates (Costar, 
UK) prior to treatment.  
Upon reaching 80% confluence, myoblast differentiation was induced by changing 
the media to 2% horse serum (HS) in DMEM containing 0.45% (w/v) glucose 
supplemented with 2mM glutamine over a 6 day period. Media was replaced daily. 
The change in cellular media promotes the formation of myotubes through the 
fusion of myoblasts. Development of myoblasts was continually assessed by light 
microscopy throughout the 6 day period.  
2.1.4 Treatment of cells  
 
 Tumour Necrosis Factor-Alpha TNF-α (murine) endoxin-free (R&D 
Systems, UK) 
 Dimethyl Sulphoxide (DMSO) (Sigma Aldrich, Dorset, UK) 
 Resveratrol (Sigma Aldrich, Dorset, UK) 
 Epigallocatechin Gallate (EGCG) (Sigma Aldrich, Dorset, UK) 
 Curcumin (Sigma Aldrich, Dorset, UK) 
 Dulbecco’s Phosphate Buffered Saline (PBS) (Sigma Aldrich, Dorset, UK) 
 
At 6 days post differentiaton C2C12 myotubes were exposed to carrier free 
recombinant TNF-α (5 or 25ng/ml) for 3, 8 and 24 hours (Alvarez et al., 2002, 
Lightfoot et al., 2015). Thirty microlitre aliquots of 50μg/ml TNF-α were stored at 
-80°C prior to analysis. Following treatment cell culture media was removed and 
stored for cytokine analysis by Luminex®. Figure 2.1 illustrates the time course of 
TNF-α treatment. Cell viability was assessed using a LIVE/DEAD assay 
(Invitrogen, UK). 
 
Figure 2.1 Time course of TNF-α treatments to determine the effect on TNF-α 
induced cytokine release from C2C12 myotubes.  
 
For polyphenol treatments myotubes were exposed to either curcumin, EGCG or 
resveratrol (1 or 10μM) dissolved in DMSO for 24 hours (Howells et al., 2007). 
Control wells of cells were treated with DMSO only to elucidate whether the DMSo 
alone was exerting an effect on the cells. Following treatment, media were 
discarded and replaced with fresh differentiation media containing carrier free 
recombinant TNF-α (25ng/ml) for 24 hours. The time course of polyphenol pre-
treatment and TNF-α treatment shown below. Cell culture media was aspirated and 
stored at -80°C for future cytokine analysis by Luminex® and cells were harvested 
in DPBS on ice and centrifuged at 14,000g, 4°C for 10 minutes. Cell pellets were 
stored at -80°C for analysis by western blotting, qPCR and Luminex®. Cells were 
used immediately for a LIVE/DEAD viability assay (Invitrogen, UK).   
 
Figure 2.2 The time course of polyphenol and TNF-α treatments for studies of the 
effect of polyphenols on TNF-α induced cytokine release from C2C12 myotubes.  
 
  
2.1.5 LIVE/DEAD Viability Assay 
 
A commercially available Live/Dead Assay Cell Imaging Kit was used to assess 
cell viability (Invitrogen, UK).  
 Calcein AM ester in DMSO (Invitrogen, Paisley, UK). 
 Ethidium homodimer-1 (Invitrogen, Paisley, UK). 
 Dulbecco’s Phosphate Buffered Saline (PBS) without CaCl/MgCl (Sigma 
Aldrich, Dorset, UK). 
 
The kit contained two fluorescent dyes, calcein AM solution and Ethidium 
homodimer, which detect both living and necrotic cells respectively. Non-
fluorescent cell-permeant calcein AM ester is enzymatically cleaved by esterases to 
calcein within the cytosol and retained within viable cells. Ethidium homodimer is 
a cell-impermeant nuclear fluorochrome and consequently only enters cells with a 
compromised membrane and intercalates between nucleotide bases. Ethidium 
homodimer has been widely used to identify necrotic cells in culture due to its high 
affinity for DNA (Markovits et al., 1979). This assay provides a strong indication 
of necrotic cell death/cytotoxicity.  
C2C12 myotubes were cultured in 9.5cm² 6 well plates (Costar, UK) and treated 
with a polyphenol (curcumin, EGCG or resveratrol) only and/or TNF-α at 6 days 
post-differentiation (Section 2.1). Control C2C12 myotubes and myotubes treated 
cells were exposed to LIVE/DEAD assay solution comprised of 4mM calcein-AM 
ester and 2mM ethidium homodimer-1 in DPBS for 15 minutes at room 
temperature, protected from light.  
Confocal laser microscopy was used to image the cells. Calcein and ethidum was 
visualised using a fluorescein and a rhodamine optical filter respectively. Live cells 
produce a strong, even green fluorescence (excitation/emission 488 nm/515 nm). 
Dead cells produce a nuclear red fluorescence (excitation/emission 570 nm/602 
nm).  
  
2.2 Recruitment of patients with Chronic Fatigue Syndrome and Healthy 
Controls 
 
2.2.1 Recruitment of patients with Chronic Fatigue Syndrome 
The study recruited 95 patients with CFS. Subjects with newly diagnosed CFS were 
recruited through the local Merseyside CFS services. Following a referral from their 
local general practitioner (GP) individual cases are reviewed by consultant 
physicians from the Royal Liverpool University Hospital. Patients diagnosed with 
CFS entered the Liverpool CFS specialist outpatient NHS Service at Broadgreen 
Hospital. In exceptional cases, patients were fast-tracked through to Broadgreen 
CFS Services with diagnosis by their GP only. All subjects were newly diagnosed 
by clinicians in accordance to the Oxford Criteria (1990) and recommended NICE 
guidelines (2007).  
Prior to their first appointment session at the CFS specialist outpatient NHS Service 
all patients received the study participant information sheet allowing them more 
than 24 hours to consider the study. The study team attended an introductory session 
provided to newly diagnosed CFS sufferers. A short presentation was given at the 
end of the session to remind patients about the study. Patients were invited to 
consent into the study, complete all the necessary study material and questionnaires 
and provide a blood sample after the talk. A schematic flow diagram of the study 
design and subject recruitment is shown in Figure 2.3. 
Main inclusion criteria for CFS subjects: 
 Age range including 18-55 years 
 There should be a definitive onset i.e. it is not lifelong 
 Fatigue must be the main symptom 
 The fatigue should be severe, disabling and affect both physical and mental 
functioning i.e. significant impairment of short term memory or 
concentration 
 The fatigue must be present for at least 6 months, during which it has to 
have been present for more than 50 % of the time 
 All subjects must be able to provide written informed consent 
 
 Other symptoms may be present; 
 Myalgia 
 Sore throat 
 Tender lymph glands in the neck region or under the armpits 
 Headaches of a new type, pattern and severity 
 Malaise following effort that lasts more than 24 hours 
 Pains in several joints occurring without swelling or redness 
 Mood and sleep disturbance 
 Palpitations without heart disease 
 Dizziness, with or without nausea 
 
2.2.2 Recruitment of Healthy Controls 
 
Ninety-five age and sex matched healthy controls (HCs) were recruited within the 
Merseyside area through recruitment posters. Volunteers who contacted the study 
team were provided with the participant information forms. Volunteers needed to 
consider the study information for a minimum of 24 hours before consenting into 
the study.  
Main inclusion criteria for healthy controls: 
 Age limit 18-55 years 
 All subjects must be able to provide written informed consent 
 Subjects needed to be in good health, without any inflammatory based 
disease  
 
Main exclusion criteria for CFS subjects and healthy controls: 
 Individuals with a history of substance misuse 
 Smokers 
 
Through consenting into the study, all participants agreed to the provision of a 
blood sample and completion of a 7-day food and activity diary and study 
questionnaires. During consent, participants granted the study team access to their 
medical notes to obtain subjects medical history. Patients could additionally consent 
into further study investigations by provision of a muscle biopsy and the completion 
of muscle function testing.  
 
Figure 2.3 Schematic flow diagram of the human fatigue study design illustrating 
the recruitment of patients with CFS and HCs.  
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**Any information from questionnaires that are already collected by the Royal Liverpool and 
Broadgreen Hospital NHS CFS staff, from CFS patients, which we have proposed to also 
collect (Chalder Fatigue questionnaire, SF-36, HADS, EQ-5D, VSR, Epworth Sleepiness scale, 
Self-Efficacy Scale) will not be given to patients by the research team but, the information will 
be collected from the NHS in order to avoid duplication. 
Appointment: 
Potential CFS 
patients will be 
screened and 
diagnosed 
according to the 
Oxford Criteria 
(1990) NICE 
guidelines (2007) 
 
First 34 participants (17 
healthy/17CFS) who agree 
to the biopsy and body 
muscle function 
measurements *subject to 
participants availability 
will be assessed for 
eligibility  
 
Referral of CFS 
patients 
 
Healthy 
Volunteers 
contact for 
information 
(n=100) 
 
 
>24 hrs 
Contact to indicate 
willingness to 
participate 
Healthy Volunteers will be sent /receive 
the participant information sheet 
 
Appointment: Fill in SF-36, HADS, PSS, 
STAI, VAS, Self-efficacy, EQ-5D, 
Epworth Sleepiness Scale and the Chalder 
fatigue questionnaire. 
The consent form and the 7 day food 
diary will also be completed 
 
Clinical/Research blood sample taken  
 
GP letter sent out 
Appointment booked for 
biopsy & muscle function 
measurements  
>24 hrs 
Contact to indicate willingness to 
participate. Appointment booked 
for the consent form to be 
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Appointment: Consent form 
signed, 7 day food diary, 
PSS and the STAI 
questionnaire completed** 
Clinical/Research blood 
sample taken.  
 
 
Appointment: 
Biopsy  
Patients will be given/sent the study 
participant information sheet  
 
 
Fast tracked 
diagnosed CFS 
patients 
 n=100 
Fast tracked 
patients not 
diagnosed in the 
CFS clinic, will 
be contacted via 
letter to see if 
they wish to take 
part in the study 
Fast Track Patients who 
attend the CFS clinic , 
have received the 
participant information 
sheet and are willing to 
take part in the study will 
be consented at their first 
CFS clinic meeting.  The 
Consent form will be 
signed, 7 day food diary, 
PSS and the STAI 
questionnaire 
completed** and the 
Clinical/Research blood 
sample taken.  
 
2.3 Health questionnaire assessment 
 
CFS patients entering the NHS services were required to complete a series of health 
questionnaires in their CFS Initial Postal Assessment Pack. Participants granted 
permission for study team members to access these questionnaires during consent. 
The assessment pack contained the Chalder Fatigue Questionnaire, Visual 
Analogue Pain Rating Scale, Hospital Anxiety and Depression Score, Self-Efficacy 
Scale, The Short Form (36) Health Survey (SF-36), EQ-5D, Epworth Sleepiness 
Scale. Questionnaires are described in detail in Section 5.3.2. Questionnaires are 
displayed in Section 8.5. Healthy controls were provided with all questionnaires by 
the study team upon consent into the study. NHS questionnaires were scored by the 
study team or NHS nurses from Broadgreen hospital NHS services or the study 
team. University questionnaires were scored by the study team.  
2.4 Blood collection  
 
All blood collection tubes were supplied from Sarstedt AG & Co, Germany. 
 4 X 4.7ml Brown Cap S-Monovette Serum Collection Tubes  
 2 X Pink Cap S-Monovette Plasma Collection Tubes  
 1 X S-Monovette 2.7 ml, K3 EDTA Full Blood Count Tubes 
 1 X S-Monovette 3 ml Clotting Tubes 
 
All blood samples were taken from patient and controls by trained individuals 
registered in the study log. Blood was drawn from the right/left arm using a butterfly 
needle. 
2.4.1 Serum processing  
 
Serum was collected in brown cap 4.7ml blood collection tubes (no additive), 
incubated for at least 30 minutes to induce clotting, and then processed within 3hrs 
of collection. Samples were centrifuged at 1500g for 15 minutes at 4°C. Supernatant 
was aspirated from the samples band stored at -80°C for future analysis.   
2.4.2 Isolation of plasma from human blood  
 
Plasma was collected in S-Monovette 7.5ml K2EDTA gel pink capped blood 
collection tubes (Sarstedt AG & Co, Germany). Blood was stored on ice until they 
were ready to be spun. All samples were processed within 3hrs of collection. 
Samples were centrifuged at 1500g for 15 minutes at 4°C. Supernatant was 
aspirated from the samples band stored at -80°C for future analysis.  
2.4.3 Clotting Screen and Full Blood Count for muscle biopsy participants 
 
Additional bloods were drawn from subjects willing to donate a muscle biopsy. 
Blood was collected in S-Monovette 2.7ml K3 EDTA, red cap collection tubes for 
full blood count analysis and S-Monovette 3ml green cap collection tubes for 
clotting screen.  Samples were taken to Liverpool Royal Hospital to be processed 
by the Haematology department. The clotting screen involves a collection of tests 
which aim to detect potential problems with a person’s blood coagulation / clotting 
mechanism. Prothrombin time (PT) is a blood test that measures the time it takes 
the blood to clot. The APTT, in contrast to the PT, measures the activity of the 
intrinsic and common pathways of coagulation. The APTT measures the formation 
of a complex formed from various plasma clotting factors which converts 
prothrombin to thrombin and the subsequent formation of the fibrin clot. These tests 
were used to determine whether a person has an increased risk of bleeding during 
the biopsy. The Full Blood Count included a group of tests designed to investigate 
markers of blood cell profile, including red blood count, platelet and haemoglobin 
levels.  
 
 
Platelets 
(x10^9/L) 
Prothromin 
(secs) 
APTT Partial 
Thromboplastin 
Time (secs) 
Healthy Range 150 - 400 9.0 - 13.0 25.0 - 36.0 
 
Table 2.1 Healthy ranges for platelet count and clotting screen from blood samples 
according to NHS guidelines.  
  
2.5 Muscle biopsy procedure 
 
 TSK Acecut Biopsy System (TSK Laboratory, Oisterwijk, Netherlands) 
 2% Lidocaine  
 Scalpel 
 Sterile wipes/dressings pack  
 
A percutaneous needle biopsy was taken from newly diagnosed patients with CFS 
and healthy volunteers providing their FBC and clotting screening was within 
normal laboratory range. Clotting Screen - Prothrombin (seconds). A fully trained 
physician carried out the procedure. An aseptic Acecut automatic Biopsy system – 
Needle 22mm was used for each procedure. Biopsies were taken from vastus 
lateralis of the right leg. Subjects lay supine on a padded table with the thigh 
exposed. The leg was positioned in a relaxed manner, with the knee fully extended, 
thus placing the vastus lateralis in a shortened position. The area was shaven and 
sterilized with swabs pre-soaked with a topical antiseptic, (chlorhexidine gluconate) 
prior to the procedure.  The skin and thigh were both anaesthetised with 4ml 2% 
lidocaine. A needle was inserted approximately horizontal to the skin into the 
dermis, 100 µl of lidocaine was infiltrated. The needle was withdrawn and then 
advanced into the subcutaneous tissue. After 2-3 minutes’ post anaesthetic, the 
biopsy site was probed to ensure the patient could not feel anything. A small 1cm 
incision was made through the skin, subcutaneous tissues and fascia using a scalpel. 
The biopsy needle was advanced into the skeletal muscle through an incision in the 
skin, subcutaneous tissue, and fascia. Three passes of muscle were collected from 
the muscle from different regions. Pressure was applied directly to biopsy site with 
sterile gauze. Once haemostasis was achieved, to the wound was cleaned and steri-
strips were applied (Lacomis, 2000, Owens et al., 2015).  
  
2.6 Plasma cytokine analysis  
 
2.6.1 Bio-Plex multi-bead cytokine analysis  
 
 Bio-Plex Pro™ Cytokine Reagent Kit (Bio-Rad, Hercules, USA) 
 Assay Buffer (PBS-0.05% Tween 20, pH 7.4, 0.1% BSA, 0.01% NaN3) 
 Wash Buffer (PBS-0.05% Tween 20, pH 7.4) 
 Streptavidin-phycoerythrin fluorophore 
 96-well nano-pore filter membrane microplate or 96-well flat bottom 
microplate (Invitrogen/ Bio-Rad, Hercules, USA) 
 Bioplex® single-plex (mouse or human) cytokine coupled magnetic beads 
and detection antibodies 
 
All buffers, standards, coupled beads and samples were brought up to room 
temperature prior to use. A vacuum pressure or magnetic plate washing system was 
utilised to aspirate liquid from each well of the filter plate during a wash. During a 
plate wash, 200μl of wash buffer was added to each well. The plate was either 
placed onto the vacuum filtration platform and pressure (a pressure of 1-3mmHg) 
was applied ensuring the plate was tightly sealed down pulled liquid in the wells 
through. Alternatively, the plate was placed on a magnetic plate station and inverted 
allowing the wash buffer to drain out whilst the beads are retained.  
A 96-well filter plate was initially pre-wetted with 200μl of assay buffer followed 
by 50μl of diluted coupled magnetic beads. Standards were made using Bio-Plex 
Pro™ mouse cytokine standards (Bio-Rad, Hertfordshire, UK) and were loaded 
onto the plate along with the samples. These were incubated under set conditions: 
30 min under constant agitation, protecting the plate from light. The plate was 
washed 3 times before samples and standards were incubated with a complementary 
detection antibody for 30 minutes under agitation. 3 further wash steps were 
performed using the vacuum filtration or a magnetic plate station. The penultimate 
step involved the addition of Streptavidin-phycoerythrin fluorophore to each well. 
Samples and standards were incubated for 10 minutes in darkness under agitation 
(300rpm). Samples and standards underwent a final wash with 100μl of assay buffer 
before being analysed using the Bioplex® 200 platform (Bio-Rad Hercules, USA).   
 
2.6.1 Cytokine analysis by ELISA  
 
 Human TNF-α Quantikine ELISA (R&D Systems, UK). 
 Human TNF-α Microplate, conjugate and standard 
 Assay Dilutent (RD1F - Buffered protein base with preservatives) 
 Wash Buffer (Concentrate & ddH2O) 
 
Levels of TNF-α in plasma samples was analysed using a commercial TNF-α 
ELISA. Plasma was obtained using the plasma isolation protocol as previously 
described in Section 2.2.4.2.  The kit provided a 96-well microplate pre-coated with 
human TNF-α monoclonal antibody.  
50μL of assay diluent was added to each well followed by 200μL of standard, 
sample or control per well. The plate was covered and incubated for 2hours at room 
temperature. Each well was aspirated and washed a total of four times. 200μL of 
Human TNF-α conjugate was added to each well and incubated for 2 hours at room 
temperature. A second set of washes was completed before 200μL of substrate 
solution was added to each well. The plate was incubated for 20minutes at room 
temperature. The final step of the protocol involved the addition of 50μL of stop 
solution. Optical density of each well was determined at 540 nm using a Flurostar 
Optima (BMG Labtech, Aylesbury, UK).  
  
2.7 Quantification and analysis of proteins in human tissue and cells 
 
2.7.1 Preparation of human biopsy tissue samples  
 
 RIPA Buffer - 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1mM EDTA, 2.5 
mM sodium deoxycholate, 1:1000 protease inhibitor cocktail (Sigma- 
Aldrich).  
Prior to analysis, muscle was ground under liquid nitrogen. The resulting powder 
was placed in to an eppendorf with 200μl of RIPA buffer and homogenised 
(Sartorius BBI Systems, Model POTTER S, Germany). Samples were then 
centrifuged at 10,000 g for 10 minutes at 4°C (Eppendorf Centrifuge 5402, London, 
U.K.) and the supernatants were stored at –80°C until further analysis. 
2.7.2 Preparation of C2C12 cells  
 
 Dulbecco’s Phosphate Buffered Saline (DPBS) (Sigma Aldrich, Dorset, 
UK). 
 1% Sodium dodecyl sulphate (SDS) (Sigma Aldrich, Dorset, UK). 
 Protease Inhibitor -1mM iodoacetimide, 1mM benzithonium chloride, 
5.7mM Phenylmethylsulphonyl fluoride (Sigma Aldrich, Dorset, UK). 
 
Cells were harvested from the 6-well tissue culture plates in 2ml PBS solution 
(without MgCl2 or NaCl) using sterile cell lifters (Corning Incorporated, USA). 
Cells were centrifuges at 10,000g for 10 minutes at 4°C to form a pellet. The 
supernatant was removed and cell pellets were re-suspended in 100µl of 1% sodium 
dodecyl sulphate (SDS) containing protease inhibitors (1/1000) to prevent protein 
degradation. Samples were stored at -80°C until further analysis. 
 
  
2.7.3 Bradford assay  
 
The Bradford assay was used to determine total protein content of each human 
muscle sample according to the manufacturer’s protocol.  
 Bovine Serum Albumin (BSA) – Protein Standard 
 Bradford Reagent (Sigma Aldrich, Dorset, UK) 
 
The principle of the Bradford assay is based on the binding of Coomassie blue dye 
to proteins (Bradford, 1976). Under neutral conditions, the dye exits in a green 
form. However, when the dye binds to protein, it is converted to a stable un-
protonated blue form (Compton and Jones, 1985). It is this blue protein-dye form 
that is detected at 595nm in the assay using a spectrophotometer.  
 A set of standards ranging from 25-500μg/ml were made from a 2mg/ml stock 
solution of bovine serum albumin (BSA) with dH2O. Samples were diluted in a 1:20 
dilution with dH2O. 200μl of Bradford reagent was added to each well and mixed 
well. The absorbance of both the samples and standards was measured using a 
microplate spectrophotometer (Bio-Tek instruments, Vermont, USA) at 570nm. 
The protein content of each sample was calculated using the standard curve.  
  
2.7.4 Bicinchoninic Acid (BCA) Assay 
 
The BCA is a reliable, sensitive assay used to assess the total protein content of 
C2C12 cells. 
 Reagent A: Bicinchoninic acid (BCA) solution consisted of 160mM 
NaCO3.H2O, 25mM BCA-Na, 7mM Na2 tartrate & 0.95% NaHCO3.  
 Reagent B: 160mM CuSO4.5H2O 
 Bovine serum albumin (BSA) 1mg/ml.  
 Reagent C was comprised of 12.5ml of Reagent A to 250μl of Reagent B. 
The principle of the bicinchoninic acid (BCA) protein assay depends on the 
formation of a Cu2+ protein complex. This is followed by reduction of the Cu2+ to 
Cu+. The amount of reduction is proportional to the amount of protein present. BCA 
forms a purple-blue complex with Cu+ (Smith et al., 1985).  
A 1mg/ml stock solution of BSA was utilised to prepare a series of standards 
ranging from 50-1000μg/ml. Samples were analysed against these standards. A 
total volume of 20μl of samples and standards were added to a 96-well microplate 
before 180μL of Reagent C was added to each well. The microplate was incubated 
for 30 minutes at 50°C. A microplate reader was used to read the absorbance of 
both the samples and standards at 570nm. Protein content was determined by using 
the standard curve. 
  
2.8 Gel Electrophoresis  
 
2.8.1 Preparation of gels  
 
 12% Acrylamide Solution (40% Acrylamide Solution, 26% resolving buffer 
and 34% ddH2O 
 4% Acrylamide Solution (13% Acrylamide Solution, 25% stacking buffer, 
61% ddH2O 
 Stock Acrylamide Solution: 30% Acrylamide, 0.8% methylene 
bisacrylamide stabilised solution (37.5:1 ratio) (Protogel, National 
Diagnostics, USA) 
 Stock Resolving Buffer: 0.375M Tris-HCl, 0.1% SDS, pH 8.8. (Protogel, 
National Diagnostics, USA) 
 Stock Stacking Buffer: 0.125M Tris-HCl, 0.1% SDS, pH 6.8. (Protogel, 
National Diagnostics, USA) 
 NNN’N –Tetramethylethylene (TEMED), (Sigma Aldrich, Dorset, UK) 
 10% (W/V) Ammonium Persulphate (APS), (Sigma Aldrich, Dorset, UK) 
Gels were cast in 2mm sections between 2 x (8x10cm) glass plates. 10ml of 12%gel 
was prepared for each gel as detailed above. The polymerisation of each gel 
required 100μl of 10% APS solution and 10μl TEMED to catalyse the reaction. A 
4% stacking gel was prepared and cast on top of the 12% gel. 10ml of 4% gel 
required 100μl 10% APS and 25μl TEMED. A comb was inserted into the 1-1.5cm 
of stacking gel to form the wells for protein loading.   
2.8.2 Protein Electrophoresis 
 
 Running buffer -10X  Tris/Glycine/SDS (0.25M Tris base, 1.92M glycine 
and 1% (w/v) SDS (National Diagnostics, Georgia, USA) 
 Lamelli loading buffer (2X) – 0.5M Tris-HCl, pH 6.8, 4.4% (w/v) SDS, 
20% (v/v) glycerol, 2% (v/v) 2-mercaptoethanol and bromophenol blue in 
ddH2O 
Fifty micrograms of total protein was aliquoted from each sample and combined 
with an equal volume of Lamelli loading buffer. Samples were boiled for five 
minute to ensure all proteins were denatured and to help break up any complexes. 
Samples were left to cool to room temperature for 15 minutes before being loaded 
into the wells in the 4% stacking gel. Gels were placed into an electrophoresis tank 
filled with 1X running buffer in ddH2O. Proteins were run through the 4% gel at a 
constant current of 20mA per gel until they reached the 12% gel. Proteins were 
separated by electrophoresis across the 12% gel at 30mA per gel.  
2.8.3 Western Blotting  
 
 Anode I Buffer – 0.3M Tris in 20% methanol solution, pH 10.4 
 Anode II Buffer – 25mM Tris in 20% methanol solution, pH 10.4 
 Cathode Buffer – 40mM 6-amino-n-hexanoic acid in 20% methanol 
solution, pH 7.6 
 
Gels were removed from the electrophoresis tanks and separated from the glass 
plates. The gel was placed on top of a nitrocellulose membrane over two layers of 
Whatman No°1 filter paper which had been previously soaked in Anode I and II. A 
third layer of filter paper which had been pre-soaked in cathode was laid on top 
(Figure 2.4). Proteins were transferred on to the nitrocellulose membrane by a 
Multiphore Continuous Blotting System (Pharmacia, Uppsala, Sweden). A constant 
current of 45mA per gel was applied for 90 minutes. Graphite electrodes facilitated 
the electrical current between the layers of filter paper, allowing the transfer of the 
separated proteins from the gels to the nitrocellulose membrane. Confirmation that 
the proteins had been transferred homogenously was achieved through ponceau 
staining of the nitrocellulose membrane. 
 
 
Figure 2.4 Schematic diagram of western blotting, arrangement of gel and 
nitrocellulose membrane and filter paper between the two electrodes for efficient 
protein transfer. 
 
2.8.4 Membrane probing for specific proteins  
 
 Blocking Solution – 5% (w/v) powdered milk in TBS-Tween. 
 10X TBS solution (1L) – 24.23g Tris-HCl, 80.06g NaCl, in ddH2O.  pH 7.6.  
 TBS-Tween Solution (1L) – 1X TBS in ddH2O, 0.05% (v/v) 
polyoxyethylene-sorbitan monolaurate (Tween 20). 
 SuperSignal West Dura Chemiluminescence Kit (Thermo Fisher Scientific, 
UK) 
 
Membranes were incubated for 60 minutes in a 5% milk solution to prevent non-
specific binding between the membrane and the primary antibody followed by 3x 5 
minute washes in TBST. Membranes were cut according to the size of proteins 
being analysed. Sections of blots were analysed for the presence of Catalase, IκBα, 
MnSOD and CuZnSOD using antibodies raised against these proteins (Enzo Life 
Sciences, Exeter, UK) (Sigma Aldrich, Dorset, UK). Antibodies were prepared in 
10mls of 3% (w/v) powdered milk in TBS-Tween and incubated with the 
appropriate section of membrane overnight at 4°C on an agitator. Membranes were 
washed in TBS-Tween  3x 10 minutes before being incubated with a second species 
specific peroxidise conjugated secondary antibody relevant to the primary antibody 
of interest for 60 minutes under agitation at room temperature. Following this, 
membranes underwent 3x 10 minutes washes in TBS-Tween. The membrane was 
exposed under a chemiluminescent agent using SuperSignal West Dura Kit 
(Thermo Fisher Scientific) before being placed between two sheets of acetate. It 
was then placed under a Bio-Rad Chemi-doc XRS system with QuantityOne 
software (Bio-Rad, Hercules, USA).  
Protein levels were quantified by assessing the intensity of each band using 
densitometry. Pixel saturation was avoided by ensuring linear intensity during the 
exposure.  
  
Antibody 
 
Company Cat Number Species Dilution 
GAPDH  Abcam Ab8245 Mouse 1:5000 
SOD1  Enzo Life Sciences ADI-SOD-100-F Rabbit 1:1000 
SOD2  Enzo Life Sciences ADI-SOD-111-F Rabbit 1:1000 
nNOS  Abcam Ab76067 Rabbit 1:1000 
eNOS  Abcam Ab76198 Mouse 1:1000 
iNOS  Abcam Ab49999 Mouse 1:1000 
PRX3 Abcam Ab16751 Mouse 1:1000 
4-HNE Abcam Ab46545 Rabbit 1:1000 
3-NT Cayman 189542 Rabbit 1:1000 
Prot. 
Carbonyls  
Cell Biolabs, Inc.  STA-308 Rabbit 1:1000 
Catalase Sigma C 0979 Mouse 1:1000 
HSP 10 Abcam Ab53106-100 Mouse 1:1000 
HSP 25  Enzo Life Sciences  ADI-SPA-801 Rabbit  1:1000 
IκBα Abcam  Ab32518 Rabbit 1:1000 
 
Table 2.2 Antibodies used for western blotting. Company details - Abcam, 
Cambridge, UK. Sigma Aldrich, Dorset, UK. Cell Biolabs, Inc. San Diego, USA. 
Enzo Life Sciences, Exeter, UK.    
 
  
2.9 Assessing markers of oxidative damage in muscle biopsy tissue 
  
2.9.1 Assessing changes in the 3-nitrotyrosine (3-NT) content of proteins 
 
Previous research has indicated that the 3-nitrotyrosine (3-NT) content of the major 
muscle protein, carbonic anhydrase III (CAIII), is a relatively sensitive marker of 
muscle oxidative stress (Vasilaki et al., 2007). Peroxynitrite was assessed via 
changes in the level of nitration of tyrosine using the techniques described by 
(Vasilaki et al., 2007). 
Skeletal muscles were ground under liquid nitrogen as described in Section 2.4 and 
total cellular protein (50μg) was separated on 1D SDS-PAGE followed by western 
blotting as described in Section 2.5. A mouse monoclonal antibody was used to 
assess the content of 3-NT (Cayman Chemical Co., Ann Arbor, Michigan, USA). 
Bands were visualized using a Bio-Rad Chemi-Doc System (Bio-Rad Laboratories 
Ltd, Hemel Hempstead, UK). The density of bands quantification of the CAIII band 
was undertaken, and the protein content was normalized to the GAPDH content of 
the same sample. Comparisons were made between samples on the same gel. 
2.9.2 Assessing changes in protein oxidation 
 
Protein carbonyls were analysed as a marker of protein oxidation in muscle tissue. 
Proteins (50μg) were separated on 1D SDS-PAGE and transferred on a PVDF 
membrane. 
2.9.2.1 Derivatization 
 
Following the electroblotting step (Section 2.8.2), PVDF membranes were 
immersed in 100% methanol for 15 seconds, and then allowed to dry at room 
temperature for 5 minutes. Membranes were equilibrated in TBS containing 20% 
methanol for 5 minutes and were washed in 2N HCl for 5 minutes. Membranes 
were incubated with 1X DNPH solution (a solution used to derivatize the carbonyl 
groups) for exactly 5 minutes and were washed three times in 2N HCl, 5 minutes 
each time, followed by five minute washes in 100% methanol. 
  
2.9.2.2 Immunoblotting 
 
Membranes were blocked and probed for 2 hours using a freshly diluted 1:1000 
Rabbit Anti- DNP antibody (Cell Biolabs, San Diego, CA, USA). 
2.9.3 Assessing changes in lipid peroxidation 
 
Lipid peroxides are unstable indicators of oxidative stress that decompose to form 
more complex and reactive compounds such as Malondialdehyde (MDA) and 4-
hydroxynonenal (4-HNE), natural bi-products of lipid peroxidation (Sakellariou et 
al., 2013). Lipid peroxidation was assessed via changes in 4-HNE protein 
conjugates. Both markers were assessed using the same protocol as for 3-NT 
(Section 2.11.1). Rabbit Anti-MDA primary antibodies (Cell Biolabs, San Diego, 
CA, USA) and rabbit anti 4-HNE (Abcam, Cambridge, UK) were used. 
  
2.10 RNA extraction, purification and cDNA synthesis 
 
2.10.1 RNA Extraction 
 
 TRI Reagent (Sigma Aldrich, Dorset, UK) 
 Isopropanol (Sigma Aldrich, Dorset, UK) 
 Chloroform (Sigma Aldrich, Dorset, UK) 
 Ethanol (75%) 
 RNase-free H2O (Sigma Aldrich, Dorset, UK) 
 
Supernatant were aspirated and the cell pellets (Section 2.7.1 and 2.7.2) were re-
suspended in 200µl of Tri reagent and centrifuged at 12,000g for 10 minutes in 4°C 
to remove insoluble material. Samples were left for 5 minutes at room temperature 
before 200μl of chloroform was added to the supernatant. Samples were then 
agitated for 15 seconds at room temperature before standing at room temperature 
for 15 minutes. Samples were centrifuged at 12,000g for 15 minutes at 4°C causing 
3 phase separations of the lysate. A lower red phase containing organic protein, a 
middle DNA interphase and a colourless upper RNA phase containing aqueous 
residue is produced. The upper RNA phase was removed from each sample and 
aspirated into a new tube.  
Samples were vortexed with 500μl of isopropanol and left to stand at room 
temperature for 10 minutes. Samples were centrifuged at 12000rpm for 10 minutes 
at 4°C. Aspirated supernatant from the samples was discarded from each sample 
leaving a pellet of RNA. Pellets were washed with 1ml of 75% ethanol and 
centrifuged at again at 12,000g for 5 minutes at 4°C. The supernatant was aspirated 
and discarded. Pellets were air dried at room temperature for 5 minutes. The RNA 
pellet was re-suspended in 100μl DNase/RNase free ddH2O pipetting the solution 
repeatedly to break it up. Samples were incubated at 55°C for 15 minutes before 
being stored at -80°C for future analysis.  
  
2.10.2 Purification and DNase treatment of total RNA 
 
All RNA samples were purified and DNase-treated using the RNeasy MinElute 
cleanup-kit (Qiagen) as described below. 
 Buffer RLT (lysis buffer) 
 Buffer RPE (washing buffer) 
 RNase- Free water 
 RNeasy MinElute Spin Columns 
 Collection tubes (1.5 & 2ml) 
 
The total volume of RNA samples was adjusted to 100μl with RNase-free water. 
Three hundred and fifty microliters RLT buffer and 250μL 100% ethanol were 
added to the samples and mixed well by pipetting. Samples were transferred to an 
RNeasy MinElute Spin column which was placed in a 2mL collection tube. 
Columns were centrifuged for 15sec at 8,000g. The flow-through was discarded 
and the RNeasy MinElute Spin columns were placed in a new 2ml collection tubes. 
Five hundred microliters RPE buffer was added before centrifuging the spin 
columns for 15sec at 8,000g to wash the column membrane. The flow-through was 
again discarded. Five hundred microliters of 80% Ethanol was added to the RNeasy 
MinElute spin column and samples were centrifuged for 2min at 8,000g to wash 
the spin column membrane. The collection tubes were discarded. RNeasy MinElute 
Spin columns were placed in a new 2mL collection tubes and centrifuged at 20,800g 
for 5 min. The collection tubes were discarded. The spin column was placed in a 
new collection tube (1.5mL) and 14μL of RNase-free water was added directly to 
the centre of the spin column membrane. Columns were centrifuged for 1 minute at 
full speed 20,800g to elute the RNA.  
 
 
 
 
2.10.3 RNA quantification 
 
RNA was quantified using a Nanodrop 2000 (Thermo Scientific, Massachusetts, 
USA). 1μl RNase free ddH2O was initially used to calibrate the system. One 
microlitre of sample was pipetted onto the measurement pedestal of the nanodrop 
and quantified. The purity of RNA was assessed though the ratio of absorbance at 
260/280. RNA absorbs at 260nm whilst protein, phenol and other contaminants 
absorb strongly at or close to 280 nm. A ratio of ~2.0 is generally accepted as “pure” 
for RNA. If the 260/280 ratio is considerably lower, it may indicative of protein, 
phenol or other contaminants being present. The 260/230 ratio is a secondary 
measure of nucleic acid purity. Expected 260/230 values are commonly in the range 
of 2.0-2.2. If the ratio is appreciably lower than expected, it may indicate the 
presence of contaminants which absorb at 230 nm suggesting phenol contamination 
or excess guanidine.  
2.10.4 Complimentary DNA (cDNA) synthesis 
 
First-strand cDNA was generated from the purified RNA using the iScript cDNA 
Synthesis kit (Bio-Rad, Hertfordshire, UK).  
 5 x iScript reaction mix 
 iScript reverse transcriptase 
 Nuclease-free water 
 
cDNA synthesis was carried out by combining 4μL of 5 x iScript reaction mix and 
1μL of iScript reverse transcriptase to create a reaction master mix. One microgram 
sample of template RNA was combined with 5μL of master mix in DNase-RNase 
free eppendorfs. Nuclease free water was added to each sample to bring the total 
volume of each reaction mixture up to 20μL. Separate reaction mixes were prepared 
in which template RNA was combined with the 5x iScript reaction mix and nuclease 
free water only with a total volume of 20 μL. Samples were assessed for the 
presence of genomic DNA.  Each reaction mix was incubated in a PCR thermal 
cycler (Bio Gene Rapid cycler, Idaho Technology, Idaho Falls, USA) using the 
following reaction protocol: 5 minutes at 25°C, 30 minutes at 42°C, 5 minutes at 
85°C, 5 minutes at 4°C. Newly synthesised cDNA was diluted 1:100 into new 
DNase-RNase free eppendorfs with nuclease-free water. Samples were stored in -
20°C until further analysis.  
 
2.11 qPCR  
 
 SensiMix SYBR & Fluorescein Kit (Bioline, UK). 
 cDNA Sample  
 Forward and Reverse Primer  
 
Twelve and a half microliters of qPCR SensiMix containing SYBR green 
fluorescence was combined with 2μL of forward and 2μL of reverse primer formed 
the PCR reaction master mix within each well of a 96-well plate. 8.5μL of cDNA 
sample was added to each master mix in triplicate. The plate was sealed and run 
under conditions to suit the primers being analysed (primer sets are described in 
methodology of results chapters). The PCR reaction was carried out using a PCR 
thermal cycler (Bio Gene Rapid cycler, Idaho Technology, Idaho Falls, USA). The 
specificity of the PCR products was determined by melt curve analysis and agarose 
gel electrophoresis. 
Fluorescence detected by the intercalation of SYBR green in double stranded DNA 
was quantified during each cycle allowing the threshold of each gene to be obtained 
(Ct value). The delta-delta Ct (ΔΔCt) method was used to quantify changes in gene 
expression between the control and experimental samples (Livak and Schmittgen, 
2001). Genes of interest were standardised against a housekeeping gene. Data were 
expressed as fold change.  
  
Primer 
Name 
(ID) 
Forward Primer 
Sequence 
Reverse Primer 
Sequence 
Amplico
n Size 
(BP) 
TNF- α 
CCCAGGGACC 
TCTCTCTAATC 
ATGGGCTACA 
GGCTTGTCACT 
360 
IL-6 
GGTACATCCT 
CGACGGCATCT 
GTGCCTCTTTG 
CTGCTTTCAC 
81 
KC 
(CXC1) 
ATGGCCCGCGCTGCT
CTCTC 
GTTGGATTTGTCACT
GTTCAG 
344 
RANTES 
(CCL5) 
GCTGTCATCCTCATT
GCTACTG 
TGGTGTAGAAATACT
CCTTGATGTG 
175 
MCP-1 
(CCL2) 
CCCCAGTCACCTGCT
GTTAT 
TGGAATCCTGAACCC
ACTTC 
171 
Eotaxin 1 
AGGAGAATCACCAGT
GGCAAAT 
GCACAGATATCCTTG
GCCAGTT 
451 
MIP-1 α 
CCCGGTGTCATCTTC
CTAAC 
GTGTGGCTGTTTGGC
AACAAC 
236 
MIP-1 β 
AGCTTCCTCGCAACT
TTGTG 
AGTCCTGAGTATGGA
GGAGA 
241 
IL-8 
CCAGGAAGAAACCAC
CGGA 
GAAATCAGGAAGGCT
GCCAAG 
92 
 
Table 2.3 Sequences of the specific primers used for q-PCR.  
 
Primer 
Name 
(ID) 
Forward Primer 
Sequence 
Reverse Primer 
Sequence 
Amplico
n Size 
(BP) 
GAPDH 
TGAAGGTCGGAGTC
AACGGATTTGGT 
CATGTGGGCCATGAGG
TCCACCAC 
983 
B-Actin 
ATTGGCAATGAGCG
GTTCC 
GGTAGTTTCGTGGATG
CCACA 
87 
B2M 
GAGTATGCCTGCCG
TGTG 
AATCCAAATGCGGCAT
CT 
110 
 
Table 2.4 Sequences of the specific primers used for q-PCR amplification of 
housekeeping genes.  
 
2.12 Preparation of human muscle samples for analysis of mitochondrial 
respiration, ROS production and mitochondrial membrane potential  
 
2.12.1 Preparation of permeabilised muscle fibre bundles 
 
Skeletal muscle samples were obtained from the VL muscle using Acecut needle 
biopsy performed while the subjects were under local anaesthesia. Approximately 
80 mg of muscle was collected.  
 Saponin (50µg/ml) in Buffer A  
 Buffer A  
 Buffer B 
 Buffer Z  
 
Muscle biopsy samples were immediately placed into ice-cold stabilizing buffer A 
composed of 2.77 mM CaK2 ethylene glycolbis-(2-aminoethylether)- N,N,N=,N=-
tetraacetic acid (EGTA), 7.23mMK2 EGTA, 6.56mM MgCl2, 0.5mM dithiothreitol 
(DTT), 50mM 2-(N-morpholino) ethanesulfonic acid potassium salt (KMES), 20 
mM imidazol, 20 mM taurine, 5.3 mM Na2 ATP, and 15 mM phosphocreatine, pH 
7.3 at 4°C. Visible fat and connective tissue were both removed and the muscle was 
manually teased into small fibre bundles. Once the mechanical separation into fibre 
bundles was completed, fibre bundles were transferred into buffer A supplemented 
with 0.05 mg/ml saponin for 30 min at low rocking speed to selectively 
permeabilise the sarcolemma (Gouspillou et al., 2014).  
Fibre bundles prepared for respiration analyses were then washed 3 times 10 min 
in buffer B, composed of 2.77 mM CaK2 EGTA, 7.23 mM K2EGTA, 1.38 mM 
MgCl2, 3.0 mM K2HPO4, 0.5 mM DTT, 20mM imidazole, 100 mM K-MES, and 
20 mM taurine, pH 7.3 at 4°C, supplemented with fatty acid-free bovine serum 
albumin (BSA: 2 mg/ml).  
Fibre bundles prepared for ROS production analyses were then washed 3 times for 
10 min in buffer Z, composed of 110 mM K-MES, 35 mM KCl, 1 mM EGTA, 3 
mM MgCl2, and 10 mM K2HPO4, pH 7.3 at 4°C, supplemented with BSA (5 
mg/ml).   
2.12.2 Mitochondrial respiration  
 
 Glutamate (5mM) and Malate (5mM) (G/M) 
 ADP (2mM) 
 Buffer B (See Section 2.9.1 for details) 
 
An oxygen electrode measurement systems from Hansatech Instruments Ltd, 
King’s Lynn, UK was utilised to assess mitochondrial respiration (Clark et al., 
1956).  Within the instrument, a S1/MINI Clark type electrode is contained at the 
bottom of a water-jacketed respiratory chamber (Walke, 1987). The temperature of 
the chamber was set at 37 °C and sealed with a plunger. Oxygen dissolves in the 
chamber of the liquid-phase system and is detected polarographically by the 
electrode. Four hundred and fifty microliters of buffer B (2.77mM CaK2 EGTA, 
7.23mM K2EGTA, 1.38mM MgCl2, 3.0mM K2HPO4, 0.5mM DTT, 20mM 
imidazole, 100mM K-MES, and 20mM taurine, pH 7.3 at 4°C) was added to the 
chamber alongside an electromagnetic stirrer bar to mix its contents. Following a 
period of stabilisation 10μL of 10mM glutamate + 5mM malate was added into the 
oxytherm chamber. After 3 minutes, the permeabilised myofibre bundles (14-16mg 
wet weight) were added into the chamber. After a further three minutes 2mM ADP 
was added into the chamber. The bundles were left until all the O2 within the 
chamber had been utilised or the muscle had run out of substrates. After respiration 
measurements were completed, bundles were removed and placed in liquid nitrogen 
and stored at -80°C for protein quantification. Analysis of the oxygraph results is 
subject to interpretation. Analysis of the output was completed by 2 individuals 
blinded. Respiratory control index (RCI) was calculated by dividing state 3 by state 
4 respiration and the efficiency of oxidative phosphorylation was determined by 
calculating the ratio of ATP amount to consumed O2 during state 3 respiration (P:O 
ratio) (Gnaiger et al., 2000).  
 
 Figure 2.5 Schematic diagram of a typical oxygraph output. G/M 
(Glutamate/Malate), ATP (Adenosine Triphosphate).  
 
2.13 Analysis of mitochondrial ROS production in skeletal muscle  
 
2.13.1 Mitochondrial H2O2 generation – Amplex Red Assay 
 
 Hydrogen Peroxide Solution (Sigma Aldrich, Dorset, UK) 
 Amplex Red Reagent (Life Technologies, UK)  
 Horse Radish Peroxidase (HRP) (Sigma Aldrich, Dorset, UK) 
 Superoxide Dismutase from bovine erythrocytes (Sigma Aldrich, Dorset, 
UK) 
 Buffer Z (Recipe – See Section 2.9) 
 Glutamate/Malate (5mM) (Sigma Aldrich, Dorset, UK) 
 Succinate (0.5M) (Sigma Aldrich, Dorset, UK) 
 Rotenone (1mM) (Sigma Aldrich, Dorset, UK) 
 Antimycin Alpha (Sigma Aldrich, Dorset, UK) 
 
Mitochondrial hydrogen peroxide release was measured using Amplex Red- HRP 
(Molecular Probes, Eugene, OR, USA) as previously described (Muller et al., 2004, 
Vasilaki et al., 2006). Rate of ROS production was detected by measuring the rate 
of resorufin red formation at an excitation/emission wavelength of 571/585 nm. 
Resorufin red is formed through the hydrogen peroxide-dependent oxidation of the 
non-fluorescent Amplex Red compound. This process is catalysed by horseradish 
peroxidase (HRP). Resorufin is formed by the 1:1 reaction of H2O2 and Amplex 
Red. The assay only detects hydrogen peroxide which has been released from the 
mitochondria. This is a result of size constraints which restricts HRP from entering 
the mitochondria. To preventing any interaction between superoxide molecules and 
HRP, CuZnSOD was added to ensure superoxide was converted to hydrogen 
peroxide. 
At the onset of the experiments a standard curve was generated using successive 
amounts of H2O2. Each permeabilised myofibre bundles, prepared as described 
previously, were added to a single well within a 96 well microplate containing 
l00μL Amplex Red solution (19.44mM Amplex Red, 5U/ml HRP, 37.5U/μL SOD 
in Buffer Z). Samples were incubated in the dark at 37°C for 5 minutes. Substrates 
were added as follows Glutamate/Malate (10 + 5 mM), succinate (10 mM), ADP 
(100M), and Antimycin Alpha (10 μM). H2O2 production was measured using a 
Flurostar Optima (BMG Labtech).  The increase in fluorescence produced a slope; 
this converted to the rate of hydrogen peroxide production with a standard curve. 
At the end of the ROS measurements, muscle fibre bundles were placed in liquid 
N2 and stored at -80°C. H2O2 production was expressed as picomoles per minute 
per protein content of the sample. 
 
Well 1 2 3 4 5 6 7 8 9 10 11 12 
 Amplex 
Red 
Solution 
Only 
Bundle of 
Fibres 
Only 
Bundles 
+ 
Glutamate 
Malate 
Bundles  
+ 
Succinate 
Bundles  
+ 
Succinate 
Rotenone 
Bundles  
+ 
Antimycin 
A 
 
Table 2.5 Representative row from a 96 well plate illustrating the Amplex Red 
assay preparation.  
  
2.13.2 Mitochondrial superoxide generation. fluorescence-based method to 
measure mitosox red oxidation 
 
 MitoSOX Red (Invitrogen, California, USA) 
 
MitoSOX Red (Invitrogen, California, USA) 
To monitor changes in mitochondrial superoxide, a MitoSOX Red mitochondrial 
superoxide indicator (Mito-HE) probe was utilised. MitoSOX Red is a derivative 
of dihydroethidium and is a highly sensitive mitochondrial superoxide indicator 
which exhibits fluorescence upon oxidation by O2¯ (superoxide) (Robinson et al., 
2006). The reaction between superoxide and MitoSOX Red generates a highly 
specific red fluorescent product, 2-hydroxyethidium (2-OH-Mito-E+) (Zielonka and 
Kalyanaraman, 2010). Isolated fibres from the VL muscle were loaded with 250nM 
MitoSOX Red (Invitrogen, California, USA) for 30min as previously described 
(Sakellariou et al., 2013, Pearson et al., 2015). Fibres were maintained in buffer Z 
containing MitoSOX Red (20nM) during the experimental period. Fluorescence 
was quantified at an excitation/emission wavelength of 405/605nm.  
Fluorescence images were obtained using a C1 confocal laser scanning microscope 
(Nikon, Surrey, UK) equipped with a 405nm excitation diode laser, a 488nm 
excitation argon laser, and a 543nm excitation helium-neon laser. Emission 
fluorescence was detected through a set of 450/35, 515/30, and 605/15 emission 
filters. Using 10x magnification, fluorescence images were captured and analysed 
with the EZC1 V.3.9 (12bit) acquisition software. Individual images acquired from 
each section were merged into a single high-resolution image using Adobe 
photoshop CS5. 
 
2.14 Mitochondrial membrane potential  
 
In order to assess potential changes in mitochondrial membrane potential (ΔΨm) in 
intact mitochondria of isolated VL fibres, fibres were loaded with a florescent dye, 
tetramethylrhodamine, methyl ester (TMRM), as previously described in (Irwin et 
al., 2003). Changes in TMRM fluorescence of isolated skeletal muscle fibres were 
assessed by loading fibres with 30nM TMRM for 30 minutes and 20nM TMRM for 
30 minutes (Invitrogen, California, USA). Fluorescence was detected at an 
excitation/emission wavelength of 543/605nm. Changes in ΔΨm were determined 
in the presence of oxidative phosphorylation inhibitors; oligomycin (2.5μM) and 
FCCP (4μM). Images obtained using a C1 confocal laser scanning microscope 
(Nikon, Surrey, UK) as described above in Section 6.2.6. 
2.15 Analysis of mitochondrial content in skeletal muscle  
 
Citrate Synthase Assay 
 
 MitoCheck Citrate Synthase Activity Assay Kit (Cayman Chemical 
Michigan, USA) 
 
Citrate synthase is a mitochondrial enzyme, which is commonly used as a 
normalization factor for mitochondrial protein (Wiegand and Remington, 1986, 
Lopez-Lluch et al., 2006). It can also be used as a biomarker for mitochondrial 
content in a tissue homogenate. The study used a MitoCheck Citrate Synthase 
Activity Assay Kit (Cayman Chemical Michigan, USA) to determine mitochondrial 
content in muscle homogenates from CFS and control subjects. Product protocol 
was followed accordingly. The assay measured the production of SH-CoA by 
monitoring the absorbance of citrate synthase developing reagent.  
The condensation of dicarboxylate oxaloacetate and acetyl CoA to the 
tricarboxylate citrate is catalysed by the enzyme citrate synthase. It is within this 
reaction that carbon molecules (as acetyl CoA) obtained from pyruvate oxidation 
are fed into the tricarboxylic acid (TCA or citric acid) cycle.  
Samples of tissue homogenate were diluted 1:200 in assay buffer. Fifty microliters 
of 2% Citrate Acetyle Co-A Reagent, 2% Citrate Synthase Developer Reagent in 
Assay buffer was added to each well of a 96-well plate with 30μl of sample. A 
positive control was also run on the plate to ensure the kit is functioning correctly. 
Twenty microliters of 4% citrate synthase oxaloacetate reagent in assay buffer was 
added to each well. The plate was immediately placed in the microplate 
spectrophotometer (Bio-Tek instruments, Vermont, USA). Absorbance was 
measured at 412nm. 
2.16 Ex vivo single muscle fibre analysis 
 
Single fibre force analysis was undertaken by Dr Adam Lightfoot. Single muscle 
fibres isolated from the VL muscle were maintained in ice-cold stabilizing buffer 
A composed of 2.77 mM CaK2 ethylene glycolbis-(2-aminoethylether)-
N,N,N=,N=-tetraacetic acid (EGTA), 7.23mMK2 EGTA, 6.56mMMgCl2, 0.5mM 
dithiothreitol (DTT), 50mM 2-(N-morpholino) ethanesulfonic acid potassium salt 
(KMES), 20 mM imidazole, 20 mM taurine, 5.3 mM Na2 ATP, and 15 mM 
phosphocreatine, pH 7.3 at 4°C (Gouspillou et al., 2014). Fibre bundles were 
transferred into relax solution for 15 minutes on ice. Fibres were mounted onto an 
802D permeabilised fibre apparatus (Aurora Scientific, Canada). Skinned 
myofibres were attached to insect pins affixed to a 403A (5mM) force transducer 
and 312C length controller, using ultra-fine nylon thread (see Figure 2.7). Fibres 
were maintained in relax solution throughout assembly. Sarcomere length (SL) was 
measured using 900B Video Sarcomere Length (VSL) software (Aurora Scientific, 
Canada). SL was adjusted on each fibre to 2.4-2.6μm, fibre diameter was measured 
at four intervals along the length, and a circular circumference assumed for the basis 
of CSA calculation. Fibres were maximally activated in Ca2+ activating solution 
(pCa 4.5), containing in addition to Ca2+, (in mM) 5.3 MgATP, 1 free Mg2+, 20 
imidazole, 7 EGTA, 19.6 PCr, and 64 KCl (pH 7.0 at 4°C). Peak force was recorded 
and normalised to fibre CSA (Degens et al., 2010). This approach allows force 
generated by sarcomere proteins to be explored independent of fibre number, 
innervation, ATP levels and calcium release (Sartori et al., 2013). 
 
Figure 2.6 Representative image of a skinned isolated myofibre from VL muscle, 
attached to a force transducer and high-speed length controller. Scale bar, 400μm.  
2.17 In Vivo Muscle function testing  
 
Muscle Function testing was completed in the Research Institute for Sport and 
Exercise Science at Liverpool John Moores University in collaboration with Dr 
Graeme Close and Daniel Owens.   
 2.17.1 Assessing muscle function  
 
Muscle function was assessed using a Biodex isometric dynamometer (Biodex 
Medical Systems Inc. Shirley, NY, USA), previously validated for its use in reliable 
assessment of muscle function variables related to force production, (Drouin et al., 
2004). Participants were seated as per the manufacturer’s guidelines with a 90o 
flexion of the hip and non-extendable straps crossing the chest and abdomen and 
across the quadriceps to maximise isolation of the target muscle group. Information 
collected from the dynamometer was visualized and analysed using AcqKnowledge 
v.3.7.2 software (BIOPAC systems Inc. Santa Barbara, CA) (Owens et al., 2014). 
2.17.2 Assessing maximal voluntary contraction 
 
Once seated in the dynamometer as described, the angle of knee extension was set 
at 80o (assuming 0o as full extension). Participants were instructed to give 5 
submaximal voluntary isometric contractions, increasing in intensity before 
providing a maximal voluntary contraction, recorded in newton meters (nm). In an 
attempt to ensure maximal contractions were obtained, verbal encouragement was 
given to all participants and bio-feedback made available through projection of the 
force trace for the participants to view. The study investigated difference in peak 
force during MVC between subjects as previously executed in CFS research (Paul 
et al., 1999). Peak force is the highest level of force achieved during an isometric 
contraction. This generally occurs during the first 2 seconds of contraction.  
2.17.3 Involuntary contraction  
 
For the involuntary stimulation of the knee extensors, two 3 x 5 inch (8 x 13 cm) 
oval self-adhesive stimulating electrodes (Chattanooga, DJO Global, CA, USA) 
were placed approximately 2 inches above the knee joint across the vastus medialis 
(VM) and proximal to the acetabulofemoral joint across the vastus lateralis (VL) 
and rectus femoris (RM). Participants were required to contract the quadriceps to 
make the muscle body more apparent prior to electrode placement to minimise 
antagonist co-activation, although this was not monitored with electromyography 
during stimulation. Stimulation was applied through the surface electrodes, 
delivered via a BIOPAC systems MP100 stimulator (BIOPAC systems Inc., Santa 
Barbara, CA). 
2.17.4 Force frequency relationship 
 
An electrical stimulus was first delivered at 100 Hz with amplitude (mA) to elicit 
30% of the participants MVC force. Following this, at the determined amplitude, 1 
second trains of 50, 20 and 10 Hz and a single 1 Hz twitch were delivered in a 
random order to generate a force frequency relationship. 
2.17.5 Fatigue protocol 
 
Fatigue resistance was determined from two minutes repeated stimulation with 30 
Hz, 1 sec trains interspersed by 1 sec relaxation (total of 60 evoked contractions 
equating to 60 seconds of total stimulation). Fatigue index was calculated as the 
percentage force loss from the initial recorded contraction to the final recorded 
contraction.  
 
2.15 Statistics  
 
Data are presented as mean ± SEM for each experiment. Single comparisons 
between two experimental conditions at a time point were undertaken using the 
unpaired Student’s t test. For multiple comparisons analyses, One-way ANOVA 
followed by the post hoc LSD test was used. A P-value <0.05 was considered to be 
statistically significant with the exception of the Bio-Plex Luminex® cytokine 
analysis in which multiple comparisons were made in one experimental procedure. 
There is a greater probability of significance in multiple analysis assays. This was 
accounted for using the Bonferroni method of correction. SPSS 18 was used to 
analyse all data.  
  
  
 
 
 
 
 
 
 
 
Chapter Three 
Resveratrol attenuates TNF-α induced cytokine release 
from C2C12 myotubes 
3.1 Introduction  
 
Research over the last two decades has clearly demonstrated the ability of skeletal 
muscle to act to as an endocrine organ, releasing an array of different peptides into 
systemic circulation (Ostrowski et al., 1998, Pedersen, 2011, Iizuka et al., 2014, 
Lightfoot et al., 2015). These proteins mediate a broad range of processes including 
cell signalling pathways as well as critical aspects of cell behaviour, including 
differentiation, proliferation and survival (Nathan and Sporn, 1991). More 
specifically, skeletal muscle has been shown to produce an array of protein and 
polypeptide cytokine molecules, collectively termed myokines. As previously 
described in Section 1.3.1, the term cytokine includes a large family of polypeptides 
and proteins. This includes interleukins, chemokines and interferons, members of 
the tumour necrosis factor group, transforming growth factors as well as growth 
and colony-stimulating factors (Dinarello, 2007). Cytokines play a crucial role in 
the cell communication throughout the body. They are secreted by cells, and 
through their respective receptors play a regulatory role as intercellular messengers 
in both a local environment or systemically (Zhang and An, 2007).  Pedersen and 
colleagues were among the first to identify the production and secretion of 
cytokines from skeletal muscle (Ostrowski et al., 1998, Pedersen et al., 1998). 
These authors termed muscle secreted cytokines as myokines. Evidence has shown 
that myokine production is augmented during periods of disease as well as during 
contractile activity (Benatti and Pedersen, 2015). Figure 3.1 shows skeletal muscle 
is a secretary organ expressing an array of cytokines.  
The first cytokine to be identified as a product of skeletal muscle cells was IL-6, a 
pro-inflammatory cytokine secreted by muscle in response to exercises independent 
of muscle damage and released from muscle cells in vitro in response to 
inflammatory stimuli (Ostrowski et al., 1999, Nagaraju et al., 1998, Ostrowski et 
al., 1998). In contrast, IL-6 has also been shown to have an anti-inflammatory 
effects including the inhibition of endotoxin-induced tumour necrosis factor-α 
(TNF-α) secretion (Keller et al., 2006). The following cytokines have been reported 
as being produced and secreted by skeletal muscle: TNF-α, IL-6, IL-8, IL-15, IL-
18, CXCL1, CCL2, CCL5 and brain-derived neurotropic factor (BDNF) (Pedersen, 
2012). The precise function and expression pattern of these cytokines varies in 
response to changing conditions. Elevated myokine release can occur after a wide 
variety of stimuli, ranging from inflammatory cytokines, infection and endoplasmic 
reticulum stress (Lightfoot et al., 2009, Schulte et al., 2013). Knowledge in this area 
is still relatively sparse and unclear. 
 
Figure 3.1 Schematic diagram showing muscle as a secretory organ. Adapted from 
(Benatti and Pedersen, 2015). Potential sources of TNF-α include macrophages, 
endothelial cells, adipose tissue, mast cells and fibroblasts.  
A growing body of evidence is emerging which details the extent to which 
cytokines are involved in the regulation of skeletal muscle through the mediation 
of muscle satellite cell activation, proliferation, and differentiation as well as 
muscle atrophy (Kurek et al., 1998). Elevated systemic cytokine levels perturb 
normal skeletal muscle physiology and function (Spate and Schulze, 2004, Toth et 
al., 2006, Reid and Moylan, 2011). For instance, research has shown that IL-6 
knock-out mice have delayed accretion of muscle mass during muscle recovery 
from disuse atrophy (Washington et al., 2011).  
The presence of raised systemic levels of cytokines is a common feature of many 
chronic diseases including cancer, sepsis, myositis and COPD (Gan et al., 2004, 
McMillan, 2013, Lightfoot et al., 2015). Muscle atrophy, weakness and fatigue are 
commonly reported features in such diseases as chronic heart failure, cancer, AIDS 
and ageing (Engelen et al., 2000, Spate and Schulze, 2004).  
There is evidence to suggest that diseases in which muscle fatigue is a prominent 
feature are characterised by elevated systemic TNF-α (Moss et al., 1999). TNF-α is 
the most widely studied and prominently linked cytokine to muscle 
pathophysiology. TNF-α is a potent, multifunctional, pro-inflammatory cytokine, 
associated with numerous diverse physiological and pathological roles. TNF-α was 
initially associated with muscle dysfunction and fatigue and has since been 
identified as a key mediator of muscle function, affecting muscle growth and 
differentiation as well as cell death and muscle atrophy (Reid and Li, 2001, Reid 
and Li, 2001).  Muscle catabolism is commonly found in a wide range of patients 
suffering from diseases where cytokine levels are raised including sepsis and 
chronic obstructive pulmonary disease (COPD) is attributed to elevated levels of 
circulating TNF-α (Tisdale, 1999, Farber and Mannix, 2000). Evidence 
suggests that TNF-α mediated skeletal muscle wasting occurs through activation of 
the NF-κB pathway in muscle cells (Li et al., 1998, Guttridge et al., 2000, Cai et 
al., 2004). Previous work from our research group has demonstrated that C2C12 
myotubes when exposed to increased levels of TNF-α, release significantly greater 
levels of cytokines than control, untreated cells (Lightfoot et al., 2015). Moreover, 
evidence suggests that TNF-α induced cytokine secretion is, at least in part, 
mediated through increased RONS production given the increase in mitochondrial 
superoxide production from myotubes (Reid and Moylan, 2011).  
Thus, muscle is a source of inflammatory cytokines of which TNF-α is a major 
regulator of cytokine release which can in turn modify muscle function. Additional 
studies have reported lipopolysaccharide (LPS), IL-1α, IL-1β and IFN-γ as 
potential modulators of cytokine release from muscle (Nagaraju et al., 1998, Lappas 
et al., 2004). Evidence suggests patients suffering from diseases characterised by 
fatigue such as patients with CFS may have perturbed cytokine profiles. 
Intervention studies aiming to counteract raised systemic cytokine levels seen in 
some disease groups have taken several approaches; these include anti-TNF 
therapy, and dietary interventions (Charles et al., 1999, Cunningham-Rundles et al., 
2005). Naturally occurring polyphenol and polyphenolic compounds in our diet 
have been suggested to play a role in reducing pro-inflammatory cytokine levels 
and scavenge free radical species. There is a need to investigate the effect of these 
polyphenolic substances on muscle myokine release and muscle function.  
Polyphenols are naturally occurring compounds found in fruits, vegetables and 
grains (Section 1.4), produced by the plants defence mechanism in response to 
stresses. Over 8000 polyphenolic compounds have currently been identified. These 
can be classified into 4 four main groups; phenolic acids, flavonoids, stilbenes and 
lignans (Spencer et al., 2008).  A number of polyphenols including curcumin, 
resveratrol and EGCG have been identified as potent anti-inflammatory compounds 
(Gonzalez et al., 2011).  
Curcumin (diferferuloylmethane) is a natural diphenylheptanoid polyphenol, 
derived from the plant Curcuma longa and the primary active constituent of 
Turmeric. Curcumin has been used in medical practice as an anti-inflammatory in 
many Asian countries for centuries (Ammon and Wahl, 1991). Curcumin inhibits 
the release of a number of cytokines from numerous cell types including monocytes 
and fibroblasts (Abe et al., 1999, Kloesch et al., 2013). There have not been any 
studies investigating the effect of curcumin on cytokine release by skeletal muscle 
cells. However, reports from human airway smooth muscle cells (HASMC) showed 
a concentration-dependent reduction in IL-17–induced IL-8 production (Wuyts et 
al., 2005). The study identified NF-κB play as essential in IL-17-induced IL-8 
production in HASMC in vitro.  
Epigallocatechin-3-O-gallate (EGCG) is one of the major polyphenols found in 
green tea. Epidemiological studies continue to suggest that there may be significant 
health benefits associated with drinking green tea (Saito et al., 2015). Further 
research has identified potent antioxidant, chemopreventive and anti-tumour 
activity from EGCG. EGCG pre-treatment prevented atrophy in C2C12 myotubes 
exposed to increased levels of TNF-α, by reducing protein synthesis and increase 
in protein degradation (Mirza et al., 2014). In vivo studies have shown that EGCG 
to improves muscle function in dystrophic mdx5Cv mice (Dorchies et al., 2006) 
and reduces contractile dysfunction in unloaded skeletal muscle (Ota et al., 2011). 
Resveratrol (trans-3,4',5-trihydroxystilbene) is a non-flavonoid polyphenolic 
compound with natural antioxidant properties. Resveratrol is one of the most widely 
studied phenolic acids and has been associated with numerous health benefits 
including anti-inflammatory and antioxidant activities. Both in vivo and in vitro 
studies using nutritionally relevant concentrations of resveratrol demonstrated the 
ability of resveratrol to inhibit inflammatory processes, including activation of NF-
κB and the expression inflammatory genes in human monocyte (THP-1) and 
macrophage (U937 and RAW 264.7 cells) cell lines (Tsai et al., 1999, Holmes-
McNary and Baldwin, 2000, Yamamoto and Gaynor, 2001). Analysis of cellular 
cytokine release revealed that pre-treatment with resveratrol reduced the secretion 
of CCL2, IL-6 and IL-8 by HASMCs stimulated with LTA (lipoteichoic acid) 
(Knobloch et al., 2014).  
There are no published findings regarding the effect of curcumin, resveratrol or 
EGCG on cytokine release by muscle cells.  
 
3.1.2 Hypothesis 
 
Treatment of C2C12 myotubes with TNF-α results in cytokine release and this can 
be altered by pre-treatment of cells with polyphenols. 
 
 
3.1.3 Aims 
 
The current chapter aims to:  
 Validate and expand a model of TNF-α treatment of murine C2C12 
myotubes to induce release of cytokines without significant cell death.  
 Determine the effect of a range of concentrations of TNF-α exposure for up 
to 24 hours on cytokine release from C2C12 myotubes. 
 Identify an appropriate concentration of resveratrol, curcumin and EGCG 
which does not result in death of murine C2C12 myotubes.  
 Determine the effect of pre-treatment of C2C12 myotubes with resveratrol, 
curcumin or EGCG on TNF-α induced cytokine release.  
 
 
3.2 Methods  
 
3.2.1 Establishment of a suitable time course and concentration of TNF-α 
treatment in C2C12 myotubes 
 
Murine C2C12 myoblasts (Yaffe and Saxel, 1977) were grown in 6 well plates 
tissue culture (Costar, UK).  Myoblasts were seeded at 1x105 cells/well in 10% 
FBS, DMEM as described in Section 2.1. Upon reaching 60-70% confluence, cells 
were differentiated into myotubes in growth media supplemented with 2% HS over 
a 6-day period; cellular differentiation was assessed periodically over the duration. 
Following 6 days in differentiation media, myotubes were treated with 1, 5 and 
25ng/ml endotoxin free TNF-α (murine) (Research and Development Systems, 
Oxford, UK) and myotubes were examined at 3, 8 and 24 hours.  
3.2.2 Choice of concentration of TNF-α 
 
The choice of TNF-α concentrations (as shown in Table 3.1) used in this study was 
consistent with previous work from our research group which reported an increase 
in cytokine release from C2C12 myotubes at 3 hours following exposure to 25ng/ml 
TNF-α for 3 hours (Lightfoot et al., 2015).  
 
Time Point TNF-α Treatment 
3 hrs 
Control 1ng/ml 5ng/ml 
 
25ng/ml 8hrs 
24hrs 
 
Table 3.1 Cell Treatments - Time course and concentration of TNF-α treatment to 
C2C12 myotubes at 6-days following the addition of differentiation media. 
  
3.2.3 Assessment of C2C12 myotube viability in response to TNF-α  
 
Cellular viability was assessed using light-microscopy to identify any gross changes 
in cell morphology at 3, 8 and 24 hours post TNF-α treatment. A LIVE/DEAD assay 
(Invitrogen, UK) was carried out, as described in Section 2.1.5 to assess cellular 
necrosis in a semi-quantitative manner. Fluorescent confocal microscopy was used 
to visualise cell death. Observed changes in the % of necrotic cells were used as 
marker of cell viability.  
3.2.4 The effect of TNF-α on cytokine release from C2C12 myotubes  
 
The release of cytokines from C2C12 myotubes was assessed using bead based 
multiplex technology. A Bioplex® 200 Luminex immunoassay was used to analyse 
cell culture media and myotube homogenates for the presence of cytokines (Bio-
Rad, Hercules, USA) as described in Section 2.3. At each respective time point, 
cyokine levels released into the cell culture media from TNF-α treated myotubes 
was compared with media from untreated control cells. Cytokine levels in cell 
culture media was quantified at 3, 8 or 24 hours from myotubes exposed to 1ng/ml, 
5ng/ml or 25ng/ml TNF-α. 
3.2.4 The effect of TNF-α on cytokine levels in C2C12 myotubes  
Cytokine content of C2C12 myotubes was assessed using bead based multiplex 
technology. A Bioplex® 200 Luminex immunoassay was used to analyse 
homogenised cell samples re-suspended in PBS. Intracellular cytokine levels were 
normalised to total cellular protein, quantified using the BCA protein assay as 
described in Section 2.4.3. 
3.2.5 Establishment of a suitable time course and concentration of polyphenol 
treatment in C2C12 myotubes 
 
At six days following the addition of differentiating media, C2C12 myotubes were 
exposed to single polyphenol treatment (1 or 10μM curcumin, EGCG or resveratrol 
dissolved in DMSO) for 24 hours (Howells et al., 2007). DMSO was used as a 
vehicle carrier for all polyphenols due to the hydrophobic nature of EGCG and 
curcumin. Resveratrol can be dissolved in water or DMSO, however, to maintain 
uniformity across all treatment groups; DMSO was used for all three polyphenols. 
Polyphenol containing media was discarded and replaced with fresh differentiation 
media containing carrier free recombinant TNF-α (5 or 25ng/ml) for 24 hours. 
Media was aspirated and stored for future analysis of cytokine content by Luminex® 
and cells were harvested in DPBS on ice and centrifuged at 14,000g, 4°C for 10 
minutes. Cell pellets were stored at -80°C for analysis by western blotting, qPCR 
and Luminex®. 
3.2.6 Choice and concentrations of polyphenols  
 
The choice of polyphenol concentrations used in our study were 1µM and 10µM. 
This was in agreement with previous work from our research group investigating 
the effect of polyphenols and polyphenolic acids on immune cells (Ford et al., 2013) 
and in vitro polyphenol interventions (Wuyts et al., 2005). In this study, we used 
concentrations which were within the reported physiological range (Howells et al., 
2007, Nicholson et al., 2010). Similar concentrations to those used in this study 
have been reported to reduce the release of pro-inflammatory cytokines through the 
down regulation of inflammatory signalling pathways (Gupta et al., 2014).  
 
3.2.7 Pre-treatment of C2C12 myotubes with curcumin, EGCG or resveratrol 
prior to treatment with TNF-α  
 
At six days following the addition of differentiating media, C2C12 myotubes were 
treated with 1 or 10µM curcumin, resveratrol or ECGC (Epigallocatechin-3-O-
gallate) for 24 hours prior to treatment with TNF-α. Cells and cell media were 
harvested 24 hours after treatment with TNF-α. 
 
3.3 Results  
 
3.3.1 The effects of TNF-α on cytokines released by C2C12 myotubes 
 
All concentrations of TNF-α induced a significant release of the cytokines IL-6, 
CXCL1 (KC), CCL2 (MCP-1) and CCL5 (RANTES) into cell culture media when 
compared with control wells.  
Results showed a general trend in cyokine release in reponse to TNF-α treatments 
(Figures 3.1 to 3.4) whereby the increase in cytokine release appeared to be doses 
and time dependent. Data demonstrated that muscles released IL-6, CXCl1, CCL2 
and CCl5 in response to treatment with TNF-α in C2C12 cells (Figure 3.2 – 3.5).  
 
 
 
Figure 3.2 Level of IL-6 in cell cuture media from C2C12 myotubes at 3, 8, 24 
hours following treatment with 1, 5 and 25ng/ml of TNF-α. Data are presented as 
mean ± SEM (n=6) *p ≤ 0.05 compared with untreated controls for the same time 
point.  
 Figure 3.3 Level of CXCL1 (KC) in cell cuture media from C2C12 myotubes at 3, 
8, 24 hours following treatment with 1, 5 and 25ng/ml of TNF-α. Data are presented 
as mean ± SEM (n=6) *p ≤ 0.05 compared with untreated controls for the same time 
point. 
 
Figure 3.4 Level of  CCL2 (MCP-1)  in cell cuture media from C2C12 myotubes 
at 3, 8, 24 hours following treatment with 1, 5 and 25ng/ml of TNF-α. Data are 
presented as mean ± SEM (n=6) *p ≤ 0.05 compared with untreated controls for the 
same time point. 
 Figure 3.5 Level of  CCL5 (RANTES) in cell cuture media from C2C12 myotubes 
at 3, 8, 24 hours following treatment with 1, 5 and 25ng/ml of TNF-α. Data are 
presented as mean ± SEM (n=6) *p ≤ 0.05 compared with untreated controls for the 
same timepoint. 
3.3.2 The effect of polyphenol treatment alone on the release of cytokines from 
C2C12 myotubes 
 
10µM Polyphenol Treatments  
C2C12 myotubes exposed to 10μM resveratrol alone for 24 hours did not elicit an 
increase in secretion of IL-6, CXCL1 (KC), CCL2 (MCP-1) and CCL5 (RANTES) 
into cell culture media (Figures 3.6 to 3.9). Media harvested from C2C12 myotubes 
treated with 10μM curcumin or 10μM EGCG at 24 hours had secreted significantly 
higher levels of IL-6, CXCL1 and CCL5 into the media compared with untreated 
or DMSO treated control cells. Media collected at 24 hours from DMSO 
(polyphenol vehicle carrier) treated cells revealed no difference in cytokine levels 
to media collected from untreated control cells.  
 
 
Figure 3.6 Levels of IL-6 in cell culture media from C2C12 myotubes at 24 hours 
following 25ng/ml of TNF-α and 10µM resveratrol, 10µM EGCG, 10µM curcumin. 
Data presented as mean ± SEM (n=6) *p ≤ 0.05 compared with untreated control 
cells.  
 Figure 3.7 Levels of CXCL1 (KC) in cell culture media from C2C12 myotubes at 
24 hours following 25ng/ml of TNF-α and 10µM resveratrol, 10µM EGCG, 10µM 
curcumin. Data presented as mean ± SEM (n=6) *p ≤ 0.05 compared with untreated 
control cells.  
 
 
Figure 3.8 Levels of CCL2 (MCP-1) in cell culture media from C2C12 myotubes 
at 24 hours following 25ng/ml of TNF-α and 10µM resveratrol, 10µM EGCG, 
10µM curcumin. Data presented as mean ± SEM (n=6) *p  ≤ 0.05 compared with 
untreated control cells. 
 Figure 3.9 Levels of CCL5 (RANTES) in cell culture media from C2C12 myotubes 
at 24 hours following 25ng/ml of TNF-α  and 10µM resveratrol, 10µM EGCG, 
10µM curcumin. Data presented as mean ± SEM (n=6) *P ≤ 0.05 compared with 
untreated control cells. 
 
1µM Polyphenol Treatments  
There was no difference in the cytokine levels in media of Il-6, CXCL1, CCL2 and 
CCL5 harvested at 24 hours from cells treated with 1µM polyphenols compared 
with cytokine levels in media from control, untreated wells (Figures 3.10 to 3.13).  
 
 
Figure 3.10 Levels of IL-6 in cell culture media from C2C12 myotubes at 24 hours 
following 25ng/ml of TNF-α, DMSO , 1µM resveratrol, 1µM EGCG, 1µM 
curcumin. Data presented as mean ± SEM (n=6) *p ≤ 0.05 compared with untreated 
control cells.  
 
 
Figure 3.11 Levels of CXCL1 (KC) in cell culture media from C2C12 myotubes at 
24 hours following 25ng/ml of TNF-α, DMSO and 1µM Resveratrol, 1µM EGCG, 
1µM Curcumin. Data presented as mean ± SEM (n=6) *p ≤ 0.05 compared with 
untreated control cells.  
 
Figure 3.12 Levels of CCL2 (MCP-1) in cell culture media from C2C12 myotubes 
at 24 hours following 25ng/ml of TNF-α, DMSO and 10µM resveratrol, 10µM 
EGCG, 10µM curcumin. Data presented as mean ± SEM (n=6) *p ≤ 0.05 compared 
with untreated control cells. 
  
Figure 3.13 Levels of CCL5 (RANTES) in cell culture media from C2C12 
myotubes at 24 hours following 25ng/ml of TNF-α, DMSO  and 10µM resveratrol, 
10µM EGCG, 10µM curcumin. Data presented as mean ± SEM (n=6) *p ≤ 0.05 
compared with untreated control cells. 
3.3.3 The effect of 1μM curcumin and 1μM EGCG pre-treatment on TNF-α 
induced cytokine release from C2C12 myotubes 
 
Release of IL-6, CXCL1, CCL2 and CCL5 was significantly greater from C2C12 
myotubes at 24 hours following treatment of cells with 25ng/ml TNF-α in 
comparison with cytokine release from untreated control cells. Treatment of C2C12 
myotubes with the polyphenols curcumin (1µM) or EGCG (1µM) had no effect on 
the release of IL-6, CXCL, CCL2 and CCL5 from C2C12 myotubes at 24 hours 
compared with untreated control cells (Figures 3.14 to 3.17). Prior treatment of cells 
with polyphenols curcumin or EGCG had no effect on TNF-α induced release of  
IL-6, CXCL1, CCL2 and CCL5 release from C2C12 myotubes with the exception 
of EGCG which significantly reduced CXCL media content (P=0.04) (Figures 3.14 
to 3.17). 
 
Figure 3.14 Levels of IL-6 in cell culture media from C2C12 myotubes at 24 hours 
following treatment with 25ng/ml of TNF-α, 1µM EGCG or 1µM curcumin for 24 
hours and culture media from C2C12 myotubes at 24 hours following treatment 
with 1µM EGCG or 1µM curcumin pre-treatment for 24 hours followed by 25ng/ml 
of TNF-α for 24 hours. Data presented as mean ± SEM (n=6) *p ≤ 0.05 compared 
with with 25ng/ml of TNF-α. 
Figure 3.15 Levels of CXCL1 (KC) in cell culture media from C2C12 myotubes at 
24 hours following treatment with 25ng/ml of TNF-α, 1µM EGCG or 1µM 
curcumin for 24 hours and culture media from C2C12 myotubes at 24 hours 
following treatment with 1µM EGCG or 1µM curcumin pre-treatment for 24 hours 
followed by 25ng/ml of TNF-α for 24 hours. Data presented as mean ± SEM (n=6) 
*p ≤ 0.05 compared with with 25ng/ml of TNF-α. 
 
Figure 3.16 Levels of CCL2 (MCP-1) in cell culture media from C2C12 myotubes 
at 24 hours following treatment with 25ng/ml of TNF-α, 1µM EGCG or 1µM 
curcumin for 24 hours and culture media from C2C12 myotubes at 24 hours 
following treatment with 1µM EGCG or 1µM curcumin pre-treatment for 24 hours 
followed by 25ng/ml of TNF-α for 24 hours. Data presented as mean ± SEM (n=6) 
*p ≤ 0.05 compared with with 25ng/ml of TNF-α. 
 Figure 3.17 Levels of CCL5 (RANTES) in cell culture media from C2C12 
myotubes at 24 hours following treatment with 25ng/ml of TNF-α, 1µM EGCG or 
1µM curcumin for 24 hours and culture media from C2C12 myotubes at 24 hours 
following treatment with 1µM EGCG or 1µM curcumin pre-treatment for 24 hours 
followed by 25ng/ml of TNF-α for 24 hours. Data presented as mean ± SEM (n=6) 
*p ≤ 0.05 compared with with 25ng/ml of TNF-α. 
 
 
3.3.4 The effect of resveratrol on TNF-α induced cytokine release from C2C12 
myotubes 
 
Media concentrations of IL-6, CXCL1 and CCL5 were significantly lower from 
cells pre-treated with 1µM resveratrol for 24 hours prior to treatment with 25ng/ml 
of TNF-α when compared with cells treated with 25ng/ml TNF-α (Figure 3.18 to 
3.21). Prior treatment of cells with 1µM resveratrol had no effect on TNF-α induced 
MCP-1 release from C2C12 myotubes. 
 Figure 3.18 Levels of of IL-6 in cell culture media from C2C12 myotubes at 24 
hours following a treatment with 1µM resveratrol for 24 hours prior to treatment of 
25ng/ml of TNF-α for 24 hours. Data presented as mean ± SEM (n=6) p≤0.05.  
 
 
Figure 3.19 Levels of of CXCL1 (KC) in cell culture media from C2C12 myotubes 
at 24 hours following a treatment with 1µM resveratrol for 24 hours prior to 
treatment of 25ng/ml of TNF-α for 24 hours. Data presented as mean ± SEM (n=6) 
p≤0.05. 
 Figure 3.20 Levels of of CCL2 (MCP-1) in cell culture media from C2C12 
myotubes at 24 hours following a treatment with 1µM resveratrol for 24 hours prior 
to treatment of 25ng/ml of TNF-α for 24 hours. Data presented as mean ± SEM 
(n=6) p≤0.05. 
 
 
Figure 3.21 Levels of of CCL5 (RANTES) in cell culture media from C2C12 
myotubes at 24 hours following a treatment with 1µM resveratrol for 24 hours prior 
to treatment of 25ng/ml of TNF-α for 24 hours. Data presented as mean ± SEM 
(n=6) p≤0.05. 
3.3.5 The effect of resveratrol pre-treatment on the viability of TNF-α treated 
C2C12 myotubes  
 
Little cell death was seen between control C2C12 myotubes and myotubes treated 
with 25ng/ml of TNF-α for 24 hours, 1µM resveratrol for 24 hours, or 1µM 
resveratrol for 24 hours followed by a treatment of 25ng/ml of TNF-α for 24 hours 
(Figure 3.21).  
 
 
Figure 3.22 Representative LIVE/DEAD images of C2C12 myotubes. (A) 
Untreated C2C12 myotubes, (B) myotubes at 24 hours following treatment with 
25ng/ml of TNF-α, (C)  mytoubes at 24 hours following treatment with 1µM 
resveratrol and (D) mytoubes at 24 hours follwing treatment with 1µM resveratrol 
for 24 hours followed by a treatment of 25ng/ml of TNF-α for a further 24 hours. 
Calcein-AM ester enters live cells staining them green while ethidium enters 
necrotic cells and stains red. Representative confocal microsopy image for each 
treatment.  
 
3.3.6 Intracellular cytokine content of C2C12 myotubes pre-treated with 1µM 
resveratrol for 24 hours followed by a 25ng/ml TNF-α for 24 hours   
 
Data revealed no difference in the level of IL-6, CCL2 and CCL5 between treatment 
groups (Figure 3.23). No detectable levels of KC were reported in any groups. All 
replicates for each treatment were out of range; i.e. less than the lowest standard.  
 
 
 
A 
C 
B 
 Figure 3.23 Levels of IL-6 (A), CCL2 (MCP-1) (B) and CCL5 (RANTES) (C) in 
C2C12 myotubes at 24 hours following exposure to TNF-ɑ (25ng/ml) for 24 hours, 
1uM resveratrol, or combined individual treatments. Data were normalised to total 
cellular protein and presented as mean ± SEM (n=6) *p≤0.05 compared with control 
cells. 
 
3.4 Discussion  
 
The work presented in this chapter describes the effect of polyphenol pre-treatment 
on TNF-α induced cytokine release from C2C12 myotubes. Initial work focussed 
on the development of a suitable treatment course of TNF-α on C2C12 myotubes 
to stimulate the release of pro-inflammatory cytokines which could then be used to 
assess the effect of polyphenols on TNF-α induced cytokine release. 
 Since the early work identifying muscle as a source of cytokines (Pedersen et al., 
1998), large gene-array screening has been used to determine the expression of 
inflammatory genes in skeletal muscle (Bhatnagar et al., 2010). Previous work from 
our group revealed an increase in the release of IL-6, CXCL-1 (KC), CCL2 (MCP-
1) and CCL5 (RANTES) from C2C12 myotubes at 3 hours following treatment of 
myotubes 25ng/ml TNF-α (Lightfoot et al., 2015). This chapter has confirmed and 
expanded these observations, to demonstrate that C2C12 myotubes treated with 1, 
5 and 25ng/ml TNF-α for 3, 8 or 24 hours all showed an increase in the release of 
IL-6, CXCL-1 (KC), CCL2 (MCP-1) and CCL5 (RANTES) into cell media while 
cell viability was maintained.  
This chapter examined the effects of polyphenol pre-treatments on TNF-α induced 
cytokine release by muscles. The study investigated the effects of 1µM and 10µM 
curcumin, EGCG and resveratrol on TNF-α mediated cytokine release from C2C12 
myotubes. Polyphenols were chosen following a literature search identifying these 
polyphenols as they are associated with the modulation of cytokines in vitro (Jobin 
et al., 1999, Lacomis, 2000, Conover et al., 2006). Treatment of cells with 
concentrations of 10µM curcumin, EGCG or resveratrol had no effects on TNF-α 
induced cytokine release with curcumin and EGCG treatments alone causing an 
increase in cytokine release suggesting a pro-inflammatory effect of these 
polyphenols. These polyphenols may be potentially stressors of the cells exerting a 
pro-oxidant effect thus increasing cytokine release. Potential reasons behind these 
effects of curcumin and EGCG on cytokine release from muscle may relate to the 
differences in chemical structure. The study identified 1µM resveratrol as a 
modulator of TNF-α induced cytokine release with a reduction in the release of IL-
6, CCL2 (MCP-1) and CCL5 (RANTES) from C2C12 myotubes. Neither TNF-α 
or 1µM resveratrol treatments caused any gross or apparent effects on myotube 
viability. Intracellular levels of cytokines were unchanged in C2C12 myotubes 
treated with TNF-α or myotubes pre-treated with resveratrol prior to TNF-α 
treatment in comparison to control mytoubes. These data suggests that the cytokines 
produced by cells in response to TNF-α are rapidly exported from the cells. A 
potential mechanism by which this concentration of resveratrol (1µM) exerts these 
effects may be through the down regulation of inflammatory regulators. Pro-
inflammatory cytokines and chemokines are under the transcriptional control of the 
ubiquitous inducible factor named nuclear factor-κB (NF-κB) (Chen et al., 1999). 
This is supported by data showing that pre-treatment of myotubes with sodium 
salicyate (as an inhibitor NF-kB activation) prevented the increase in cytokine 
release mediated by TNF-α (Lightfoot et al., 2015). Data from the current study 
suggests that the reduction in media levels of cytokine from myotubes pre-treated 
with resveratrol was not a result of impaired mechanisms associated with golgi-
mediated release of peptides from myotubes as there was not an accumulation of 
intracellular cytokines. These data are supported by other work which has assessed 
the effects of pre-treatment of mytotubes with Brefeldin A (BFA) prior to treatment 
with TNF-α. BFA indirectly inhibits protein transport from the endoplasmic 
reticulum to the golgi apparatus and pre-treatment also resulted in reduced release 
of cytokines from TNF-α treated myotubes.  
The mechanisms of cytokine production from skeletal muscle are poorly 
understood and understanding of the physiological relevance of cytokine release by 
muscle also remains unclear. Skeletal muscle is the largest organ system and protein 
store in the human body. The generation of skeletal muscle cytokines may 
potentially have a significant impact upon systemic inflammation (Raj et al., 2005, 
Lightfoot, 2011).  
Studies show an association between reduced muscle function and fatigue and 
elevated cytokine levels (Gan et al., 2004, McMillan, 2013). Raised local and 
systemic levels of pro-inflammatory cytokines may act as inhibitory modulators of 
muscle force production, particularly Tumour Necrosis Factor-α (TNF-α) through 
a cascade of events including raised levels of ROS (Reid and Moylan, 2011).  
The clinical relevance of studies that examine the effects of polyphenols such as 
EGCG, resveratrol and curcumin on in vitro cell cultures is limiting.  The work in 
this chapter highlights resveratrol as a potential modulator of cytokine release and 
supports previous epidemiological studies which suggest that increased levels of 
dietary polyphenols are associated with reduced systemic inflammation and we 
propose that this may in turn alleviate muscle dysfunction. Caution should be taken 
in the interpretation of studies assessing the direct effect of polyphenols on cells in 
vitro. Unlike many polyphenols, resveratrol has been detected in plasma or serum 
following oral administration at a level of ≤ 2% (Goldberg et al., 2003, Wenzel and 
Somoza, 2005).   
 The next stage of this work would be to identify the mechanisms through which 
resveratrol attenuates TNF-α induced cytokine release. Reports have shown that 
C2C12 myotubes treated with TNF-α have increased levels of ROS production 
(Lacerda et al., 2006). As mentioned in Section 1.5, there are 5 main sources of 
ROS production within the cell: cyclo-oxygenase-2 (COX-2), xanthine oxidase, 
reduced nicotinamide adenine dinucleotide/nicotinamide adenine dinucleotide 
phosphate oxidase system (NADPH oxidase), nitric oxide synthase and 
mitochondrial ROS, however the exact source of ROS in TNF-α treated cells is yet 
to be fully characterised although evidence suggests that TNF-α may alter 
mitochondrial electron transport chain function resulting in increased mitochondrial 
ROS production (McLean et al., 2013).   
Evidence for a role of mitochondrial ROS production in the mechanisms by which 
TNF-α mediates its effects comes from studies where prior SS31 treatment resulted 
in the attenuation of TNF-α induced cytokine release from C2C12 myotubes 
(Lightfoot et al., 2015). SS31 is an antioxidant peptide that accumulates on the inner 
mitochondrial membrane thus targeting mitochondrial ROS production. From these 
and the current data we hypothesis that the effects of resveratrol in attenuating TNF-
α mediated cytokine release from muscle cells may be due to the potential 
antioxidant properties of this compound. However further work is needed to 
confirm this.  
 
 
Figure 3.24 Schematic diagram illustrating the potential mechanism through 
which resveratrol exerts effects.   
3.5 Summary   
 
This study successfully:  
 Validated and expanded the effect of TNF-α treatments on cytokine release 
from murine C2C12 myotubes. 
 Assessed the effects of varying concentrations of TNF-α exposure for up to 
24 hours on cytokine release from C2C12 myotubes.  
 Developed a suitable model of resveratrol, curcumin and EGCG polyphenol 
treatments on C2C12 myotubes. 
 Identified the polyphenol resveratrol as capable of altering the effects of 
TNF-α on skeletal muscle by attenuating TNF-α induced cytokine release. 
In summary, resveratrol might be helpful in understanding conditions where 
elevated cytokines may be associated with aspects of muscle dysfunction and 
fatigue such as chronic fatigue syndrome (CFS).   
  
 
 
 
 
 
 
 
 
 
 
Chapter Four 
Skeletal muscle function in patients with CFS 
 
  
4.1 Introduction  
 
Patients with chronic fatigue syndrome (CFS) are a highly heterogeneous group of 
sufferers reporting complex and multifactorial aetiologies which manifest in similar 
symptoms. Sufferers of CFS describe a wealth of different symptoms and potential 
causes/triggers with each case of CFS being unique (Section 1.6). A common factor 
between all patients is the symptom of recurrent or persistent fatigue/exhaustion 
(including descriptions of both mental/cognitive fatigue and outer limb/muscular 
sensations of fatigue) at rest which is exacerbated by physical exertion and exercise 
resulting in severe post-exertional fatigue. This is the only compulsory symptom 
for diagnosis within the majority of CFS diagnostic criteria/guidelines (Holmes et 
al., 1988, Fukuda et al., 1994, Sharpe et al., 1991). The use of the term fatigue by 
patients with CFS is a generalised perception of their health or well-being, which is 
potentially unrelated to any objective markers of impaired physical health; such as 
compromised contractile function and fatigue within the muscle. The range of 
symptoms exhibited by patients with CFS may plausibly be associated with altered 
skeletal muscle function; these symptoms include restless legs, muscle twitching, 
muscle pain (myalgia) and the overall sensation of reduced functional capacity 
(Vercoulen et al., 1994, Afari and Buchwald, 2003). The relationship between 
increased sensation of fatigue in patients with CFS and the functioning and skeletal 
muscle physiology has not yet been fully elucidated. Inconsistencies are commonly 
found in a large proportion of studies into CFS and this includes there are 
discrepancies in the data from muscle function and physical activity assessments in 
these patients (Lloyd et al., 1988, Stokes et al., 1988, Lloyd et al., 1991, Gibson et 
al., 1993, Paul et al., 1999).  
The sensation of weakness and fatigue is typical following vigorous exercise in all 
individuals regardless of health (Boerio et al., 2005). The decline in muscle 
contractile force during repeated contractions was originally thought to be a result 
of muscle cell dysfunction (peripheral fatigue) only, however there is also evidence 
to suggest a relationship between central impairment (central motor drive and force 
output) in healthy individuals which occurs from feedback from fatiguing muscles 
to the brain (Amann et al., 2008).  
The process which leads to muscle contraction includes a combination of central 
and peripheral signalling (full schematic representation of the chain of command in 
muscle contraction shown in Figure 1.2.2, (Kent-Braun, 1999). A failure at any 
point in the process can lead to a decline in force generation or failure to elicit 
muscle contraction (Westerblad et al., 1991, Allen et al., 2008). The causes of 
fatigue may be classified as central or peripheral (Gandevia, 2001). Central fatigue 
is due to failure of neural drive and may result from lack of motivation, from 
impaired firing frequency at or proximal to the anterior grey column, or from 
impaired recruitment of motor units. Peripheral fatigue results from failure at or 
beyond the neuromuscular junction. These include factors such as metabolic 
depletion, the accumulation of intramuscular metabolites, excitation contraction 
coupling failure (Kent-Braun, 1999). The rate of fatigue varies between different 
muscle groups, as a result of fibre type composition, mitochondrial density and 
motor neuron innervation (Enoka and Duchateau, 2008).  
A lack of formal definition for general fatigue hinders researchers and leads to the 
formation of study specific definitions resulting in a lack of comparability between 
studies (Aaronson et al., 1999). The current work has focussed on muscle fatigue 
which is defined as a failure to maintain a required force or output of power during 
sustained or repeated muscle contractions (Allen et al., 2008). Functional 
assessment using a combination of voluntary contractile assessment and 
involuntary contractile force (using percutaneous electrostimulation) allow 
researchers to assess contractile properties of skeletal muscle more closely and 
helps decipher between reductions in central and peripheral driven force (Edwards 
et al., 1977b).  
A high proportion of patients with CFS report extreme fatigue/exhaustion 
particularly in the arms and legs both at rest and following physical activity (Hickie 
et al., 2006). The functional assessment of muscle contraction in patients with CFS 
(PVFS, PVF and Effort Syndrome) has been recurrent since the 1980’s (Lloyd et 
al., 1988, Stokes et al., 1988, Vos-Vromans et al., 2013). These studies have 
reported mixed results as to whether skeletal muscle function is altered/impaired in 
CFS patients. 
A study (Gibson et al., 1993) in which voluntary and involuntary (stimulated 
contraction) muscle function of the quadriceps femoris was assessed by 
dynamometry revealed both patients with CFS and HCs were able to produce 
maximal contractile force. There was no significant difference in MVC force 
between patients with CFS and HCs. A minority of patients with CFS required 
twitch interpolation to reach maximal force. Following a voluntary incremental 
exercise test until exhaustion using a cycle ergometer, five minutes post exercise, 
MVC force was lower in both groups with no significant difference in MVC force 
reduction between patients with CFS and HCs. The ability to reproduce pre-
exercise MVC force was recovered in both groups at 24 hours post-exercise. 
Patients with CFS had higher perceived exertion scores during the incremental 
exercise test (Gibson et al., 1993). Further evidence supporting a potential central 
limiting factor in muscle function in patients with CFS is present by (Stokes et al., 
1988). These authors reported no difference in contractile properties of muscle in 
patients (classified is the study as sufferers of “Effort Syndrome” - patients with a 
history of excessive general and muscular fatigue but no evidence of neuromuscular 
disease on clinical, biochemical, histological, or histochemical examinations). 
Voluntary maximal isometric strength measurements of the quadriceps femoris in 
the patient cohort fell below that of the authors' expected normal range except in a 
minority of subjects who had evidence of impaired central motor drive (Edwards et 
al., 1977b). A voluntary resistance exercise to exhaustion test using a cycle 
ergometer revealed an inability of some patients with Effort Syndrome to reach 
their predicted maximum heart rate. These data correlated with the inability of 
individuals to reach their MVCs. Involuntary muscle function of the adductor 
pollicis was assessed through direct electrical stimulation of the motor nerve 
(stimulation in the absence of volition). This showed no differences in the 
contractile performance and relaxation rates between patients and control subjects 
suggesting a central impairment in MVC forces (Stokes et al., 1988). Direct 
electrical stimulation of the motor nerve rather than direction stimulation of the 
muscle allows measurement of an impairment in nerve function. These data also 
suggest the absence of any failures in contractile elements of the muscle and 
suggested potential central impairments in muscle function.  
There have been reports of significantly reduced voluntary maximal force in the 
quadriceps of patients with CFS (Paul et al., 1999). However, twitch interpolation 
testing was not included in this study. Further investigation by these authors 
included a fatiguing protocol in which force for all patients with CFS and HCs fell 
during the 18 maximal voluntary contractions. Results revealed no differences in 
absolute changes in peak force or when expressed as a percentage of the initial 
MVC between the patients and control groups. Subjects were also assessed at 24 
hours following the fatigue protocol; absolute changes in force were still 
significantly lower that initial MVC forces in the CFS participants, suggesting an 
inability for patients to recover at the same rate as healthy individuals (Paul et al., 
1999).  
Subtle differences in study outcome may potentially be a consequence of the 
heterogeneity amongst patients with CFS. There may be differences in perceived 
activity effort. There is disparity between studies with regard to the muscle (groups) 
investigated; to date there have been investigations on a number of muscles 
including the anterior tibialis, quadriceps and elbow flexor muscle. Different 
muscle groups fatigue at varying rates. The adductor pollicis predominantly 
composed of type 1 muscle fibres in contrast to the quadriceps which is a 
combination of both fibre types (Round et al., 1984). Skeletal muscle physiology 
also varies between men and women and across age groups. Age and sex matching 
is an important confounder which needs to be considered. For example; age related 
changes in muscle include a reduction in muscle fibre number and fibre cross 
sectional area as well as a reduction in whole muscle and single fibre force 
production (Narici and Maganaris, 2006, Nilwik et al., 2013). Muscle physiology 
and function is highly adaptable to factors such as nutritional status and exercise as 
well as changes in inflammatory and redox environment.  To date, involuntary 
muscle contractile force of the quadriceps muscle has not been assessed during a 
fatigue protocol in patients with CFS. This may help elucidate the role of central 
and peripheral contributors in muscle function in patients with CFS.  
A major issue regarding muscle functional assessment is the effect of physical 
status on the majority of objective measures used in muscle contraction. Despite 
using activity matched or sedentary controls, fitness level may still be significantly 
different to patients CFS. It is questionable as to whether changes in muscle 
function reported in some studies is a consequence or the disease or a secondary 
outcome resulting from reduced physical activity. A number of studies assessing 
habitual physical activity reported lower activity levels in patients with CFS in 
comparison with HCs (Vercoulen et al., 1997). Periods of activity were reportedly 
less intense and were followed by longer episodes of rest (van der Werf et al., 2000). 
However, there is also evidence to suggest there are no differences in habitual 
physical activity between patients with CFS and age and sex matched healthy 
individuals (Evering et al., 2011).  
Underlying questions remain surrounding the physical fitness of patients with CFS 
and whether the condition leads to reduced activity and increased sedentary 
behaviour leading to the deconditioning of numerous health parameters including 
the condition of muscle. A number of studies have investigated physical fitness in 
patients with CFS which in part covers muscle health and function. Robust evidence 
confirms the effects of prolonged bed rest on reduced physical work capacity, 
muscle disuse and musculoskeletal deconditioning (Convertino et al., 1997). 
However, the evidence to suggest that deconditioning is a perpetuating factor in 
CFS remains inconclusive. There is evidence for (Fulcher and White, 2000, De 
Becker et al., 2000) and against (Bazelmans et al., 2001) this hypothesis. Despite a 
lack of robust evidence to suggest a physical ailment or physical deconditioning in 
patients with CFS, physical activity intervention studies are used in CFS therapy. 
Research has focussed on graded exercise therapy (GET) and physical pacing as a 
therapeutic option for patients with CFS (Larun et al., 2015). The evidence to 
support the use of GET and pacing in CFS is mixed given the lack of a formal 
identification of contractile impairments in patients.  
The complex nature of muscle contractile function in different muscle groups has 
resulted in a multifaceted, unclear picture of muscle function in CFS. Mixed reports 
surround both MVC and muscle fatigue with inconsistent data. Further studies are 
warranted to clarify if CFS in associated with altered skeletal muscle function.  
  
4.1.2 Hypothesis  
 
Patients with CFS show greater evidence of fatigue and impaired muscle force 
generation compared with age and sex matched healthy controls. 
 
4.1.3 Aims 
 
The current chapter aims to determine: 
 Maximal voluntary isometric force generation of the quadricep muscle in 
patients with CFS compared with HCs.  
 Force frequency relationship using percutaneous electrical stimulation of 
the quadriceps muscle in patients with CFS compared with HCs. 
  Percentage force reduction during a muscle fatigue protocol in patients with 
CFS compared with HCs.  
 Maximal Ca2+ activated force of single fibres from the VL muscle.  
 
 
 
 
 
  
4.2 Methods 
 
4.2.1 Patient and HC recruitment  
 
Subjects with CFS were recruited through the Merseyside CFS services. All 
subjects were newly diagnosed by clinicians in accordance the Oxford Criteria 
(1990) and recommended NICE guidelines (2007). 95 age and sex matched HCs 
were recruited within the Merseyside area through recruitment posters.  The study 
recruited subjects between 18 and 55 years old, non-ambulatory and non-smoking. 
See Section 2.2 for full details of inclusion and exclusion criteria.  
Following the provision of a blood sample for cytokine analysis and completion of 
questionnaire assessment, subjects were invited to complete an additional, optional 
component of the study which involved muscle function testing. Sixteen HC and 
16 patients with CFS agreed to participate in the muscle function testing (study 
population characteristics are shown in Table 4.1). HCs subjects were matched 
according to the age and sex of CFS patients prior to the completion of the testing. 
 HC CFS 
Sample Acquisition 16 16 
Women 13 13 
Men 3 3 
Age 36.2 ± 2 36.4 ± 2.6 
Height (m) 1.7 ± 0.02 1.7 ± 0.02 
Weight (kg) 69.1 ± 2.6 63.6 ± 4.3 
BMI (kg/m²) 23.9 ± 0.7 23 ± 1.4 
SF-36 Score 29.9 ± 0.1 17 ± 1* 
 
Table 4.1 - Baseline characteristics of study participants completing muscle 
function testing. Height reported in meters (m) and weight reported in kilograms 
(kg). Short form health survey (SF-36) for physical functioning. Data shown as 
average ± SEM. *p ≤ 0.05 compared with HCs. 
  
4.2.2 Questionnaire assessment 
 
The Short Form Health Survey (SF-36) (Version 1.0 - physical functioning section) 
was used to assess functional status and well-being/quality of life. The SF-36 is a 
self-reporting, standardised questionnaire widely used in research (Stewart et al., 
1988). The full questionnaire is presented in thesis appendix (Figure 8.19). Patients 
with CFS and HCs completed the 10 scaled questions in assessment. Low scores 
are indicative of greater disability.  
 
4.2.3 Muscle function testing  
 
Muscle function was assessed using isometric dynamometry and percutaneous 
isometric electromyostimulation using a Biodex isometric dynamometer (Biodex 
Medical Systems Inc. Shirley, NY, USA) (described in Section 2.10). Application 
of these methods have been validated for their use in reliable assessment of force 
production and muscle function (Drouin et al., 2004). Participants were seated with 
a 90° flexion of the hip and non-extendable straps crossing the chest and abdomen 
and across the quadriceps to maximise isolation of the target muscle groups.  
 
4.2.3.1 Maximal voluntary contraction  
 
Once seated in the dynamometer (Section 4.3.3), the angle of knee extension was 
set at 80o (assuming 0o as full extension). Participants were instructed to give 5 
submaximal voluntary isometric contractions, increasing in intensity, before 
providing a maximal voluntary contraction, recorded in newton meters (nm). 
Verbal encouragement was given to all participants and bio-feedback made 
available through projection of the force trace for the participants to view. 
 
4.2.3.2 Percutaneous isometric electromyostimulation 
 
Percutaneous stimulation was applied through surface electrodes, was delivered via 
a BIOPAC systems MP100 stimulator (BIOPAC systems Inc., Santa Barbara, CA, 
USA) and knee extension forces were recorded with a tension compression load 
cell (Tedea-Huntleigh, Vishay Precision Group Inc. Malvern, PA, USA) connected 
to a non-extendable strap attached to the lower leg, approximately 2–3 inches above 
the ankle (malleolus). Information collected from the force transducer was 
visualized and analysed using AcqKnowledge v.3.7.2 software (BIOPAC systems 
Inc. Santa Barbara, CA, USA) (Owens et al., 2014).  
 
4.2.3.3 Force frequency relationship 
 
An electrical stimulus was first delivered at 100 Hz with an amplitude (mA) to elicit 
30% of the participants individual MVC force. Following this, at the determined 
amplitude, 1 second trains of 50, 20 and 10 Hz and a single 1 Hz twitch were 
delivered in a random order to generate a force frequency relationship. 
 
4.2.3.4 Fatigue protocol  
 
For the determination of fatigue resistance, contractions were evoked by 20 Hz, 200 
ms square wave pulses, previously defined to be representative of normal voluntary 
human motor neuron firing rates (Biglandritchie et al., 1979) and thus 
physiologically valid when used to assess the fatigue resistance of human skeletal 
muscle. For every session, the position of the participant in the isometric chair (Lido 
Active, Loredan, Davis, CA, USA) was standardised in accordance with previously 
published guidelines (Morton et al., 2005). Two 3 × 5 inch (8 × 13 cm) oval self-
adhesive stimulating electrodes (Chattanooga, DJO Global, CA, USA) were placed 
approximately 2 inches above the knee joint across the vastus medialis (VM) and 
proximal to the acetabulofemoral joint across the vastus lateralis (VL). Participants 
were required to fully extend and contract the quadriceps to make the muscle body 
more apparent prior to electrode placement to minimise antagonist co-activation, 
although this was not monitored with electromyography during stimulation. Fatigue 
resistance was determined from 2 min repeated stimulation with 20 Hz, 200 ms 
square wave pulses every 750ms (total of 160 evoked contractions equating to 32 
seconds of total stimulation). Fatigue index was calculated as absolute force loss 
from the first stimulated contraction to the final stimulated contraction. 
 
4.2.4 Biopsy procedure 
 
Of these 16 patients and HCs, 11 completed a muscle biopsy procedure. HCs were 
invited to biopsy according to the age and sex of CFS biopsy subjects. A biopsy 
was taken from the Vastus lateralis (VL) muscle of patients with CFS and HCs 
(Section 2.2.5). An Acecut automatic Biopsy system (TSK Laboratory, Oisterwijk, 
Netherlands) was used for each procedure.  The leg area was sterilised with a topical 
antiseptic, (povidone-iodine or chlorhexidine gluconate). The skin and thigh area 
were both anaesthetised with 4ml 2% lidocaine. Three biopsies were collected from 
the muscle from different areas of the VL muscle. 
 HC CFS 
Sample Acquisition (n) 11 11 
Women (n) 9 9 
Men (n) 2 2 
Age (Average ± SEM) 35.8 ± 3.4 35.8 ± 3.5 
SF-36* 30 ± 0 16.2 ± 1.4 
 
Table 4.2 Baseline characteristics of study participants that undertook a muscle 
biopsy (SF-36 - Short Form Health Survey - Physical Activity). *P≤0.05.   
 
Muscle biopsy samples were immediately placed into ice-cold stabilizing buffer A 
composed of 2.77mM CaK2 ethylene glycolbis-(2-aminoethylether)- N,N,N=,N=-
tetraacetic acid (EGTA), 7.23mMK2 EGTA, 6.56mMMgCl2, 0.5mMdithiothreitol 
(DTT), 50mM 2-(N-morpholino)ethanesulfonic acid potassium salt (KMES), 
20mM imidazol, 20mM taurine, 4.3mM Na2 ATP, and 15 mM phosphocreatine, pH 
7.3 at 4°C.  
 
  
4.2.6 Ex vivo single muscle fibre analysis 
 
Single muscle fibres isolated from the vastus lateralis (VL) muscle were maintained 
in ice-cold relax solution, containing 4.5mM MgATP, 1 free Mg2+, 10mM 
imidazole, 2mM EGTA, and 100mM KCl (pH 7.0 at 4°C) (Degens et al., 2010). 
Fibres were treated with 50μg/ml saponin (in relax solution) for 15 minutes on ice 
and then mounted onto an 802D permeabilised fibre apparatus (Aurora Scientific, 
Canada). Skinned myofibres were attached to insect pins and fixed to a 403A 
(5mM) force transducer and 312C length controller, using ultrafine nylon thread 
and maintained in relax solution throughout assembly. Sarcomere length (SL) was 
measured using 900B Video Sarcomere Length (VSL) software (Aurora Scientific, 
Canada). SL was adjusted on each fibre to 2.4-2.6μm, fibre diameter was measured 
at four intervals along the length, and a circular circumference assumed for the basis 
of CSA calculation. Fibres were maximally activated in Ca2+ activating solution 
(pCa 4.5), containing in addition to Ca2+, 4.3mM MgATP, 1 free Mg2+, 20mM 
imidazole, 7mM EGTA, 19.6mM PCr, and 64mM KCl (pH 7.0 at 4°C). Peak force 
was recorded and normalised to fibre CSA (Degens et al., 2010).   
4.3 Results 
 
4.3.1 Clinical characteristics 
 
A cohort of 16 CFS patients and 16 HCs from the main study cohort consented to 
take part in additional muscle function testing. Testing was available to all subjects 
in the main study cohort. 16 HCs and 16 patients with CFS completed the muscle 
function testing. Both groups did not differ significantly in age, height or weight 
(BMI) (Table 4.1). Both groups contained a higher proportion of women; which is 
characteristic of the main study cohort group. Patients with CFS and HCs had a 
mean age of (36.4 ± 2.6 and 36.2 ± 2 years, respectively). The mean height of the 
patients was 1.7 ± 0.02m and 1.7 ± 0.02m for the control group, mean weights were 
63.6 ± 4.3 kg and 69.1 ± 2.1kg, respectively (Table 4.1). 
 
4.3.2 Physical functioning assessment  
 
The physical functioning status of all 16 subjects was assessed using the SF-36 
activity questionnaire. The SF-36 questionnaire performs well in assessing 
functional status and well-being/quality of life in patients with CFS (Buchwald et 
al., 1996). The assessment contains 10 questions. High scores are indicative of 
superior health and less body pain. Control subjects obtained higher scores than the 
patients with CFS (mean 29.9 ± 0.01 vs. 17 ± 1; P < 0.05) indicating impaired 
physical functioning in the CFS patient group (Table 4.1).   
 
4.3.3 Maximal voluntary contractile force   
 
Maximal voluntary force measurements were assessed in all 32 subjects using an 
isokinetic dynamometer. The final analyses on peak torque production included 31 
subjects; results from one CFS subject were excluded due to extremely poor mental 
motivation. The subject was unable to elicit a maximal voluntary contraction and 
force was > 2 SD away from the group average. Subjects were encouraged to 
provide >2 attempts at eliciting maximal voluntary force contraction. Isometric 
maximal voluntary contractile force was lower in subjects with CFS compared to 
HCs (p= 0.02) as shown in Figure 4.1. 
  
 
Figure 4.1 - Maximal voluntary isometric force (nm) of the right knee extensors in 
HCs (n=16) and patients with CFS (n=15). P≤0.05. 
 
4.3.1.2 Electrically stimulated force frequency relationship 
 
Following MVC, all subjects underwent involuntary muscle contraction analysis. 
Quadricep muscle was stimulated to produce a force 30% equivalent to each MVC 
at 1, 10, 20, 50 and 100Hz. The relation between force (relative to 30% MVC) and 
stimulus frequency over the frequency range from 1 to 100 Hz is shown in the force 
frequency curve below (Figure 4.2). There was no difference in force produced 
between patients with CFS and HCs across any of the stimulation frequencies.  
 
 
 Figure 4.2 Electrically stimulated force frequency relationship of the right knee 
extensors in HCs (n=16) and patients with CFS (n=15). The intensity of the applied 
current was set at an amplitude to elicit 30% of the participants MVC force when 
stimulated at 100Hz.  
 
4.3.1.3 Fatigue index  
 
The study further investigated muscle fatigue in CFS subjects and HCs. A fatigue 
index was created by assessing the % loss in force over a 2 minute repeated 
contractile protocol. Results revealed no difference between groups in the 
percentage loss of force over the 2 minute fatiguing protocol (Figure 4.3). Data 
from three subjects were excluded; 1 control and 2 CFS patients due to errors in the 
execution of the protocol.  
 
 Figure 4.3 Fatigue index of the right knee extensors in HCs and patients with CFS 
when subjected to 120 seconds of repeated 1 second, 30 Hz trains interspersed with 
1 second rest. The intensity of the applied current was set to an amplitude which 
would elicit 30% of the participant’s MVC force when stimulated at 100Hz. 
 
4.3.2 Single muscle fibre cross sectional area, force and specific analysis  
 
Finally, to evaluate force generation at the single-fibre level, ex-vivo muscle force 
of single isolated skinned fibres from VL muscle was measured. Cross sectional 
area (CSA) did not significantly differ (p=0.07) between patients with CFS and HCs 
(Figure 4.5).  Maximal Ca2+ activated force (absolute force) was not significantly 
different between patients with CFS and HCs (Figure 4.4). Comparable results were 
observed when maximal Ca2+ activated force was normalised to fibre CSA (Figure 
4.6).  
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 Figure 4.4 Maximum Ca2+ activated tetanic force of isolated single muscle fibres 
from patients with CFS and HCs (n=11). Data presented as mean ± SEM.  
 
Figure 4.5 Single fibre cross-sectional area (CSA) of the vastus lateralis muscle in 
HCs and patients with CFS (n=11). Data presented as mean ± SEM.  
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 Figure 4.6 Maximum Ca2+ activated force in isolated single muscle fibres 
normalised to fibre cross-sectional area in HCs and patients with CFS (n=11). Data 
presented as mean ± SEM.  
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4.4 Discussion  
 
This study investigated functional characteristics of the quadriceps muscle in 
patients with CFS. Patients with CFS reported lower SF-36 scores suggesting 
individuals are limited in performing physical tasks as a consequence of their 
health. Healthy subjects scored highly which suggests no limitations in physical 
functioning with individuals able to perform all activities including the most 
vigorous.  
Previous studies have assessed contractile function in a range of different muscle 
groups. Major differences between muscle groups with regards to fibre typing, 
fatigue resistance, mitochondrial density etc. can often make comparison between 
studies difficult. Results from the current study show that patients with CFS have 
significantly lower MVC force of the quadriceps in comparison with HCs (Figure 
4.1). This supports previous work (Stokes et al., 1988, Paul et al., 1999). 
Physiological characterisation of fatigue as assessed by percutaneous 
electromyostimulation revealed no difference between groups (Figure 4.2). The 
fatiguing of muscle through involuntary contraction of the quadriceps does not 
appear to have been investigated before in CFS. The advantage of percutaneous 
electrostimulaton is the removal of volition. Results revealed no difference in 
muscle fatigue between patients and HCs (Figure 4.3). In other studies, similar 
testing of muscle fatigue using repeated voluntary maximal isometric contractions 
and incremental exercise testing (cycle ergometer) until exhaustion also found no 
difference between patients with CFS and HCs (Gibson et al., 1993, Paul et al., 
1999). This is supported by single fibre specific force analysis; this approach 
allowed force generated by sarcomeric proteins to be assessed independently of 
fibre number, innervation, ATP levels and calcium release (Sartori et al., 2013). 
This study also revealed no difference between patients with CFS and HCs 
suggesting no inherent dysfunction in actin-myosin cross bridge interactions.  
CFS is a heterogeneous group of individuals with individual triggers (including a 
range of physical and psychological traumas) and symptom profiles. Variation of 
CFS diagnostic criteria and populations is widespread in CFS research. This 
undoubtedly contributes to failings to obtain uniformity across findings. Potential 
reasoning behind the difference in MVC data between studies may arise from 
suboptimal effort and motivation from patients in groups who have significantly 
lower MVCs (Stokes et al., 1988, Schillings et al., 2004). Many researchers use the 
addition of percutaneous electromyostimulation (twitch interpolation) which 
superimposes a stimulus at maximal voluntary contraction and aids in the 
differentiation between central and peripheral deficiencies. The development of any 
additional force during twitch interpolation enables researchers to decipher whether 
muscles are capable of producing a maximal contraction or if “effort” is 
submaximal. The benefits of electrical stimulation include assessing muscle 
function independently of volition as shown in previous studies suggesting sub-
maximal effort or a central impairment in CFS subjects (Stokes et al., 1988, 
Schillings et al., 2004). A previous study (Gibson et al., 1993) in which voluntary 
and involuntary (stimulated contraction) muscle function of the quadriceps femoris 
was assessed by dynamometry for both voluntary and stimulated contractions in 12 
patients with CFS and 12 age, sex and physical activity matched controls revealed 
that some subjects were able to produce maximum force however submaximal 
effort was reported in 5 of the 12 patients with CFS when assessed following twitch 
interpolation. Unfortunately, this could not be tested in the current cohort of patients 
with CFS due to the time necessary to familiarise the patients with the twitch 
interpolation technique.  
The majority of muscle function testing uses MVC as an objective marker in 
determining the potential pathophysiology of fatigue in CFS. This type of maximal 
exercise is not generally common to everyday life in these patients (Noonan and 
Dean, 2000). Repetitive, submaximal exercise is more effective in imitating the 
demands of everyday activities on skeletal muscles. Increasing evidence points to 
altered central processing and an increased perception of fatigue during physical 
activity in these patients (Schillings et al., 2004). 
Involuntary force analysis removes any effects of volition on contractile function. 
A lack of difference in force produced at different frequencies suggests no 
difference in the recruitments of motor units between patients with CFS and HCs. 
Average isometric force was slightly lower in the patients with CFS due to the lower 
MVC forces. Direct stimulation of the muscle does not allow for nerve function to 
be assessed. The 2 minute fatiguing protocol used in this study showed a similar 
reduction in muscle force across both HCs and patients with CFS suggesting no 
difference in fatigue resistance between these groups. 
Patients with CFS report extreme feelings of fatigue after minor physical activity 
as well as an inability to perform tasks that were previously achieved with ease. 
This is supported by data showing that patients with CFS reported significantly 
lower physical functioning in the SF-36 score. It would therefore be plausible that 
these individuals have reduced physical activity and a more sedentary life style. 
Further investigation into muscle function in patients with CFS needs to account 
for any variations in muscle physiology and function between subjects who are able 
to continue everyday activities and physical functioning compared with those who 
have reduced their physical activity, are immobilised or those who have non-
specific underlying muscular myopathies which may be causing their symptoms. 
Despite proposals for these measures in the early 1990’s, little research has been 
undertaken taking these issues into consideration (Edwards et al., 1993). In general, 
the relationship between CFS and habitual physical activity levels is unclear. 
Physical activity is an important consideration in patients with CFS given the 
evidence surrounding the effects of prolonged periods of physical inactivity on 
altered on muscle function and physiology. Muscle disuse is characterised by a 
reduction in contractile function and induces changes including a reduction in 
muscle fibre size and protein content through increased rates of degradation and 
reduced protein rates of protein synthesis. To try and reduce the inclusion of patients 
suffering from gross muscle disuse, patients who were non-ambulatory were 
excluded from the current study. Some reports have shown evidence of muscle 
atrophy in patients with CFS reporting a reduction in fibre number and cross-
sectional area (Powers et al., 2005) however there is little evidence to support the 
presence of muscle atrophy across individuals with CFS (Lane et al., 1998).  
The study assessed physical function through the use of the SF-36 score. Physical 
function relates to habitual physical tasks which are generally undertaken in 
everyday life (dressing, bathing, etc.). This is different to physical activity and 
exercise which focusses on defined periods of physical exertion such as walking, 
cycling, running.  The SF-36 score is a good marker of health related function status 
in patients with CFS however it cannot be used to differentiate between the 
severities of fatigue and cannot be used to differentiate between physical activity 
status in subjects (Buchwald et al., 1996).  As expected, patients with CFS were 
found to have impaired physical functioning as a consequence of their health.  
Within the large majority of studies assessing CFS there are often basic errors in 
study design. Recruitment of a comparable control group taking into consideration 
for age, gender, body weight, height and current physical activity level have been 
mixed. A recent systematic review has underlined the uncertainty in this area (Nijs 
et al., 2011). The current study addressed factors including age, gender, body 
weight and height.  
A single exercise test may be insufficient to assess muscle function in CFS patients 
given previous evidence demonstrating functional impairment in participants only 
following repeated exercise testing. A recent study found no significant differences 
between control and CFS patients during the first exercise protocol. However, 
during a second repeated exercise protocol CFS patients achieved significantly 
lower values for oxygen consumption and workload at peak exercise and at the 
anaerobic threshold (Snell et al., 2013). There is a lack of studies investigating 
muscle function fatigue and recovery. Given the presence of post-exertional fatigue 
symptoms in all patients with CFS, further investigations into this area are 
necessary.  
One of the limitations of the current study was that post-exertional fatigue was not 
assessed in the subjects. A study in which subjects performed 18 consecutive 
isometric contractions using a 50% duty cycle (10 seconds contraction/10 seconds 
rest) with a 1 minute rest interval between each contraction and showed no 
difference in absolute changes in peak force or when expressed as a % of the initial 
MVC between the patients and controls groups (Paul et al., 1999). Peak force for 
all subjects fell during the 18 contractions indicating fatigue which was still present 
24 hours following the fatigue protocol. Absolute changes in peak force were 
significantly lower in patients with CFS in comparison with controls. Normalised 
absolute values of MVC at 24 hours following exercise were significantly lower in 
the patient group but not in the control group. 
Further work could include a larger study cohort to allow for greater stratification 
of patients with CFS regarding disease severity and physical activity. This would 
enable researchers to stratify and subgroup patients according to more objective 
marks of physical status and disease severity whilst maintaining a strong sample 
size. Given the extent to which activity status can influence muscle strength and 
physiology, this may be key in establishing the relationship between CFS and 
muscle function which may be otherwise masked by collectively analysing all 
patients in one group. Additionally, the use of transcranial magnetic stimulation 
would aid researchers confirm whether there is a central or peripheral deficit in this 
patient cohort.   
One of the major therapies used in CFS management is graded exercise therapy 
(GET) (Edmonds et al., 2004). Patients are encouraged to participate in a range of 
aerobic exercises such as walking, swimming, cycling or dancing. Exercise 
intensity is dependent on the severity of the CFS. Results from a systematic review 
reveal that patients with CFS who undertook exercise therapy feel less fatigued than 
control participants, have improved physical functioning, sleep and mood (Larun et 
al., 2015). Additional scores of resting systolic blood pressure and net blood lactate 
were investigated in a randomised control trial of graded exercise therapy. 
Following the GET intervention, subjects reported improved scores (Wallman et 
al., 2004).    There was a high dropout rate in some studies which suggests GET 
may not be suitable for all patients with CFS (Powell et al., 2001). Experts within 
CFS research have called for the use of pacing therapy rather than GET to improve 
patient outcome to ensure all severities can be included however this is the topic of 
much debate (White et al., 2011, Shepherd, 2015). There is evidence to suggest 
patients suffering from either psychological illness or physical myopathies, benefit 
from physical exercise has numerous benefits in health related outcomes (Oldervoll 
et al., 2003, Cicek et al., 2015, Lightfoot and Cooper, 2016). The general benefits 
of exercise may result in health related improvements in patients rather than any 
effect of improving any muscle ailments. 
Data presented in this chapter support previous findings that the symptoms of 
fatigue experienced in CFS may be a result of suboptimal motivation and/or 
impaired central processing during muscle contraction and not as a result of 
peripheral abnormalities. Potential peripheral abnormalities may still exist which 
are more subtle in patients with CFS and therefore do not cause a significant 
reduction in objective measures of force production, but may elicit the symptoms 
described by CFS patients. Additionally, peripheral causes of impaired maximal 
voluntary contraction may exist surrounding the function of neuromuscular 
junctions. 
 
  
4.5 Summary   
 
This study successfully identified: 
 Patients with CFS have a reduced maximal voluntary contractile (MVC) 
force in comparison with HCs.  
 Normal force frequency relationship of the quadriceps in patients with CFS 
compared with HCs.  
 No difference in fatigue in patients with CFS compared with HCs. 
 No difference in VL muscle single fibre force generation in patients with 
CFS compared with HCs suggesting no defect in actin-myosin cross bridge 
interactions.  
Further investigations are required to understand the cause of reduced MVC in 
patients with CFS and whether there may be perturbed systemic and/or local 
cytokine levels, skeletal muscle redox homeostasis and mitochondrial function 
which may potentially contribute to a deficit in peripheral neural function.  
  
  
 
 
 
 
 
 
Chapter Five 
Plasma cytokine levels and expression of cytokine genes in 
skeletal muscle of patients with CFS 
 
 
  
 5.1 Introduction  
 
Chronic Fatigue Syndrome (CFS) is a debilitating condition which is characterised 
by an overwhelming sensation of mental and physical fatigue (NICE, 2010). Full 
details of the pathophysiology of CFS are described in Section 1.6.1. CFS 
reportedly affects 0.3 – 2.5% of the population depending on the criteria used to 
diagnose patients (Prins et al., 2006). The diagnosis of patients with CFS occurs 
through the assessment of primary symptoms and the exclusion of other illness or 
diseases. Multiple diagnostic criteria exist for CFS; as described in Section 1.6.2. 
The process through which CFS diagnostic criteria was developed was a result of 
there being no direct, well-characterised biomarkers for CFS.  
Since its early origins, CFS has been proposed to be linked with immune 
dysfunction and viral infections such as glandular fever and Lyme disease (Bansal 
et al., 2012). There have been several similar syndromes described under different 
names, such as post vial syndrome (PVS) and chronic fatigue immune dysfunction 
syndrome (CFIDS) (Archer, 1987, Uchida, 1992). One prospective cohort study 
followed patients infected with Epstein-Barr virus (glandular fever), Ross River 
virus (epidemic polyarthritis) and Coxiella burnetti (Q fever) and reported that 11% 
of individuals suffered from prolonged illness symptoms of 6 months post-
infection. Patients displayed symptoms such as disabling fatigue, musculoskeletal 
pain, mood disturbances and impaired cognitive function (Hickie et al., 2006); all 
of which are commonly present in individuals with CFS. Additional symptoms 
commonly reported by patients with CFS include sore throat, aches and pain 
(fibromyalgia), headaches, tender lymph nodes and neurocognitive disorders, 
disturbed sleep and disrupted thermoregulation (Fukuda et al., 1994). Thus, a large 
number of the symptoms associated with CFS are similar to those associated with 
flu and/or the common cold. This set of “flu-like” symptoms has been termed the 
“sickness behaviour/response” (Morris et al., 2013). The “sickness response” is 
associated with acute infections/injury and the symptoms presented by the patients 
are thought to be mediated through increased expression of a range of pro-
inflammatory cytokines (Dantzer, 2001, Konsman et al., 2002). The presentation of 
flu-like symptoms at the onset of CFS accompanied by evidence showing a high re-
occurrence of bacterial and viral infections in patients with CFS (Chia and Chia, 
2008) has led many researchers to associate CFS with altered immune response and 
perturbed circulating cytokine profiles (Buchwald et al., 1996).  
A detailed overview of the role and function of cytokines and chemokines is 
described in Section 1.3. In brief, cytokines are small intercellular signalling 
molecules, typically polypeptides or proteins, which have the ability to mediate a 
wide-range of cellular functions throughout the body (Kelso, 1998). Cytokines are 
associated with immune regulation and host response to trauma, injury and 
infection (Zhang and An, 2007). Cytokines are intricately involved in a number of 
physiological processes, such as tissue homeostasis, cellular relocation and cell 
cycle regulation; proliferation and differentiation (Austin et al., 1992, Fujigaki et 
al., 2001). Cytokines are produced and secreted by multiple cell types from both 
within and outside of the immune system. Cytokines have the ability to signal to 
both immune and non-immune cells locally and systemically. Cytokine producing 
immune cells include monocytes, macrophages, B and T lymphocytes and NK 
(natural killer) cells (Cooper et al., 2001). Non-immune cells which have been 
identified as cytokine producing cells in response to various stimuli include 
endothelial, fibroblasts, adipose tissue and skeletal muscle (Sironi et al., 1989, 
Hotamisligil et al., 1993, Murwani and Armati, 1998, Pedersen et al., 1998). 
Evidence has shown cytokine levels fluctuate in response to various factors 
including, sleep, physical exercise, stress and anxiety. Gender specific differences 
are also present. Thus, serum cytokines levels vary during different stages of the 
menstrual cycle, pregnancy and between pre and post-menopausal women 
suggesting an association between hormone levels and cytokines (Verthelyi and 
Klinman, 2000).  Given the increased prevalence of CFS in females, there may be 
gender specific changes in cytokines levels in this cohort of patients. 
A number of studies have been published examining altered cytokine levels in 
serum/plasma from patients with CFS (Patarca et al., 1994, Swanink et al., 1996, 
Lattie et al., 2012, Khaiboullina et al., 2015, Hornig et al., 2015). Despite such 
studies, results remain inconclusive. This is demonstrated in a recent systematic 
review, aimed at collectively assessing whether patients with CFS have altered 
circulating cytokine levels, from the results of 38 individual investigations 
(Blundell et al., 2015). The study identified one potential cytokine, TGF-β to be 
modified in patients with CFS.  
A study investigating immune function in patients with CFS revealed reduced 
Natural Killer (NK) cell cytotoxic activity is one of the most predominant and 
consistent outcomes of immunological studies in CFS (Hardcastle et al., 2015). 
Cytokines, IFN-γ, macrophage colony-stimulating factor (M-CSF), IL-10 and IL-
13 are all produced by NK cells an innate immune response (specifically 
CD56bright NK cells) (Fauriat et al., 2010).  
Chapter 3 provided evidence that skeletal muscle can produce and secrete a number 
of cytokines. Although, the full expression profile of cytokines by skeletal muscle 
is unknown (Pedersen, 2011, Lightfoot et al., 2015). Skeletal muscle is the largest 
store of protein in the body and so it is reasonable to hypothesise that muscle could 
be a significant contributor to the overall systemic pool of cytokines in certain 
conditions. However, the direct assessment of muscle as a secretory organ in vivo 
is methodologically difficult; there is no robust way of directly examining the 
ability of muscle to release cytokines. Arteriovenous measures of cytokines have 
been used to assess acute cytokine release post-exercise, but this process is 
complicated by the presence of other cells and tissues, such as adipose tissue and 
endothelium (Korsheninnikova et al., 2002).  
Systemic and local raised levels of inflammatory cytokines can affect both muscle 
function and physiology in a number of ways. Diseases characterised by increased 
levels of pro-inflammatory and reduced levels of anti-inflammatory cytokines can 
drive muscle atrophy through a reduction in protein synthesis and degradation 
resulting in impaired contractile function. This is thought to occur via ROS 
mediated signalling pathways (Reid and Moylan, 2011).  
It is unknown whether there is a link between muscle dysfunction and the flu-like 
symptoms exhibited in patients with CFS. To date, there has been no research in 
the area of muscle cytokine production in patients with CFS despite the widespread 
interest in cytokines and muscle function. This is the first study to assess both 
systemic cytokine levels and cytokine gene expression in muscles of patients with 
CFS.   
5.2 Hypothesis 
 
Low MVC seen in patients with CFS is potentially due to modified levels of 
cytokines either systemically resulting in increased mental fatigue or through local 
peripheral effects on the neuromuscular tissue. 
 
5.3 Aims 
 
The current chapter aims to: 
 Investigate plasma cytokine levels in patients with CFS and compared with 
those of matched HCs.  
 Investigate plasma cytokine levels in female patients with CFS and 
compared with those of matched HCs.  
 Examine cytokine gene expression in skeletal muscle of patients with CFS 
compared with those of matched healthy controls. 
 
  
5.3 Methods  
 
5.3.1 Recruitment of patients and HCs  
 
Full details of the inclusion and exclusion criteria for the study are described in 
Section 2.2. In brief, 95 subjects with CFS were recruited through the Royal 
Liverpool and Broadgreen University Hospital NHS Trust Chronic Fatigue 
Syndrome services. All subjects were diagnosed by clinicians from the Royal 
Liverpool and Broadgreen University Hospital NHS Trust in accordance with the 
Oxford Criteria (1990) and recommended NICE guidelines (2007). Ninety-five age 
and sex matched healthy controls were recruited from within the Merseyside area. 
The study did not recruit subjects over the age of 55 years. Research has reported a 
natural increase in pro-inflammatory cytokines with age which are significantly 
greater in persons ages >55years (Alvarez-Rodriguez et al., 2012). Fifty-five years 
of age was deemed an appropriate cut off to ensure age related increments in 
cytokine levels would not mask any findings associated with CFS. Individuals were 
excluded from the study if they smoked, had a history of substance misuse, or had 
any underlying inflammatory-based medical conditions such a cold/flu, infection, 
arthritis, diabetes, heart disease etc (These factors were reported at the subjects own 
discretion). Upon study consent, CFS subjects provided members of the research 
team access to their NHS medical history records. CFS symptoms were assessed 
upon diagnosis. 
 
 HC CFS 
Women 63 63 
Men 32 32 
Age (Years) 34 ± 1 38 ± 1 
Height (m) 1.7 ± 0.01 1.7 ± 0.01 
Weight (kg) 71.8 ± 1.2 73 ± 1.5 
BMI (kg/m²) 24.5 ± 0.3 25.9 ± 0.4 
Illness Duration (Months) 0 37 ± 4.9 (6-276) 
 Table 5.1: Baseline characteristics of all study participants. Average ± SEM. 
 
5.3.2 Health questionnaire assessment 
 
Patients were obliged to complete a series of health questionnaires (As described in 
Section 2.2). The study included the Chalder Fatigue Questionnaire, Hospital 
Anxiety and Depression Score, The Short Form (36) Health Survey (SF-36) 
physical functioning section and Epworth Sleepiness Scale. These questionnaires 
were included in the NHS CFS assessment pack and were then used in the study. 
Questionnaires were anonymously scored by nurses in the CFS services, Royal 
Liverpool and Broadgreen University Hospital NHS Trust. Questionnaires 
completed by healthy controls and all non-NHS questionnaires were assigned a 
subject code and anonymously scored.  
Chalder Fatigue Questionnaire  
The Chalder Fatigue Questionnaire is an effective measure of fatigue in patients 
with CFS. It is comprised of 11 questions associated with fatigue, i.e. Do you lack 
of energy? The questionnaire asks if the feature is less of a problem than usual, no 
more than usual, more than usual, much more than usual (Appendix - Figure 8.15). 
The total sum of the CFQ is quantified (e.g. the sum total of all answers in the CFQ) 
using continuous (Likert Scoring) which allocates 0, 1, 2 and 3 to the answers. 
Scores can range from 0 – 33 with the higher the score representing a greater level 
of fatigue. 
Short Form Health Survey 36 (SF-36) – Physical functioning assessment 
As previously described in Section 5.3.2, the Short Form Health Survey (SF-36) 
(Version 1.0) physical functioning section was used to assess functional status and 
well-being/quality of life. Low scores are indicative of greater disability. The full 
questionnaire is displayed in thesis appendix (Figure 8.19). The SF-36 
questionnaire is a suitable, reliable, and valid measure of physical functioning and 
health status in patients with CFS (Garratt et al., 1993).    
Epworth Sleepiness Scale  
One of the most widely used scales to assess subjective sleepiness is the Epworth 
Sleepiness Scale (Neu et al., 2008). The scale contains eight questions designed to 
assess daytime sleepiness (Figure 8.21). Scores above 10 are commonly interpreted 
as increased daytime sleepiness and a high risk of dozing (Johns, 1991). Scores 
greater than 16 suggest individuals are “dangerously” sleepy. 
Hospital Anxiety and Depression Questionnaire (HADS)  
The Hospital Anxiety and Depression (HADS) questionnaire contains 14 questions 
split equally to assess anxiety and depression. The score HADS has been shown to 
perform well in screening a range of patient groups as well as the general population 
the symptom severity and cases of anxiety disorders and depression. (Bjelland et 
al., 2002). The HADS questionnaire grades anxiety and depression as mild for 
individuals who score between 8-10, moderate for scores between 11-14 and severe 
for scores between 15-21. The full questionnaire is displayed in thesis appendix 
(Figure 8.18). 
 
5.3.3 Blood donation   
 
Blood was collected for full blood count (FBC) analysis, clotting screen analysis 
and plasma isolation.  Following collection, samples for FBC and clotting blood 
was kept at room temperature whilst plasma samples were placed immediately on 
ice. FBC and clotting samples were analysed by the Department of Haematology at 
the Royal Liverpool University Hospital whilst samples for plasma isolation were 
processed within the Institute of Ageing and Chronic Disease, University of 
Liverpool. All samples were processed within 3 hours of collection. 
 
5.3.3.1 Isolation of plasma from human blood  
 
Plasma was isolated from blood samples by centrifugation at 1500g for 15 minutes 
at 4°C. The plasma was aspirated from the monovettes into cryovials and stored at 
-80°C for future analyses.  
 
5.3.4 Bioplex multi-bead cytokine analysis of plasma samples  
 
The concentration of cytokines in isolated plasma samples was determined using 
Bioplex® multi-bead analysis as described in Section 2.6. A multi-plex panel of 27 
markers of inflammation including cytokines from the TNF family proteins, IFN 
family proteins, CCL chemokines, CXCL chemokines and growth factors; a full list 
is detailed in Table 5.2. Samples were analysed across three separate plates. Inter-
plate variation was assessed and corrected for by running a randomly selected group 
of samples across all three luminex plates. 
 
TNF-α 
 
IL-15 
IL-1β 
 
IL-17 
IL-1ra 
 
IFN-γ 
IL-2 
 
CCL2/MCP-1 (MCAF) 
 
IL-4 
 
CCL5/RANTES 
 
IL-5 
 
CCL3/MIP-1α  
 
IL-6 
 
CCL4/MIP-1β 
IL-7 
 
CXCL10/IP-10 
 
IL-8 
 
Eotaxin 
IL-9 
 
GM-CSF 
IL-8 
 
G-CSF 
IL-9 
 
PDGF-BB 
IL-10 
 
FGF Basic 
IL-12 
 
VEGF 
IL-13 
 
 
 
Table 5.2 List of analytes of Bioplex® Pro Human Cytokine Assay – 27-Plex.  
 
5.3.5 Cytokine analysis by ELISA  
 
 Human TNF-α Quantikine ELISA (R&D Systems, UK). 
 Human TNF-α Microplate, Conjugate and Standard 
 Assay Dilutent (RD1F - Buffered protein base with preservatives) 
 Wash Buffer (Concentrate & ddH2O) 
 
Levels of TNF-α in plasma samples was analysed using a commercial TNF-α 
ELISA as previously described in Section 2.6.2. The kit provided a 96-well 
microplate pre-coated with human TNF-α monoclonal antibody. Following the 
addition of 50μL of assay diluent and 200μL of standard, sample or control to each 
well, the plate was covered and incubated for 2 hours at room temperature. Each 
well was aspirated and washed a total of four times. Two hundred microliters of 
human TNF-α conjugate was added to each well and incubated for 2 hours at room 
temperature. A second set of washes was competed before 200μL of substrate 
solution was added to each well. The plate was incubated for 20 minutes at room 
temperature. The final step of the protocol involved the addition of 50μL of stop 
solution. Optical density of each well was determined at 540 nm using a Flurostar 
Optima (BMG Labtech, Aylesbury, UK.  
 
5.3.7 Muscle biopsy procedure 
 
Full details of the biopsy procedure are described in Section 2.2.5. A percutaneous 
biopsy was performed on the vastus lateralis muscle of patients with CFS and 
healthy controls, providing their FBC and clotting screening was within the normal 
laboratory range. Clotting Screen - Prothrombin (seconds).
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 HC CFS 
Sample Acquisition (n) 11 11 
Women (n) 9 9 
Men (n) 2 2 
Age (Average ± SEM) 35.8 ± 3.4 35.8 ± 3.5 
SF-36* 30 ± 0 16.2 ± 1.4 
 
Table 5.3 Baseline characteristics of biopsy study participants. Average ± SEM. 
 HC CFS 
Prothrombin (secs) 11.6 ± 0.2 11.6 ± 0.05 
APTT (secs) 30.7 ± 0.6 31.2 ± 0.2 
Platelets (x10^9/L) 239.4 ± 7.5 240.4 ± 3.8 
 
Table 5.4 Clotting factors from study participants. APPT (Activated Partial 
Thromboplastin Time). Seconds (Secs). Average ± SEM.  
 
5.3.8 RNA isolation and qPCR analysis of cytokine expression in VL muscle 
 
The method for RNA extraction and qPCR is detailed in Section 2.10. Briefly, RNA 
from muscle was isolated using Tri Reagent (Qiagen, Sussex, UK). First-strand cDNA 
was synthesised using the iScript cDNA synthesis kit (Bio-Rad, Hertfordshire, UK). 
The primers for real-time PCR analyses used in this study are described in Table 4.3.  
GAPDH, B-Actin and Beta-2-microglobulin (B2M) were used as housekeeping 
(reference) genes. A range of cytokine targets were selected based upon findings from 
the literature and from the multiplex cytokine analysis of human plasma samples in 
the study. 
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5.4 Results 
 
5.4.1 Study population demographics   
 
As previously described in Section 4.3, the main study recruited 95 patients with CFS 
and 95 healthy controls. Recruitment took place over 1 year from April 2014 to April 
2015. 63 patients with CFS were female; healthy controls were matched ± 3 years of 
the patients with CFS. The average age within the group of patients with CFS was 38 
± 1 years and healthy controls was 34 ± 1. There was no significant difference between 
the average weight and height of the CFS and HC recruits and subsequently there was 
no difference in BMI between the two groups (Table 5.1). The average illness duration 
in the CFS group was 36 months ± 4.8 (Ranging from 6-276 months).  
 
5.4.2 Cohort characteristics of patients with CFS and HCs  
 
5.4.2.1 Questionnaire Analysis 
 
Health questionnaire scores are shown in Table 5.5. The Chalder Fatigue Questionnaire 
(CFQ) is highly regarded as an effective and valid measure of fatigue in patients with 
CFS. Patients with CFS had significantly higher CFQ scores than HC (p ≤ 0.05). 
Subjective sleepiness was assessed using the Epworth Sleepiness Scale (ESS) (Neu et 
al., 2008). On average patients with CFS scored significantly higher than HCs in the 
study with the majority scoring greater than 10 on the questionnaire scale (p ≤ 0.05). 
This indicates patients with CFS are excessively sleepy and may have a dangerously 
high risk of falling asleep during day-to-day tasks. Patients with CFS had significantly 
higher scores of both anxiety and depression as reported by the HADS (p ≤ 0.05). 
Physical functioning was assessed using the SF-36 health survey and showed patients 
with CFS scored significantly higher scores than HC (p ≤ 0.05) suggesting reduced 
physical functioning in patients with CFS.   
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 HC CFS P 
Chalder Fatigue 
Score 
10.2 ± 0.36 28 ± 0.39 p ≤ 0.05 
SF-36 Score 29.6 ± 0.36 17.6 ± 0.48 p ≤ 0.05 
Epworth Sleepiness 
Scale (ESS) 
4.5 ± 0.22 10.8 ± 0.37 p ≤ 0.05 
HADS Anxiety 5.2 ± 0.14 10.4 ± 0.49 p ≤ 0.05 
HADS Depression 2.1 ± 0.4 9.8 ± 0.49 p ≤ 0.05 
 
Table 5.5 Health Questionnaire Scores from Patients with CFS and HCs.  
 
5.4.2.2 Symptom assessment in patient cohort  
Upon diagnosis, medical staff assessed symptoms of patients with CFS. A 
comprehensive list of symptoms commonly reported in patients with CFS is listed in 
the NHS diagnostic pack (Appendix).  
The current investigation was focussed upon serum and muscle cytokine levels and the 
association with loss of muscle function. Symptoms associated with perturbed 
cytokine levels and signs of the illness/common cold flu included sore throat, 
malaise/flu like systems and painful lymph nodes. 29/95 recruited subjects reported 
malaise and flu-like symptoms whilst 17/95 reported sore throats and 7/95 painful 
lymph nodes. 100% of patients reported post-exertional malaise, whilst 42/95 suffered 
from muscle pain (Table 5.6).   
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 CFS (%)  CFS (%) 
Sleep disturbances 64 Post exertional malaise 100 
Muscle pain 42 Cognitive dysfunction 29 
Joint pain 33 General malaise/flu-like 29 
Headaches 35 Dizziness 25 
Painful lymph nodes 7 Nausea 17 
Sore Throat 17 Palpitations 8 
 
Table 5.6 Symptom assessment in patients with CFS. Data presented as % of study 
population with symptom.   
 
5.4.3 Full blood count assessment in patients with CFS and HCs 
  
Results from a full blood count (FBC) analysis were examined to determine markers 
of anaemia (haemoglobin and haematocrit) to confirm patients with CFS were not 
suffering from anaemia (a potential causes of fatigue). The FBC provided information 
regarding patient clotting profile (platelet count). An adequate platelet count was 
required to ensure blood would clot successfully following the biopsy procedure. A 
full blood count was undertaken in all patients willing to donate a muscle biopsy. 
Results from the full blood count revealed no significant differences in haemoglobin, 
red blood count, haematocrit and platelets between patients with CFS and HCs.  
Inflammatory blood measures included white blood cell (WBC) counts of neutrophil 
granulocytes, lymphocytes, monocytes and eosinophil granulocytes. Raised levels of 
neutrophil granulocytes may indicate bacterial infection or be a sign of acute viral 
infection and are part of the body’s first line of defence. There was no difference in 
neutrophil count between patients with CFS and HCs. Lymphocytes levels are raised 
in response to invading bacteria, viruses, and toxins and increase during viral 
infections such as glandular fever. Lymphocyte levels were similar in both cohorts. 
Monocytes count increases in a range of conditions, such as bacterial infection or 
tuberculosis. Eosinophil granulocytes are raised in parasitic infections, asthma, and 
during allergic reactions. Eosinophil levels were slightly higher in patients with CFS 
than HCs however the difference did not reach statistical significance. A high number 
of eosinophils (eosinophilia) are linked to allergic diseases (asthma, hay fever, 
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eczema) and some infections. The average number of basophils in the blood was 
significantly lower in patients with CFS than the HC group. Raised basophil secretion 
is associated with allergic reactions. 
 
 HC CFS p 
Haemoglobin (g/L) 136.89 ± 1.53 138.92 ± 1.6 0.45 
Red Blood Count (x1012/L) 4.39 ± 0.1 4.55 ± 0.1 0.22 
Haematocrit (L/L) 0.44 ± 0.03 0.41 ± 0.0 0.27 
MCV (fL) 89.19 ± 0.58 89.56 ± 0.6 0.71 
MCH (pg) 30.54 ± 0.24 30.6 ± 0.2 0.8 
Platelets (x109/L) 237.89 ± 5.93 238.2 ± 7.5 0.98 
WBC (x109/L) 6.99 ± 0.3 7.1 ± 0.4 0.9 
Neutrophils (x109/L) 4.36 ± 0.24 4.3 ± 0.3 0.9 
Lymphocytes (x109/L) 1.94 ± 0.08 2.0 ± 0.1 0.7 
Monocytes (x109/L) 0.53 ± 0.02 0.5 ± 0.03 0.99 
Eosinophils (x109/L) 0.14 ± 0.01 0.2 ± 0.02 0.06 
Basophils (x109/L) 0.06 ± 0.01 0.04 ± 0.007 0.03 
 
Table 5.7 Full blood count analysis – markers of anaemia, clotting, and inflammation. 
Mean corpuscular volume (MCV), mean corpuscular haemoglobin (MCH), white 
blood cell (WBC). Data presented as average ± SEM. p ≤ 0.05 
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5.4.4 Plasma levels of cytokines in patients with CFS and HCs 
 
The multiplex assay utilised in this study examined 27 key cytokines and chemokines 
including TNF-α, a wide range of interleukins, growth factors and chemokines in 
plasma samples. Analytes IL-2, IL-15, GM-CSF and MCP-1 (MCAF) were excluded 
from analysis. Since >90% of samples reported values less than the bottom value on 
the standard curve in both study groups.  Data revealed no significant differences 
between the CFS patient group and the HC group for any of the analytes (Figures 5.1-
5.20) as average plasma levels (mean ± SEM) for patients with CFS and HCs and box 
plots as median (the box depicts the middle 50th percent of the distribution. Outliers 
which are between 1.5 and 3 interquartile ranges and those >3 interquartile ranges from 
the nearest edge of the 50th percentile box are symbolised by circles and stars 
respectively. Results for growth factor analytes are (VEGF, PDGF-bb and FGF-basic) 
found in the thesis appendix. A more sensitive assay of cytokine detection was 
performed for plasma levels of TNF-α. Data revealed no significant difference 
between patients with CFS and HCs Figures 5.1-5.21.   
 
 
Figure 5.1 Plasma levels of TNF-α in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95).  
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Interleukins  
 
Figure 5.2 Plasma levels of IL-1β in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95).  
 
Figure 5.3 Plasma levels of  IL-1ra in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95).  
 
Figure 5.4 Plasma levels of IL-4 in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95). 
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Figure 5.5 Plasma levels of IL-5 in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95). 
 
 
Figure 5.6 Plasma levels of IL-6 in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95). 
 
Figure 5.7 Plasma levels of IL-7 in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95).  
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Figure 5.8 Plasma levels of IL-8 in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95). 
 
Figure 5.9 Plasma levels of IL-9 in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95). 
 
Figure 5.10 Plasma levels of IL-10 in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95). 
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Figure 5.11 Plasma levels of IL-12 in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95). 
 
Figure 5.12 Plasma levels of IL-13 in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95). 
 
Figure 5.13 Plasma levels of IL-17 in patients with CFS compared with HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95). 
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Figure 5.14 Plasma levels of G-CSF (Granulocyte-Colony Stimulating Factor) in 
patients with CFS compared with HCs. Data are presented as mean ± standard error of 
the mean (SEM) and box plots as median ± interquartile ranges (n=95).   
 
CC Chemokines  
 
Figure 5.15 Plasma levels of RANTES/CCL5 in patients with CFS compared with 
HCs. Data are presented as mean ± standard error of the mean (SEM). Distribution of 
data shown in box plots as median ± interquartile ranges (n=95).  
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Figure 5.16 Plasma levels of MIP-1α/CCL3 in patients with CFS compared with HCs. 
Data are presented as mean ± standard error of the mean (SEM). Distribution of data 
shown in box plots as median ± interquartile ranges (n=95). 
 
Figure 5.17 Plasma levels of MIP-1β/CCL4 in patients with CFS compared with HCs. 
Data are presented as mean ± standard error of the mean (SEM). Distribution of data 
shown in box plots as median ± interquartile ranges (n=95). 
 
Figure 5.18 Plasma levels of Eotaxin/CCL11 in patients with CFS compared with 
HCs. Data are presented as mean ± standard error of the mean (SEM) and box plots as 
median ± interquartile ranges (n=95).   
CXCL Chemokines  
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Figure 5.19 Plasma levels of IP-10 (CXCL10) in patients with CFS compared with 
HCs. Data are presented as mean ± standard error of the mean (SEM) and box plots as 
median ± interquartile ranges (n=95).   
 
Interferons 
 
Figure 5.20 Plasma levels of IFN-γ in patients with CFS compared with HCs. Data 
are presented as mean ± standard error of the mean (SEM) and box plots as median ± 
interquartile ranges (n=95).   
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Figure 5.21 Plasma concentration of circulating TNF-α in patients with CFS and HCs 
(detected through ELISA). Average ± SEM. (n=95)   
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5.4.4.2 Plasma cytokine levels in female patients with CFS  
Due to potential differences in plasma cytokine values between sexes. Data for female 
patients with CFS and HCs are presented below. CFS is more predominant in female 
sufferers. The current study included ~70% females. Data revealed no significant 
changes between female patients with CFS and HCs as shown in (Table 5.10). 
Additionally, there was no difference between cytokine levels between male CFS 
sufferers and male HCs.  
Cytokine Female CFS Female HCs  P Value  
PDGF-bb 61.81±12.28 66.56 ± 10.83 0.77 
IL-1b 0.37 ± 0.06 0.29 ± 0.05 0.30 
IL-1ra 36.94 ± 14.59 25.11 ± 6.41 0.46 
IL-4 0.83 ± 0.09 0.81 ± 0.09 0.89 
IL-5 1.44 ± 0.27 1.6 ± 0.14 0.36 
IL-6 1.88 ± 0.38 1.44 ± 0.27 0.34 
IL-7 5.60 ± 0.64 5.69 ± 0/64 0.93 
IL-8 6.61 ± 0.78 5.49 ± 0.70 0.28 
IL-9 3.09 ± 0.78 3.08 ± 0.91 0.99 
IL-10 2.58 ± 0.63 5.48 ± 3.73 0.44 
IL-12 4.29 ± 0.99 6.96 ± 3.72 0.48 
IL-13 3.02 ± 0.60 2.54 ± 0.67 0.59 
IL-17 5.74 ± 1.85 5.64 ± 1.36 0.97 
Eotaxin 19.55 ± 1.93 18.87 ± 1.82 0.80 
FGF basic 13.16 ± 1.76 11.64 ± 1.75 0.54 
G-CSF 54.42 ± 4.88 50.44 ± 4.27 0.54 
GM-CSF 27.64 ± 2.81 30.94 ± 2.49 0.87 
Hu IFN-g 41.22 ± 4.85 37.50 ± 4.41 0.57 
IP-10 259.25 ± 26.87 203.58 ± 18.84 0.09 
MIP-1a 1.43 ± 0.18 1.47 ± 0.20  0.88 
MIP-1b 12.70 ± 1.23 10.66 ± 0.87 0.18 
RANTES 2108.00 ± 267.65 1608.10 ± 230.99 0.16 
TNF-a 5.01 ± 0.57 3.0 ± 0.41 0.01 
VEGF 1.15 ± 0.48 0.79 ± 0.26  0.51 
 
Table 5.8 Plasma cytokine levels in female patients with CFS compared with female 
HCs. Data are presented as average ± SEM (n=63).  
 
5.4.5 Expression of cytokines in skeletal muscle of patients with CFS 
 
5.4.5.1 Housekeeping genes 
 
The expression of three housekeeping genes, B-Actin, GAPDH and B2M was 
examined in skeletal muscle biopsies from patients with CFS and HCs. All 
housekeeping genes showed stable levels of expression across both cohorts of samples. 
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All samples were normalised to a single gene; B-Actin. Relative mRNA expression of 
the three housekeeping genes from all samples is displayed in the appendix in Figures 
8.1 to 8.3 respectively. Achieving stable levels of expression for housekeeping genes 
in muscle can be difficult (Thomas et al., 2014).  
 
5.4.5.2 Cytokine (myokines) expression in skeletal muscle from patients with CFS 
and HCs 
 
The cytokine genes measured are reported in Table 5.3. Gene targets for qPCR analysis 
were based on data from the multiplex cytokine analyses and current literature. 
Quantitative qPCR analysis was performed and demonstrated that the gene expression 
of all cytokine targets was not significantly different between patients with CFS and 
HCs (Figure 5.22). However, CCL2 and IP-10 appeared to be raised in a significant 
proportion of patients with CFS compared with HCs however, this did not reach 
significance. Expression of MIP-1β (CCL4) and CXCL1 (KC) were not detected in 
skeletal muscle.   
 
Figure 5.22 Relative mRNA expression for TNF-α, IL-6, IL-8, CXCL10 (IP-10), 
CCL2 (MCP-1), CCL5 (RANTES), Eotaxin 1 and MIP-1α(CCL3). Data are presented 
as mean ± standard error of the mean (SEM) n=11. Black bars represent HCs and grey 
bars represent patients with CFS.  
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5.5 Discussion  
 
The current study recruited 95 patients with CFS and 95 HCs, and is one of the largest 
cross-sectional studies to have been conducted in patients with CFS investigating 
plasma cytokine levels. Within the current study >70% patients with CFS were female. 
This is supported by recent reports confirming females are the predominant sufferers 
(Bested and Marshall, 2015), however, the syndrome can affect both men and women. 
The study was open to participants aged 18-55 years of age across this age bracket, 
with the youngest participant at 18 years and 54 being the oldest. The study 
encompassed a wide age range reflecting CFS affecting people of all ages. However, 
recruitment was excluded for people >55 years of age due to the natural increase in 
pro-inflammatory cytokines with age (Pedersen et al., 2000) as evidence suggests that 
cytokine levels are influenced by age and sex (Kleiner 2013). The study had age and 
sex matched HCs to remove any confounding effects. The mean age of patients with 
CFS and HCs was 38±1 years and 35±1 years respectively. Patients were age matched 
to a healthy control because of natural variations between males and females across 
different age groups (Larsson et al., 2015). This ensured that any age/sex related 
differences in cytokines were accounted for.  
Given the open diagnostic criteria of CFS and lack of objective markers to define 
patients, CFS cohorts are naturally more heterogeneous than other patient groups. The 
characteristics of this large CFS cohort are, in general, typical of those within the wider 
CFS community with the exception of bed ridden patients. The patient cohort was 
characterised regarding age, sex, disease duration, disease symptoms, mental health, 
physical functioning, and sleep health. The use of health questionnaires is beneficial 
in detecting general differences between patients with CFS and HCs; however the lack 
of depth and simplicity of these assessments prevents discrimination between patients 
(potential subgroups) and accurate determination of disease severity. 
As expected, patients with CFS scored higher in subjective fatigue questionnaires in 
comparison to healthy control individuals. However, scores were lower among both 
patients with CFS and HCs compared with more recent studies of adults (Cella and 
Chalder, 2010). This might be partly explained from the exclusion of the most disabled 
patients (i.e. bedridden) in the present study and study design (Loge et al., 1998). The 
use of the Chalder Fatigue Questionnaire does not allow for stratification across the 
CFS cohort. A more detailed perceived fatigue scale would have allowed the study to 
differentiate between perceived fatigue level in patients with CFS and grade subjects 
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accordingly (Jason et al., 2011). Perceived fatigue severity may act as a significant 
differentiator between different subgroups of patients.  
Anxiety and depression scores reported in the HADS questionnaire were high in 
patients with CFS in comparison with health controls. Approximately 50% of the 
patients with CFS within this cohort of CFS patients scored >10 in the HADS 
questionnaire. Both depression and anxiety (mental health) have been proposed as 
potential modulators of systemic cytokine levels (Gadek-Michalska et al., 2013). Thus, 
there is evidence to suggest both individuals with high levels of anxiety and/or 
depression may have raised cytokine profiles independently of disease (Reichenberg 
et al., 2001, Miller et al., 2009). Further analysis examining sub-groups of patients 
with raised anxiety and depression scores (using the HADS questionnaires) and their 
respective cytokine profiles would be interesting to determine any potential effects of 
anxiety/depression. 
On average patients with CFS in this study are at a greater risk of dozing/falling asleep 
during the day time than HCs. This may be as a result of inadequate night sleep or 
reduced quality of sleep. Sixty five patients with CFS subjects in this study reported 
sleep disturbances during diagnosis. Sleep disturbances are a common complaint 
across CFS populations (Jackson and Bruck, 2012). Systemic cytokines levels may 
also be perturbed in patients with sleep disorders (Alberti et al., 2003) and healthy 
participants deprived of sleep. 
The study reported symptoms at diagnosis as reported in the NHS CFS service 
introductory assessment. These included, sleep disturbances, muscle pain, joint pain, 
headaches, painful lymph nodes, sore throat, post-exertional malaise, cognitive 
dysfunction, dizziness, nausea, palpitations and general malaise/flu like symptoms. 
The most predominant of symptoms included post exertional malaise and sleep 
disturbances (100% and 65% respectively). Patients within the CFS community report 
a much larger number of different symptoms than other patients groups. Symptoms 
assessed were limited by the NHS CFS assessment format. The grouping of symptoms 
i.e. – influenza like symptoms, sore throat would be beneficial and aid stratification 
and the identification of potential subgroups of patients.  
Common traits between CFS and diseases associated with altered cytokine profiles 
(e.g. viral infections such as the Epstein Barr virus, Lyme disease) has led many 
researchers to propose altered immune function in the form of altered cytokine levels 
may be a significant contributor to the pathogenesis of CFS. Despite some published 
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findings reporting perturbed cytokine levels in patients with CFS, there has been very 
little agreement between results (Patarca et al., 1994, Swanink et al., 1996, Lattie et 
al., 2012, Hornig et al., 2015).  Cytokines and chemokines are integral components of 
the immune system which regulate many of the immune system responses and can 
drive the inflammatory process. The balance between pro and anti-inflammatory 
cytokines is crucial in an effective immune response. In this and other ways, cytokines 
aid the body in fighting infection and dysregulation can have major consequences.  
The findings of the current investigation into plasma cytokine levels in patients with 
CFS in comparison to HCs revealed no significant differences in mean concentration 
of any of the of the 27 analytes assessed. Additional analysis revealed no significant 
differences in plasma cytokine levels in females alone with CFS compared with HCs 
or in newly diagnosed CFS subjects compared to long term CFS sufferers of the 
disease. A full list of plasma cytokine analytes is shown in Table 5.2. This study 
challenges the widely viewed hypothesis that patients with CFS have perturbed 
cytokine levels. However, it does contribute to a growing discussion that CFS is a 
collective term encompassing a wide-range of disorders, in which cytokine 
disturbances may affect one or more subgroups of patients. Due to the heterogeneity 
of CFS, collectively pooling all these disorders together might potentially mask any 
subgroups. The current study did not include assessment of Transforming Growth 
Factor β, which was identified in a comprehensive systematic review to be elevated in 
patients with CFS (Blundell et al., 2015).  
Previous investigations examining altered cytokine levels in CFS have reported 
inconsistent findings. For example, individual cytokines may be reported as raised and 
reduced in separate studies investigating cytokine profiles in patients with CFS and 
HCs. Patients with CFS may have more subtle alterations in cytokine networks rather 
than individual cytokines (Banks, 2000). A recent systematic review, investigating the 
available literature on modified cytokine profiles in patients with CFS identified one 
cytokine, TGF-β (Transforming growth factor) which was significantly elevated in 
patients with CFS in five out of the eight studies included in the review and this 
requires further exploration. Moreover, this study did not report any other cytokines to 
be abnormal. The review acknowledges the limitations of a shortage of high quality 
published papers on CFS and cytokines. The review also encompassed studies which 
used a wide range of different techniques to assess cytokine levels. A number of 
studies included potential selection bias, due to patients only being recruited from one 
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source (main a tertiary health care setting). This highlights further issues in CFS 
recruitment as the more severe sufferers (bedbound) of CFS are commonly excluded.  
The findings of the study described in this chapter are supported by a recently 
published cross-sectional study investigating adolescents with CFS (Wyller et al., 
2015). The study used a number of the same analyses including the same multiplex 
cytokine assay used in this study (The Bio-Plex Human Cytokine 27-Plex Panel) and 
the Chalder Fatigue Questionnaires. In a similar manner to the current study, data from 
(Whyler et al, 2015) showed that adolescent patients with CFS and HCs have similar 
circulating levels of all cytokines measured with no statistical differences between any 
markers studies. The study showed that patients with CFS also recorded significantly 
higher scores in the Chalder Questionnaire (p < 0.001). It is worth noting that (Whyller 
et al, 2015) did not formally match patients and controls with regards to variables such 
as age and body-mass index which may have concealed group differences. 
The current study also investigated whether cytokine expression from skeletal muscle 
was significantly altered in patients with CFS in comparison with HCs. Expression of 
IP-10 and CCL2 appears to be moderately higher in patients with CFS compared to 
HCs, however, these data are not statistically significant. Data from Chapter 3 
provided evidence that CCL2 is a cytokine that can be produced by skeletal muscle. 
Increased CCL2 production has been associated with muscle regeneration. IP-10 is 
also reportedly produced by skeletal muscle and has been shown to amplify T-cell 
tissue infiltration (Crescioli et al., 2012). Elevated levels of IP-10 have been found in 
the muscle of individuals suffering from inflammatory myopathies (De Paepe et al., 
2005). The presence of elevated cytokines in muscle cells may be consequence of T-
cell infiltration rather than increased production (Deyhle et al., 2015). A limitation of 
the current study was the study of cytokine content within the muscle through the 
analysis of mRNA levels. Data from Chapter 3 suggests that when cytokines are 
produced by skeletal muscle cells then they are rapidly exported, thus potentially 
having a greater effect on the local cytokine environment. In addition, analysis of a 
muscle biopsy does not allow for the identification of the source of mRNA and care 
must be taken in the interpretation of the evidence of modified cell content of the 
biopsy, such as the presence of connective tissue, immune, adipose or endothelial cells.  
Skeletal muscle is one of the largest organs in the body and secretes a large number of 
proteins into systemic circulation. It is unknown whether the ability of skeletal muscle 
to produce and secrete cytokines can significantly contribute to systemic cytokine 
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levels in healthy individuals or during disease. Local changes in cytokine levels in and 
surrounding the muscle may not be reflected by changes in systemic levels of 
cytokines. Cytokine targets for analysis of mRNA expression in muscle biopsy 
samples were chosen according to previous data (Chapter 3) confirming the production 
of these cytokines in muscle (Chapter 3) and published data. Analysis into the gene 
expression of cytokines from muscle biopsies taken from patients with CFS and HCs 
is a novel investigation and has not been undertaken before. These data revealed no 
differences between any targets. Some of the targets assessed have not been previously 
confirmed in skeletal muscle. The infiltration of cytokine producing immune cells in 
muscle occurs particularly during injury and is common in diseases such as 
inflammatory idiopathic myopathies (IIM) (Lepidi et al., 1998, Civatte et al., 2005, 
Lightfoot et al., 2015). Muscle biopsies taken from our participant biopsies, may 
reflect contributions from intracellular and interstitial sources of cytokines and not all 
expression may be directly from the muscle.  
Conflicting results between studies reporting changes or no differences in cytokines in 
CFS may be due to patient related variables such as the patient diagnostic criteria used, 
disease duration, the state of the CFS upon entrance into the study (relapse/remission 
cycle), the level of physical activity, stress, diet and sleep pattern and the time of day 
that blood sampling occurred as well as methodological differences. The current study 
attempted to control for a number these variables and if this is was not possible, to 
record differences between which could be used for sub-group analyses. The average 
illness duration in the CFS group was 36 months ± 4.8 (Total range: 0 – 276 months). 
The study originally aimed to recruit only newly diagnosed patients with CFS through 
the Liverpool and Broadgreen green NHS CFS services. However, logistical reasons 
in trying to screen out anyone who had already been through an NHS services and had 
been re-diagnosed with CFS preventing us from maintaining this aim. Hence the large 
discrepancies in the range of illness duration. The majority of studies published on 
serum/plasma cytokine levels in patients with CFS have used a wide range of different 
study designs and methodological techniques i.e. – direct serum/plasma analysis, 
immunoassay analysis of in vitro culture supernatants of stimulated or unstimulated 
cultures of whole blood, separated mononuclear gene expression in mononuclear cells 
and quantitative flow cytometry of intracellular protein cells (Gupta et al., 1997). Thus, 
the detection of altered cytokine levels, reported between studies has been highly 
variable. These inconsistencies may reflect variations in laboratory methods such as 
the processing and storage of serum and plasma samples. This is often dissimilar 
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between studies or study reports fail to report these details. Varying factors include the 
method of cytokine analysis (immunoassay or bioassay), CFS diagnostic criteria, as 
well as the timing of sample collection during the course of the illness.  Additionally, 
the vast majority of research to date investigating altered cytokine profiles in patients 
with CFS has been conducted on small sample sizes. 
The current study addresses systemic levels of cytokines (within plasma) and localised 
expression of cytokines from muscles within patients with CFS under basal conditions 
only. Patients with CFS may have potentially altered levels of cytokines locally or 
systemically in response to various stimuli given the fluctuating symptoms of CFS and 
bouts of high or low fatigue. Additional stresses which may significantly alter cytokine 
levels in patients with CFS only may include altered activity level (physical or mental), 
altered dietary and sleep patterns.  
A large proportion of studies used different methods of analysis. Many pro-
inflammatory cytokines are heavily influenced by pre-analytical factors and circulate 
at very low levels, requiring high sensitivity methods for reliable detection and making 
comparison between studies utilizing different assays difficult. More recently, 
published studies have utilised similar if not the same methods for assessing cytokine 
levels in plasma or serum which makes comparisons between studies easier. New 
multiplex assays such as the Bioplex® Luminex Assay used in the current study allow 
for a large number of cytokines to be assesses at once using small quantities of plasma. 
This is a highly accurate and sensitive technique for cytokine analysis thus 
strengthening the current data set. To determine whether changes were evident in 
cytokines present in very low levels in patients with CFS, the study used a very 
sensitive ELISA for analysis of plasma levels of TNF-α. Data demonstrated a non-
significant increase in mean plasma TNF-content in patients with CFS in a similar 
manner to luminex analyses.  
Studies have also assessed cytokine levels in cerebrospinal fluid of patients with CFS. 
To date, there are the only two investigations examining cytokine levels in 
cerebrospinal fluid of patients with CFS. Both utilised a multiplex bead technology 
(The Bio-Plex Human Cytokine 27-Plex Panel or the reagent set Beadlyte 48-011 
human 22-plexcytokine detection system). However, the sample size was low in both 
studies and patients were not age and sex matched to controls. Cerebrospinal fluid 
from a cohort of 18 patients with CFS revealed lower levels of the pro-inflammatory 
cytokine IL-10 in comparison to 5 healthy control samples (Marshall-Gradisnik et al., 
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2014, Peterson et al., 2015). A study from (Natelson et al, 2015) revealed that levels 
of granulocyte-macrophage colony-stimulating factor were lower in patients than 
controls, levels of IL-8 were higher in patients with sudden, influenza-like onset 
compared with patients with gradual onset of illness or controls and IL-10 levels were 
higher in the patients with abnormal spinal fluids than in those with normal fluid or 
controls (Natelson et al., 2005). This may suggest altered cytokine levels between 
patients with CFS and HCs is specifically localised to cerebrospinal fluid.   
 
5.6 Summary 
 
This study successfully identified: 
 No significant differences in plasma cytokine levels between patients with CFS 
and HCs. 
 No significant difference in cytokine mRNA expression in skeletal muscle of 
patients with CFS compared with those of matched healthy controls. A 
potential suggestion of increased IP-10 and CCl2 expression warrants furthers 
investigation.  
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Chapter Six 
Mitochondrial function and redox homeostasis in skeletal 
muscle of patients with CFS 
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6.1.1 Introduction 
 
One of the primary functions of skeletal muscle mitochondria is the production of ATP 
(adenosine triphosphate) through oxidative phosphorylation within the inner 
mitochondrial membrane (Balaban, 1990). ATP is the principal form of energy within 
all biological systems. In addition to the role of energy production, mitochondria are 
involved in neurotransmitter synthesis, calcium homeostasis, apoptosis, insulin 
secretion, heat production, the regulation of cellular substrate levels, pyrimidine and 
lipid synthesis and the production of reactive oxygen and nitrogen species (RONS) 
(Duchen, 2004, Pieczenik and Neustadt, 2007). The consequences of mitochondrial 
dysfunction can be profound and are often incompatible with life. Mechanisms 
underlying mitochondrial-related diseases have previously focussed on the production 
of ATP (Wallace, 1992, DiMauro and Schon, 2003). However there is also evidence 
to suggest a role of RONS induced oxidative damage and mitochondrial DNA damage 
in mitochondrial dysfunction (Pieczenik and Neustadt, 2007). Mitochondrial 
dysfunction can be of primary origin through inherited mutations in mitochondrial 
DNA or in nuclear DNA which codes for mitochondrial components. Secondary 
origins of mitochondrial dysfunction are acquired through life from external sources 
impacting on mitochondrial DNA, physiology and function and include environmental 
or pharmacologic toxins (Cohen and Gold, 2001). Additional factors associated with 
altered mitochondrial function include elevated RONS and oxidative stress, 
insufficient substrate levels and a reduction in intermediary metabolism, and metabolic 
acidosis (Kucharczyk et al., 2009). Oxidative phosphorylation and ATP production are 
integral components of human metabolism, however these processes are a source of 
reactive oxygen and nitrogen species (See Section 1.5 for full details). Mitochondria 
are both a source and target of increased free radial species and oxidative and 
nitrosative stress. These dynamic organelles have the ability to respond to changing 
demands in energy production and environmental stresses (Kotiadis et al., 2014). 
Mitochondrial dysfunction has been reported in a wide range of diseases/clinical 
conditions including cancer, neurodegenerative disorders and cardiovascular disease 
(Ballinger, 2005, Lin and Beal, 2006, Boland et al., 2013) as well as in premature 
ageing and age-related dysfunctions (Lin and Beal, 2006, Valko et al., 2007). Increased 
sensation of fatigue has been shown to occur in the absence of impaired objective 
markers of peripheral muscle function in severely fatigued cancer survivors (Prinsen 
et al., 2015). This suggests a potential underlying physiological mechanism of fatigue 
which may apply to additional syndromes.  
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Mitochondrial dysfunction has been proposed as a potential contributor to CFS (Wong 
et al., 1992, Kuratsune et al., 1994, Plioplys and Plioplys, 1995, Booth et al., 2012, 
Morris and Maes, 2014). There are many symptoms which overlap between patients 
with CFS and mitochondrial dysfunction (Section 1.6.5 - Table 1.6). These include 
muscle cramps and weakness and neuropathic pain. The main primary characteristics 
of CFS which is shared with mitochondrial dysfunction is a persistent, debilitating 
fatigue accompanied by post-exertional malaise (Christley et al., 2012). A recent cross-
sectional survey assessing symptom severity of perceived fatigue in patients with 
mitochondrial disease and patients with CFS reported comparably high Fatigue Impact 
Scale (FIS) scores in patient groups when compared with HC scores (Gorman et al., 
2015). In the absence of any other underlying diseases, these symptoms may be 
associated with a more subtle defect in numerous body systems, however, (Filler et al., 
2014) reported a strong association between fatigue and a failing in energy metabolism 
and mitochondrial dysfunction in CFS. Dysfunctions in the structure of mitochondria, 
levels of mitochondrial enzymes, oxidative/nitrosative stress and mitochondrial energy 
metabolism (ATP production), were investigated as potential contributors to fatigue. 
Evidence to support perturbed mitochondrial function in CFS is currently inconclusive 
(Vermeulen et al., 2010). Support for the hypothesis of mitochondrial dysfunction in 
CFS is limited to few primary studies with relatively small sample size. For example, 
only two patients with CFS (post viral relapsing myalgia) and 13 HCs were included 
in the study in which muscle histology and respirational capacity from biopsy samples 
was investigated (Byrne et al., 1985). The study identified type II fibre atrophy and 
mitochondrial respiration analysis in vitro revealed a slight reduction in State 3 
respiration rates. However, data from studies with a small sample size can often be 
misleading and/or misinterpreted.  
Markers of mitochondrial function has previously been investigated in white blood 
cells and in muscle cells of patients with CFS in a number of studies (Edwards et al., 
1993, Kurup and Kurup, 2003, Behan et al., 1991, Behan et al., 1997). However, the 
outcome of some studies is not authenticated due to the use of non-standardised or 
validated methods such as the “ATP profile” as illustrated in studies from (Myhill et 
al., 2009, Booth et al., 2012). This Chapter focuses on various aspects of mitochondrial 
function in skeletal muscle biopsies from patients with CFS. Some evidence has 
suggested the presence of structural abnormalities in muscle mitochondria of CFS 
(Behan et al., 1991, Plioplys and Plioplys, 1995) which may impact on functional 
capacity. These data suggest that impaired mitochondrial function in CFS may be 
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linked to a reduction in oxidative metabolism in muscle (McCully et al., 1996), 
reduced ATP production and/or elevated ROS production (Booth et al., 2012). These 
differences in mitochondrial function between patients with CFS and HCs are yet to 
be fully elucidated and confirmed and additional studies suggest no difference in 
mitochondrial function in biopsies of skeletal muscle from patients with CFS (Smits 
et al., 2011).    
RONS have typically been associated with oxidative/nitrosative stress and cellular 
dysfunction (Sohal and Weindruch, 1996). Increased production and excess exposure 
of cells to RONS can be detrimental, however, research has now demonstrated the 
importance of RONS in muscle cell signalling or the effect of excess RONS in 
disrupting normal ROS signalling pathways. (Powers et al., 2010). It is essential for 
skeletal muscle to maintain redox homeostasis within cells given the role of RONS in 
normal skeletal muscle physiology and function. Some evidence suggests RONS are 
elevated in plasma from patients with CFS and consequently induces oxidative damage 
to lipids, proteins and DNA. Protein carbonyls, isoprostane, 8-hydroxyguanosine, 
thiobarbuturic and malondialdehyde are all markers of oxidative damage and there is 
some evidence for increased levels in plasma of patients with CFS (Vecchiet et al., 
2003).  
Mitochondrial dysfunction can arise from a number of factors including abnormalities 
in inflammatory pathways involving elevated pro-inflammatory cytokines (Samavati 
et al., 2008), excessive production and reduced removal of RONS as well as elevated 
NF-κB activation (Li et al., 1999, Garrabou et al., 2012). Reports suggesting increased 
activation of immune-inflammatory pathways in CFS may support the potential 
presence of mitochondrial dysfunction given the relationship between immune-
inflammatory pathways, ROS signalling and mitochondrial function (Naik and Dixit, 
2011, Morris and Maes, 2014). Research suggests that altered cytokine levels can 
disrupt normal mitobioenergetics, thus affecting mitochondrial function and thereby 
increase oxidative stress (Lopez-Armada et al., 2013). However, there is also evidence 
to suggest patients with muscle weakness may have decreased muscle function without 
any signs of a pro-inflammatory environment within the quadriceps. These data report 
high levels of oxidative stress in the muscle of clinically and weight stable patients 
with COPD (Barreiro et al., 2008). 
It is plausible that patients with CFS may experience increased perception of fatigue 
and impairments in muscle function with or without known pathological changes in 
the muscle. Data shown in Chapter 4 (Figure 4.1) demonstrated that patients with CFS 
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have reduced MVC forces in comparison to HCs. Further investigation to elucidate 
whether there is an association between reduced MVC forces and altered muscle 
mitochondrial redox homeostasis and function using state of the art 
approaches/techniques to ensure accurate analysis.  
 
 
Figure 6.1 Schematic diagram illustrating the potential vicious cycle of ROS 
production and cytokines levels in skeletal muscle.  
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6.1.2 Hypothesis  
 
Mitochondrial ROS generation and respiratory function is altered in skeletal muscle of 
patients with CFS compared with HCs.  
 
6.1.3 Aims 
 
The current chapter aims to: 
 
 Assess mitochondrial content and respiratory function in situ in 
permeabilised muscle fibre bundles isolated from skeletal muscle of 
patients with CFS and HCs. 
 Characterise mitochondrial ROS production in skeletal muscle from 
patients with CFS by directly assessing mitochondrial H2O2 and 
superoxide production in situ in permeabilised muscle fibre bundles 
from skeletal muscle biopsies. 
 Assess markers of oxidative damage and the expression of redox 
proteins involved in RONS regulation in skeletal muscle from patients 
with CFS and HCs.  
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6.2 Methods 
 
6.2.1 Study secruitment  
 
Subjects with CFS were recruited through the Royal Liverpool and Broadgreen 
University NHS Trust CFS services. All subjects were newly diagnosed by clinicians 
in accordance the Oxford Criteria (1990) and recommended NICE guidelines (2007) 
(See Section 2.2 for full details of study recruitment and inclusion and exclusion 
criteria). 11 Patients with CFS (9 women and 2 males) and 11 healthy age and sex 
matched HCs (9 women and 2 males) provided muscle biopsies (Table 6.1).  
 
 HC CFS 
Sample Acquisition (n) 11 11 
Women (n) 9 9 
Men (n) 2 2 
Age (Average ± SEM) 35.8 ± 3.4 35.8 ± 3.5 
SF-36* 30 ± 0 16.2 ± 1.4 
 
Table 6.1 Baseline characteristics of study participants who undertook a muscle 
biopsy (SF-36 - Short Form Health Survey - Physical Activity). *p≤0.05.   
 
6.2.3 Biopsy Procedure 
 
A biopsy was taken from the vastus lateralis muscle of patients with CFS and HCs 
(Section 2.2.5). An Acecut automatic Biopsy system (TSK Laboratory, Oisterwijk, 
Netherlands) was used for each procedure. In brief, the thigh area was sterilized with 
a topical antiseptic, (povidone-iodine or chlorhexidine gluconate). The skin and thigh 
area were both anaesthetised with 4ml 2% lidocaine. A small 1cm incision was made 
through the skin, subcutaneous tissues and fascia using a scalpel. Three biopsies were 
collected from the muscle from different regions within 2-3 cm of the biopsy incision. 
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6.2.4 Preparation of muscle sample for analysis of mitochondrial ROS production 
and respiration function 
 
Muscle biopsy samples were immediately placed into ice-cold stabilizing Buffer A 
composed of 2.77mM CaK2 ethylene glycolbis-(2-aminoethylether)- N,N,N=,N=-
tetraacetic acid (EGTA), 7.23mMK2 EGTA, 6.56mM MgCl2, 0.5mM dithiothreitol 
(DTT), 50mM 2-(N-morpholino)ethanesulfonic acid potassium salt (KMES), 20mM 
imidazol, 20mM taurine, 5.3mM Na2 ATP, and 15 mM phosphocreatine, pH 7.3 at 
4°C. Muscle biopsy samples were manually teased into small fibre bundles and 
isolated fibres. Fibre bundles were permeabilised for 30 minutes in Buffer A 
supplemented with 0.05mg/ml saponin on ice (Gouspillou et al., 2014). The use of this 
technique to analyse intact skeletal muscle mitochondria in situ has been thoroughly 
validated and described (Anderson et al., 2009, Picard et al., 2010, Anderson et al., 
2007). In situ permeabilisation of fibres aids the preservation of mitochondria 
morphology and structural interactions and is reflective of the functioning of all 
mitochondria within the muscle fibre (Kuznetsov et al., 2008, Picard et al., 2010).  
Fibre bundles required for respiration analyses were washed 3 x 10 minutes in buffer 
B, composed of 2.77mM CaK2 EGTA, 7.23mM K2 EGTA, 1.38mM MgCl2, 3.0mM 
K2HPO4, 0.5mM DTT, 20mM imidazole, 100mM K-MES, and 20mM taurine, pH 7.3 
at 4°C, supplemented with fatty acid-free bovine serum albumin (BSA) (2mg/ml) 
(Gouspillou et al., 2014). 
Fibre bundles required for H2O2 production analyses were washed 3 x 10 minutes in 
buffer Z, composed of 110 mM K-MES, 35 mM KCl, 1 mM EGTA, 3 mM MgCl2, 
and 10 mM K2HPO4, pH 7.3 at 4°C, supplemented with BSA (5 mg/ml) (Gouspillou 
et al., 2014).  
 
6.2.5 Mitochondrial H2O2 generation  
 
To assess H2O2 release from permeabilised fibre bundles, an Amplex Red assay was 
used as previously described (Gouspillou et al., 2014, Picard et al., 2010). 
Permeabilised myofibre bundles (10 bundles), prepared as described previously 
(Section 6.2.4), were added to single wells within a 96 well microplate containing 
l00μL Amplex Red solution (19.44mM Amplex Red, 5U/ml HRP, 37.5U/μL SOD in 
50ml Buffer Z). Samples were incubated at 37°C for 5 minutes. Substrates/inhibitors 
were added as follows: Glutamate/Malate (10mM + 5mM), Succinate (S, 10mM), 
Rotenone (R, 1μM) and Antimycin A (AA, 10 μM) to activate different mitochondrial 
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complexes. H2O2 production was measured using a Flurostar Optima Fluorimeter 
(BMG Labtech, Aylesbury, UK). At the end of the H2O2 measurements, bundles were 
placed in liquid N2 and stored at -80°C. H2O2 production was expressed as picomoles 
per minute per unit protein content. 
 
6.2.6 Mitochondrial superoxide generation. Fluorescence-based methods to 
measure MitoSOX Red oxidation  
 
To monitor changes in mitochondrial superoxide, a MitoSOX Red mitochondrial 
superoxide indicator (MitoSOX Red) probe was utilised. MitoSOX Red is a derivative 
of dihydroethidium. It is a highly sensitive mitochondrial superoxide indicator and 
exhibits fluorescence upon oxidation by superoxide (Robinson et al., 2006). The 
reaction between superoxide and MitoSOX Red generates a highly specific fluorescent 
product, 2-hydroxyethidium (2-OH-Mito-E+) (Zielonka and Kalyanaraman, 2010). 
Isolated fibres from the VL muscle were loaded with 250nM MitoSOX Red 
(Invitrogen, California, USA) for 30 minutes as previously described (Sakellariou et 
al., 2013, Pearson et al., 2015). Fibres were maintained in buffer Z containing 
MitoSOX Red (20nM) during the experimental period. Fluorescence was quantified at 
an excitation/emission wavelength of 405/605nm.  
Fluorescence images were obtained using a C1 confocal laser scanning microscope 
(Nikon Instruments Europe BV, Surrey, UK) equipped with a 405nm excitation diode 
laser and a 605/15 emission filter. Using 60x magnification, fluorescence images were 
captured and analysed with the EZC1 V.3.9 (12bit) acquisition software.  
 
6.2.7 Mitochondrial membrane potential  
 
In order to assess potential changes in mitochondrial membrane potential (ΔΨm) in 
intact mitochondria of isolated VL fibres, fibres were loaded with a florescent dye, 
tetramethylrhodamine, methyl ester (TMRM), as previously described (Irwin et al., 
2003). Changes in TMRM fluorescence of isolated skeletal muscle fibres were 
assessed by loading fibres with 30nM TMRM (Invitrogen, California, USA). 
Fluorescence was detected at an excitation/emission wavelength of 543/605nm. 
Changes in ΔΨm were determined in the presence of oxidative phosphorylation 
inhibitors; oligomycin (2.5μM) and FCCP (4μM). Images were obtained and analysed 
using a C1 confocal laser scanning microscope (Nikon Instruments Europe BV, 
Surrey, UK).  
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6.2.8 Mitochondrial respiration 
 
Changes in mitochondrial O2 consumption were assessed with the use of the Oxytherm 
oxygen electrode control unit (Hansatech Instruments, Norfolk, UK) following 
permeabilisation of fibre bundle (15-17mg wet weight) as described above. Four 
hundred and fifty microliters of Buffer B containing, (in mM) 100 K-MES, 7.23 
K2EGTA, 2.77 CaK2EGTA, 20 imidazole, 0.5 DTT, 20 taurine, 3 K2HPO4, and 1.38 
MgCl2-6H2O (pH 7.3 at 4°C), supplemented with 2mg/ml BSA was added to the 
chamber and was constantly stirred. Following a period of stabilisation 10μL of 10mM 
glutamate + 5mM malate was added into the oxytherm chamber. After 3 minutes, the 
permeabilised myofibre bundles (14-16 mg wet weight) were added into the chamber. 
After a further three minutes, 2mM ADP was added into the chamber. The bundles 
were left until all the O2 within the chamber had been utilised or the muscle had used 
up all of the substrates. After respiration measurements were completed, fibre bundles 
were removed and placed in liquid N2 and stored at -80°C for protein quantification 
by Bradford assay (Section 2.4.1). 
 
6.2.9 Analysis of mitochondrial content in skeletal muscle - citrate synthase assay  
 
Citrate synthase activity can be used as a biomarker for mitochondrial content in a 
tissue homogenate. Citrate synthase activity was assessed using the Mitocheck Citrate 
Synthase Activity Assay Kit (Cayman Chemical Co., Michigan, USA). In brief, 
muscle homogenates (1:200) were added to each well of a 96-well plate in addition to 
the following reagents provided in the kit: 2% Acetyle CoA Reagent, 2% Developer 
Reagent and 4% Oxaloacetate Reagent in the provided assay buffer. The assay 
measured the production of SH-CoA by monitoring the absorbance of citrate synthase 
developing reagent at 412nm. A 96-well plate format was used and absorbance was 
detected using a microplate spectrophotometer (Bio-Tek instruments, Vermont, USA).  
 
6.2.10 Western blotting of muscle proteins  
 
Protein content was assessed by western blot analysis (Full details of western blotting 
described in Section 2.5). In brief, 20µg of total protein was loaded and separated by 
electrophoresis across an 8-15% polyacrylamide gel with a 4% stacking gel. Proteins 
were transferred onto a nitrocellulose membrane using a Multiphore Continuous 
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Blotting System (Pharmacia, Uppsala, Sweden). Ponceau-S staining was used to 
visualise the membrane, ensure the correct transfer of proteins and used as a loading 
controls against the protein of interest. Nitrocellulose membranes were blocked for 1 
hour at room temperature in 5% milk TBS Tween (Tris-Buffered Saline with Tween-
20) before being incubated overnight with primary antibodies (See Table 6.3 for 
detailed list of antibodies). Membranes were washed in TBST (3 x 5 minutes) and 
incubated with secondary antibody for 1 hour with a horseradish peroxidase 
conjugated anti-mouse IgG or anti-rabbit IgG (Cell Signalling, Hitchin, UK). 
Peroxidase activity was detected using an ECL kit. Band intensities were analysed 
using NIH Image J Software.  
 
6.2.11 Analysis of 3-nitrotrosine (3-NT) content of muscle 
 
Changes in 3-nitrotyrosine (3-NT) content were assessed in muscle biopsies as 
described in Section 2.6.1. Previous studies have shown that 3-NT levels are a sensitive 
marker of muscle oxidative stress (Vasilaki et al., 2007, Sakellariou et al., 2011). In 
brief, 20µg of total protein was separated by a 12% polyacrylamide gel and transferred 
to a nitrocellulose membrane. The content of 3-NT was analysed by using a rabbit 
monoclonal antibody according to manufacturer’s instructions (Cayman Chemical 
Co., Michigan, USA) and the bands were visualized using a Bio-Rad Chemi-Doc 
System (Bio-Rad Laboratories Ltd, Hemel Hempstead, UK). Densitometric 
quantification of bands was undertaken and the protein content was normalised to 
ponceau stains. Comparisons were made between samples on the same gel ⁄western 
blot.   
 
6.2.12 Determination of protein oxidation and lipid peroxidation 
 
Changes in muscle protein oxidation and lipid peroxidation were assessed in muscle 
samples as previously described (Section 2.6). Protein oxidation was assessed via 
changes in protein carbonyl content of the muscle. Proteins (20µg) were separated by 
12% polyacrylamide gel and transferred onto a PVDF membrane. Proteins were 
derivatised and membranes were blocked and incubated for 2 hours using an anti-DNP 
antibody (Cell Biolabs, San Diego, CA, USA). Membranes were incubated with a 
secondary HRP conjugated antibody for 1 hr before visualisation with ECL. Lipid 
peroxidation was assessed via changes in 4-hydroxynonenal (4-HNE) protein 
conjugates. Proteins were separated by 12% polyacrylamide gel and transferred to a 
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nitrocellulose membrane as detailed in Section 2.8. Membranes were probed with anti 
4-HNE primary antibody (Abcam, Cambridge, UK). Membranes were then washed (3 
x 5 minutes) and incubated for 1 hour incubation with a secondary HRP conjugated 
antibody. Bands were visualised using a Bio-Rad Chemi-Doc System (Bio-Rad 
Laboratories Ltd, Hemel Hempstead, UK). 
 
  
 
  
212 
 
6.3 Results  
 
6.3.1 Mitochondrial content of skeletal muscle  
 
Mitochondrial content of muscle homogenates from patients with CFS and HCs was 
assessed using a citrate synthase activity kit. A reduction in citrate synthase activity 
may be associated with lower mitochondrial content. Analyses revealed no difference 
in citrate synthase activity between patients with CFS and HCs indicating that CFS 
was not associated with altered mitochondrial content (Figure 6.2). 
 
 
Figure 6.2 Citrate synthase activity of muscle homogenates expressed as 
µmols/min/mg protein in patients with CFS and HCs (n=11). Data presented as mean 
± SEM. 
 
6.3.2 Mitochondrial ROS generation  
 
6.3.2.1 Mitochondrial H2O2 generation under state I respiration 
 
To assess whether mitochondria in muscle of patients with CFS produce elevated 
levels of mitochondrial ROS under state I respiration, H2O2 efflux was measured in 
permeabilised myofibres from vastus lateralis biopsy samples. There was no 
significant difference between average mitochondrial H2O2 emissions from 
permeabilised fibre bundles during state 1 respiration in data normalised to protein 
content of the muscle samples or citrate synthase activity (Figure 6.3 a and b).  
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6.3.2.2 Mitochondrial H2O2 generation by skeletal muscle in response to ETC 
substrates/inhibitors  
 
Figure 6.4. shows the changes in H2O2 generated by skeletal muscle in response to 
ETC complex substrates, and/or inhibitors. Following the addition of complex I 
substrates, Glutamate/Malate (G/M), intact mitochondria in muscle bundles of HCs 
showed a significant increase in H2O2 emission (P=0.03) in comparison with H2O2 
emission during state I respiration, whereas mitochondria from CFS bundles showed 
no significant increase. Following the addition of succinate, a complex II substrate, 
mitochondrial H2O2 emission from HCs was higher in comparison to state I respiration, 
however, this was not significant (P=0.07). Mitochondria from CFS bundles showed 
no detectable changes in response to succinate. Succinate induced increments in H2O2 
emission from HC bundles was abolished by complex I inhibitor rotenone indicating 
complex-I dependent superoxide production in response to succinate. Moreover, there 
was no effect of S/R on H2O2 emission from bundles within patients with CFS. Thus, 
patients with CFS may have altered sensitivity in response to complex 
substrates/inhibitors, particularly G/M. 
Both patients with CFS and HCs revealed a significant reduction in H2O2 emission 
from bundles exposed to antimycin alpha (AA), a complex III inhibitor compared to 
state I respiration. Overall these data suggest that there are no significant gross changes 
in mitochondrial H2O2 production between the CFS and HCs. 
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Figure 6.3 Generation of mitochondrial hydrogen peroxide (H2O2) assessed in 
permeabilised fibre bundles prepared from vastus lateralis muscle of patients with 
CFS and HCs a) Normalised to protein content of the muscle. b) Normalised to citrate 
synthase activity in musce. Mitochondrial substrates and inhibitors; Glutamate/Malate 
(G/M, 10mM + 5mM), Succinate (S, 10mM), Rotenone (R, 1μM) and Antimycin A 
(AA, 10 μM). * p<0.05 Refers to comparisons made between H2O2 emission for HCs 
during state I respiration and following the addition of the respective 
substrate/inhibitors. # P<0.05 Comparisons made between H2O2 emission from CFS 
during state I respiration and following the addition of the respective 
substrate/inhibitors.  
6.3.2.3 Superoxide Production  
 
Representative images of single isolated fibres under bright field, following loading 
with MitoSOX Red, and a merged image is shown in Figure 6.4. Levels of superoxide 
did not differ between patients with CFS and HCs over a period of 1 hour as indicated 
by changes in MitoSOX Red (Figure 6.5). These data support the previous findings 
regarding no differences in H2O2 production between patients with CFS and HCs 
(Figure 6.3) suggesting no differences in ROS generation in skeletal muscle 
mitochondria between patients with CFS and HCs.   
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Figure 6.4 Representative images of a single fibre isolated from the VL muscle under 
bright field, fluorescent image following loading with MitoSOX Red (20nM, Purple), 
and a merged image as indicated and analysed by confocal microscopy. 60x original 
magnification. Scale bar, 25m. 
 
 
 
 
  
 
Figure 6.5 MitoSOX Red fluorescence from permeabilised fibres from the VL muscle 
in patients with CFS and HCs. Indicator of superoxide production from permeabilised 
fibres. Data presented as mean ± SEM. HCs error bars presented in plus direction. CFS 
error bars presented in minus direction (n=11). 
 
216 
 
6.3.3 Mitochondrial membrane potential  
 
Mitochondrial membrane potential was assessed in isolated muscle fibres from the 
vastus lateralis using a TMRM cationic fluorophore probe as described in Section 
2.13.2. A representative image of an isolated fibre loaded with TMRM is shown in 
Figure 6.6. Data revealed no differences in TMRM fluorescence with or without the 
addition of the oxidative phosphorylation inhibitors (oligomycin, Olm) and carbonyl 
cyanide-p-trifluoromethoxyphenyl hydrazone (FCCP) between patients with CFS and 
HCs, suggesting that skeletal muscle mitochondrial of patients with CFS do not show 
altered mitochondrial membrane potential (Figure 6.7). 
 
 
Figure 6.6 Representative confocal images of an isolated fibre showing TMRM 
fluorescence. 60x original magnification. Scale bar, 25m. 
 
 
Figure 6.7 Measurement of mitochondrial membrane potential (ΔΨm) in intact 
mitochondria of isolated VL fibres from patients with CFS and HCs, assessed by 
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changes in TMRM (30nM) fluorescence in response to oligomycin (Olm, 2.5μM) and 
the protonophore carbonyl cyanide-p-trifluoromethoxyphenyl hydrazone (FCCP, 
4μM), added at the indicated time points. n=12 fibres, 11 subjects/group. 
 
 
6.3.4 Mitochondrial respiration in permeabilised fibre bundles 
 
Respiratory function of muscle mitochondria was assessed in HCs and patients with 
CFS by assessing the respiratory control index (RCI, marker of O2 consumption) and 
the ratio between state III and state IV respiration. The RCI was not different between 
patients with CFS and HCs (See Figure 6.8). The P:O ratio is another marker of 
respiratory function, which represents the amount of ATP produced by the 
reduction of one oxygen atom through the electron transport chain (Nicholls and 
Ferguson, 2002). The P:O ratio was also not significantly altered in patients with CFS 
compared with HCs however data does suggest ~38% increase in the mean ratio of 
patients with CFS  (Figure 6.9). These data indicate no differences in respiratory 
function between patients with CFS and HCs. 
 
 
Figure 6.8 Respiratory control index (RCI) of intact mitochondria in permeabilised 
myofibres prepared from vastus lateralis (VL) from patients with CFS and HCs. 
(n=11). Data presented as mean ± SEM.  
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Figure 6.9 The P:O Ratio of ATP formed against oxygen utilised of intact 
mitochondria in permeabilised myofibres prepared from VL from patients with CFS 
and HCs (n=11). Data presented as mean ± SEM. 
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6.3.4 Oxidative damage and expression of redox-regulatory proteins in skeletal 
muscle of patients with CFS 
 
To determine the overall changes in redox homeostasis in skeletal muscle of patients 
with CFS, indicators of redox status including markers of protein oxidation, lipid 
peroxidation and protein nitration and the expression of RONS regulatory proteins 
were examined. 
 
6.3.4.1 Markers of oxidative damage in skeletal muscle 
 
Protein carbonyl content is a marker of protein oxidation and data revealed no 
significant differences in protein carbonyls between patients with CFS and HCs 
(Figure 6.10). A representative protein carbonyl blot is shown in Figure 6.11. To 
determine the extent of lipid peroxidation, 4-HNE (4-hydroxynonenal) protein 
conjugates were assessed in skeletal muscle lysates. Similarly, to protein oxidation, 
lipid oxidation was not altered between HCs and patients with CFS (Figure 6.11). An 
additional marker of oxidative stress is the levels of protein nitration. This was 
determined through the assessment of 3-nitrotyrosine (3-NT) muscle content. The 
study found no difference between muscle 3-NT content between HCs and patients 
with CFS as shown in Figure 6.12. A representative western blot of 3-NT content is 
shown in Figure 6.12.  
 
Overall, these data demonstrate a lack of any gross changes in oxidative status and 
demonstrate that skeletal muscle of patients with CFS does not exhibit grossly altered 
redox homeostasis compared with HCs.   
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6.3.4.1.1 Protein oxidation 
 
 
 
 
 
 
 
 
Figure 6.10 Representative western blot of protein carbonyl content in VL muscle of 
patients with CFS and HCs and densitometric quantification of the blot. n=8. Data 
presented as mean ± SEM. p= 0.12 
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6.3.4.1.2 Lipid peroxidation 
 
 
Ponceau 
         
 
 
Figure 6.11 Representative western blot of 4-hydroxynonenal protein adducts (4-
HNE) content in VL muscle of patients with CFS and HCs and densitometric 
quantification of the blot. n=8. Data presented as mean ± SEM. p=0.30  
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6.3.4.1.3 3-Nitrotyrosine 
 
 
 
 
 
 
Figure 6.12 Representative western blot of 3-nitrotyrosine (3-NT) content in VL 
muscle of patients with CFS and HCs and densitometric quantification of the blot. n=8. 
Data presented as mean ± SEM. p = 0.13 
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6.3.5 RONS regulatory enzymes and HSPs in skeletal muscle 
 
To further determine whether patients with CFS have altered redox homeostasis, the 
expression of RONS regulatory enzymes in skeletal muscle was also determined. 
Changes in RONS levels may lead to adaptations in the expression of proteins involved 
in antioxidant defences. The study measured the expression of RONS regulatory 
enzymes and proteins including; superoxide dismutase (SOD) isoforms (SOD I and 
SOD II), H2O2 reducing enzymes including glutathione peroxidase 1, catalase and 
PRXIII,  nitric oxide synthase (NOS) isoenzymes (iNOS, eNOS, nNOS), H2O2 
reducing enzymes including glutathione peroxidase 1, catalase and PRXIII, redox 
proteins involved in the thioredoxin-peroxiredoxin system and heat shock proteins 
which have been shown to provide protection against increased RONS production 
(Jackson, 2005) . 
 
6.3.5.1 SOD protein content  
 
Figure 6.13 shows a representative western blot of SOD I and SOD II from skeletal 
muscle of patients with CFS and HCs. Figure 6.14 and 6.15 demonstrates the 
quantification of these blots by densitometry. Neither SOD I or SOD II content was 
altered in muscles of patients with CFS in comparison with HCs.  
 
 
 
 
 
Figure 6.13 Representative western blots of proteins SOD1 and SOD2 in the VL 
muscle of patients with CFS and HCs. 
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Figure 6.14 Densitometric quantification of the blot for SOD1 protein content of 
skeletal muscle of patients with CFS and HCs. n=8. Data presented as mean ± SEM. 
p= 0.11 
 
 
 
Figure 6.15 Densitometric quantification of the blot for SOD2 protein content of 
skeletal muscle of patients with CFS and HCs. n=8. Data presented as mean ± SEM. 
p= 0.22 
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6.3.5.2 Catalase protein content  
 
Protein levels of catalase were not significantly different in muscle from patients with 
CFS in comparison to HCs (Figure 6.16). A representative blot is shown in Figure 
6.16. 
 
 
 
 
 
 
Figure 6.16 Representative western blots of catalase protein in VL muscles of patients 
with CFS and HCs and densitometric quantification of the blot. n=8. Data presented 
as mean ± SEM. p= 0.89 
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6.3.5.3 NOS protein content 
 
Changes in redox homeostasis may induce changes in the expression of redox 
regulatory proteins including NOS enzymes. Protein expression of all three isoforms 
of NOS; neuronal nitric oxide synthase (nNOS), endothelium nitric oxide synthase 
(eNOS) and inducible nitric oxide synthase (iNOS)) were examined by western blot 
analysis. Analysis revealed no significant differences in the content of any NOS 
proteins between CFS and HCs (Figures 6.17 – 6.20).  
 
 
 
Ponceau   
 
Figure 6.17 Representative western blots of neuronal nitric oxide synthase (nNOS), 
endothelium nitric oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) 
protein in VL muscles of patients with CFS and HCs. 
 
Figure 6.18 Densitometric quantification of the blot for nNOS protein. n=8. Data 
presented as mean ± SEM. p= 0.72 
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Figure 6.19 Densitometric quantification of the blot for eNOS protein. n=8. Data 
presented as mean ± SEM. p= 0.44 
 
 
Figure 6.20 Densitometric quantification of the blot for iNOS protein. n=8. Data 
presented as mean ± SEM. p= 0.85  
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6.3.5.4 PRX protein content 
As previously mentioned in Section 1.5.4, PRX proteins are mainly involved in the 
degradation of H2O2.with the exception of PRXV which is also implicated in the 
reduction of peroxynitrite. Western blot probed for PRX III (mitochondrial specific 
isoform) did not reveal any differences in PRXIII muscle content between patients 
with CFS and HCs as shown in Figure 6.21 which suggests no significant changes in 
H2O2 within the mitochondrial organelles of patients with CFS and HCs.  
 
 
 
 
 
 
 
Figure 6.21 Representative western blots of PRX III protein in VL muscles of patients 
with CFS and HC recruits and densitometric quantification of the blot. n=8. Data 
presented as mean ± SEM. p= 0.73 
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6.3.5.5 Changes in HSP content in skeletal muscle  
 
Skeletal muscle from patients with CFS showed no changes in either HSP 10 or HSP 
25 content in comparison to muscle from HCs as shown in Figures 6.22, 6.23 and 6.24. 
 
 
 
 
Figure 6.22 Representative western blots of HSP 10 and HSP 25 proteins in VL 
muscles of CFS and HC recruits and densitometric quantification of the blots.  
 
 
Figure 6.23 Densitometric quantification of the blot for HSP 10 protein. n=8. Data 
presented as mean ± SEM. p= 0.37  
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Figure 6.24 Densitometric quantification of the blot for HSP 25 protein. n=8. Data 
presented as mean ± SEM. p= 0.28 
 
6.3.5.6 Changes in IκBα content of skeletal muscle 
 
Analysis of IκBα content of skeletal muscle did not reveal any differences in muscle 
content between patients with CFS and HCs as shown in Figure 6.25 and 6.26 
suggesting no gross activation of NFκB canonical pathway.  
 
 
 
 
 
Figure 6.25 Representative western blots of IκBα protein in VL muscles of patients 
with CFS and HC recruits. 
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Figure 6.26 Densitometric quantification of the blot of IκBα protein in VL muscles of 
patients with CFS and HC recruits. n=8. Data presented as mean ± SEM. p= 0.66 
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6.4 Discussion  
 
Patients with CFS exhibit a number wealth of symptoms of which a large proportion 
are also reported in individuals with mitochondrial dysfunction (Table 1.6). The 
rationale to support the hypothesis of mitochondrial dysfunction and modified ROS 
generation in patients with CFS is plausible yet limited by a lack of primary evidence. 
The majority of published literature on this subject includes CFS and mitochondrial 
dysfunction hypothesis papers, intervention studies and reviews which have very little 
primary evidence supporting these hypothesis e.g. (Booth et al., 2012, Castro-Marrero 
et al., 2013, Morris and Maes, 2012, Nicolson, 2005). Conclusions are often drawn 
from poorly designed studies in which the number of participants is exceptionally low 
(e.g. – inclusion of 2 patients with CFS) and a lack of appropriate matching to HCs 
e.g.(Byrne et al., 1985). There are concerns with regards to the interpretation of 
primary data regarding mitochondrial function in a number of reviews and the use of 
non-validated mitochondrial function tests (“ATP profile” tests) in assessing patients 
with CFS as demonstrated in studies such as (Myhill et al., 2009, Meeus et al., 2013). 
To overcome these limitations, this study aimed to determine whether CFS is 
associated with muscle mitochondrial dysfunction and redox dysregulation. 
In this study, mitochondrial function and redox homeostasis were assessed in 
permeabilised muscle fibre bundles from patients with CFS and HCs. The use of fibre 
bundles and isolated skeletal muscle fibres are likely to reflect the situation in muscle 
in vivo. Many studies have utilised mechanically isolated mitochondria from skeletal 
muscle to study mitochondrial function and ROS production. Isolation of mitochondria 
can severely affect structural integrity and potentially provide inaccurate results 
(Picard et al., 2011). The technique of in situ analysis is advantageous over 
experiments using mechanical isolation of mitochondria, by maintaining the 
mitochondria in their native intracellular and systemic environment, structure is 
preserved and structural interactions with other sub-cellular compartments are not 
disrupted (Picard et al., 2010).  
Perturbed mitochondrial ROS production from skeletal muscle is a complex process 
which contributes to oxidative damage in a wide range of muscle pathologies (Lin and 
Beal, 2006, Eckhardt et al., 2007, Prinsen et al., 2015). Altered ROS levels can disturb 
cellular redox homeostasis thus impacting on a vast number of redox sensitive 
signalling pathways (Powers et al., 2010). Despite previous evidence suggesting 
elevated ROS production through the presence of cumulative oxidative damage and a 
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subsequent decline in mitochondrial function in patients with CFS, this area of 
research remains poorly understood (Richards et al., 2000, Castro-Marrero et al., 
2013). The current study did not identify any differences in mitochondrial ROS 
generation as assessed though H2O2 and superoxide production in intact mitochondria 
of skeletal muscle fibres from patients with CFS and HCs. This is the first study to 
directly measure mitochondrial ROS production in skeletal muscle in situ, utilising 
permeabilised muscle fibres in patients with CFS. Data did reveal mitochondrial in 
muscles of patients with CFS have potentially altered sensitivity to ETC substrates. 
Evidence from our research group has identified a reduction in substrate sensitivity in 
aged mice which is reversed following a treatment with a ROS scavenging peptide SS-
31 (unpublished data).  To date, there is no published evidence on the effect of 
training/exercise on mitochondrial ETC substrate sensitivity and H2O2 production.  
To further assesses the muscle redox environment, markers of oxidative damage and 
the expression of RONS regulatory proteins were assessed. Oxidative damage in 
skeletal muscle of patients with CFS and HCs was determined through the assessment 
of changes in protein oxidation, lipid peroxidation and protein nitration. Skeletal 
muscle of patients with CFS did not show any gross changes in protein carbonyls, 4-
HNE and 3-NT content compared to HCs. Previous analyses examining protein 
carbonyl content of skeletal muscle reported similar results (Fulle et al., 2000). These 
data therefore demonstrate no evidence of elevated levels of oxidative damage in 
patients with CFS. To further assess whether the redox sensitive protective systems 
were altered in skeletal muscle CFS, the current study also examined the expression 
of a wide range of proteins including superoxide dismutase (SOD) isoforms (SOD I 
and SOD II), H2O2 reducing enzymes catalase and PRXIII, nitric oxide synthase 
(NOS) isoenzymes and heat shock proteins which have been shown to provide 
protection against increased RONS production. Protein content of all markers did not 
differ between patients with CFS and HCs, again suggesting that the redox status of 
muscle cells in patients with CFS is relatively normal. 
Studies suggest that perturbed ROS homeostasis resultant of cumulative oxidative 
damage can lead to a reduction in mitochondrial number and function within a wide 
range of pathologies. Given the lack of evidence to suggest patients with CFS have 
altered redox homeostasis is not surprising that the mitochondrial function analysis in 
skeletal muscle also showed no differences between patients with CFS and HCs.  
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The reliability of a large proportion of evidence surrounding elevated oxidative 
damage and mitochondrial dysfunction in patients with CFS is unclear. There is often 
a lack of primary evidence or direct markers used to support claims in a large number 
of reviews (Myhill et al., 2009). A large number of statements made by Maes and 
Myhill et al are often supported with reviews from the same author which include 
hypothesis papers and additional reviews rather than primary based studies (Maes et 
al., 2006, Maes, 2009, Maes and Twisk, 2010, Maes, 2011, Maes et al., 2012, Maes, 
2013).  
The majority of studies examining mitochondrial function in muscle have utilised 
mechanically isolated mitochondria from skeletal muscle to study mitochondrial 
function and ROS production. Isolation of mitohondria can severely affect structural 
integrity and provide inaccurate results. Evidence has shown that the use of isolated 
mitochondria to study mitochondrial ROS and function can provide artificially high 
levels of ROS production (exacerbated response) as the isolation process can alter ROS 
(Picard et al., 2010). Additional errors have occurred in the normalisation of data 
assessing mitochondrial function. Previous data which has reported mitochondrial 
dysfunction in patients with CFS as a result of reduced ATP production has since been 
questioned due to the lack of normalisation of ATP production e.g. protein content of 
muscle or citrate synthase activity which acts as a fundamental marker of 
mitochondrial content. The current study did not find a significant difference in citrate 
synthase activity between patients with CFS and HCs. Previous studies assessing 
citrate synthase in skeletal muscle of patients with CFS have reported reductions in 
activity (McArdle et al., 1996, Smits et al., 2011). Evidence suggesting reduced 
oxidative phosphorylation is based upon data revealing a lower Vmax (VO2 max) in 
patients with CFS (McCully et al., 1996). However, Vmax is a poor secondary measure 
of oxidative phosphorylation which may be a result of reduced physical fitness rather 
than linked directly to CFS (Tabata et al., 1996). A number of parameters commonly 
assessed during investigations into metabolic abnormalities in CFS are drastically 
affected by physical activity status (Blomstrand et al., 1997). Given the increased 
perception of fatigue in CFS patients and evidence suggesting an increase in sedentary 
behaviour and muscle disuse, there is a risk of confounding factors affecting 
parameters and the misinterpretation of results. 
Overall, the data indicate that mitochondrial ROS generation (H2O2 and superoxide), 
oxidative damage (protein oxidation, lipid peroxidation and protein nitration) and the 
expression of RONS regulatory proteins are not altered in patients with CFS. 
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Moreover, mitochondrial function assessed via changes in mitochondrial membrane 
potential and respiration were no altered in patients with CFS compared with HCs. 
Overall the data of this study suggest that changes in mitochondrial function and redox 
homeostasis are not major contributing factors to the pathophysiology or symptoms 
associated with CFS. 
 
 
6.5 Summary  
 
This study successfully identified: 
 No difference in mitochondrial content or respiratory function in situ in 
permeabilised fibres isolated from skeletal muscle between patients with CFS 
and HCs.  
 No differences in ROS production in skeletal muscle between patients with 
CFS and HCs.  
 Potential sub-group of patients have reduced mitochondrial ETC sensitivity to 
complex substrates and inhibitors.  
 No differences in markers of oxidative damage or the expression of redox 
proteins involved in RONS regulation in skeletal muscle from patients with 
CFS and HCs,  
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Chapter Seven 
General discussion and future directions   
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7.1 Summary of Findings  
  
The current study identified a number of major findings: 
1. Skeletal muscle releases cytokines including IL-6, CXCL1, CCL2 and CCL5 
in response to TNF-α treatment.  
2. Resveratrol modulated TNF-α induced cytokine release from C2C12 
myotubes, providing evidence of a potential nutritional therapy.  
3. Patients with chronic fatigue demonstrated reduced maximal voluntary but a 
normal stimulated involuntary force production suggesting centrally driven 
mechanisms of fatigue in this cohort.  
4. Force loss of the quadriceps following repeated percutaneous stimulated 
isometric contractions was similar between patients with CFS and age and sex 
matched HCs. 
5. Plasma cytokine levels were not altered in patients with CFS compared with 
HCs and expression of cytokines in the vastus lateralis muscle, revealed no 
significant difference between CFS patients and HCs. Expression of IP-10 and 
CCL2 appear to be marginally raised in patients with CFS.  
6. Muscle mitochondrial content and ROS production (Hydrogen peroxide and 
superoxide production) were not altered between patients with CFS and HCs. 
Thus, there was no major evidence of gross differences in oxidative damage 
and/or RONS regulatory proteins in patients with CFS.  
7. ETC substrate sensitivity to Glutamate/Malate and Succinate appears to be 
slightly reduced in patients with CFS compared with HCs.  
8. Mitochondrial respiration is not altered in patients with CFS compared with 
HCs.   
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7.2 General Discussion  
 
Raised systemic levels of pro-inflammatory cytokines including TNF-α have been 
reported in a wide range of conditions including COPD, cachexia, chronic heart 
failure, and sepsis (Tisdale, 1999, Bolton, 2000, Gan et al., 2004). Patients suffering 
from such conditions report a wide range of co-morbidities including chronic fatigue. 
Increased systemic levels of TNF-α have also been associated with muscle dysfunction 
and fatigue in vivo mouse animal studies (Reid and Moylan, 2011).  
The initial findings of the current study included the validation of a comprehensive, 
non-damaging model of cytokine treatment on muscle in vitro with the aim of 
mimicking increased exposure of muscle cells to circulating TNF-α. TNF-α was 
successfully validated as a modulator of cytokine release from muscle cells and 
confirms the role of muscle as an endocrine organ and its ability to produce and secrete 
cytokines, particularly IL-6, CXCL-1 (KC), CCL2 (MCP-1) and CCL5 (RANTES) 
confirming previous findings from (Lightfoot, 2011a, Lightfoot et al., 2015). TNF-α 
induced cytokine release from muscle may in turn add to the overall systemic levels 
inflammatory cytokines in a number of conditions. Thus, cytokine release from muscle 
may potentially be a significant contributor to the overall systemic cytokine profile in 
patients with elevated levels of circulating pro-inflammatory such as TNF-α creating 
a viscous cycle. The study investigated the role of polyphenols such as resveratrol, 
curcumin and EGCG on modulating the release of cytokines by muscle cells (Rahman 
et al., 2006). This preliminary cell work aimed to elucidate the potential therapeutic 
effects of polyphenols on cytokine release from skeletal muscle with the theory that it 
may be a potential therapeutic intervention in patients suffering from perturbed 
cytokine induced fatigue and muscle dysfunction. Previous literature has an 
association between perturbed cytokine levels in patients with CFS and the commonly 
reported impaired muscle dysfunction, weakness and fatigue, however the current 
study successfully dispels these theories. The study identified resveratrol as a 
modulator of TNF-α induced cytokine release, suggesting that resveratrol may be a 
potentially therapeutic compound in diseases characterised by raised pro-
inflammatory cytokines such as TNF-α. Despite not being applicable to the results 
from the current CFS study, these data are useful in the approach to alternative diseases 
characterised by increased systemic levels of TNF-α and may potentially alleviate 
cytokine induced muscle dysfunction and fatigue. 
Previous evidence has suggested that the condition CFS may be linked to altered 
circulating cytokine levels. The primary complaint/characteristic of CFS is an 
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overwhelming and debilitating sensation of fatigue (physical and mental exhaustion) 
which persists regardless of rest but often worsens following physical/mental exertion 
(Christley et al., 2012). Patients with CFS are a viable model of fatigue and potentially 
muscle dysfunction given the elevated scores of fatigue and reduced MVC force 
reported in this study. The reduction in MVC force and lack of changes in involuntary 
force, fatigue and single fibre force generation suggests impaired force generation is 
likely due impaired motivation and/or possibly impairments in the nervous system 
(potentially at the motor neurone). Among the findings observed in this study, 
expression of IP-10 within skeletal muscle of patients with CFS appears to be 
marginally raised compared with that of HCs. This is the first study to directly assess 
expression of cytokines in skeletal muscle in patients with CFS. The majority of 
cytokine targets are known to be directly produced from muscle (TNF-α, IL-6, CCL5, 
CCL2, CXCL1, IL-8). The detection of low relative expression levels from all targets 
may be due to low expression within muscle and/or the rapid export of cytokines from 
cells. A number of targets are not confirmed as muscle producing cytokines (TNF-α, 
Eotaxin 1, MIP-1 α), mRNA expression detected may be from connective, adipose or 
white blood cells rather than muscle (Wong et al., 2012).  
The study did not find any differences between plasma of patients with CFS and HCs 
for any of the 27 cytokines assessed (Chapter 4). This is supported by a recent review 
compiling data from a number of CFS cytokine studies which found no differences in 
any cytokine targets in patients with CFS compared with HCs (Blundell et al., 2015). 
Previous differences between data sets has been attributed to differences in diagnostic 
criteria used, low sample size and differences in study technique used to assess 
cytokine levels. The current study aimed to fully elucidate the cytokine profile of 
patients with CFS and examine whether it was altered in comparison to HCs using a 
large cohort of individuals diagnosed through one central CFS services ensuring 
diagnostic uniformity. Additionally, the study examined sub-groups of data from 
female subjects only with CFS and found no significant differences compared with 
HCs suggesting cytokine levels in CFS are not associated with hormonal regulation. 
Disease duration and cytokine levels were also assessed in the CFS patient cohort. 
These data did not reveal any difference between more newly diagnosed patients (<12 
months since the onset of fatigue) and those with long term CFS (suffering for >12 
months). These data contradict previously published findings (Hornig et al., 2015). 
Further assessment of the distribution of cytokine levels between individuals would 
aid in the identification of potential sub-groups with altered cytokine profiles in 
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comparison to HCs. These could include disease severity as previously shown by 
(Hornig et al., 2015). To accurately determine the significance of a potentially altered 
cytokine or chemokine profile within disease states, it is important to first identify the 
physiological range within a healthy population. A “healthy” physiological range of 
these molecules has not yet been determined. Variation in cytokine detection and 
sample processing has resulted in large variations between data sets. A new technique 
of cytokine analysis using the multiplex bead analysis is a leading strength of this study 
given the sensitivity and accuracy of the assay (Agalliu et al., 2013). A number of 
studies in both adults and children with CFS have been conducted using these systems 
in both blood and cerebrospinal fluid strengthening comparisons between studies 
(Natelson et al., 2005, Stringer et al., 2013). 
Further investigation into the production of ROS and markers of oxidative damage in 
skeletal muscle revealed no differences in mitochondrial content, respiratory function 
or mitochondrial redox changes as assessed though H2O2 and superoxide production 
in intact mitochondrial of skeletal muscle fibres from patients with CFS and HCs. 
However, data suggests patients with CFS may have decreased sensitivity to ETC 
substrates. The current study investigated mitochondrial ROS production and function 
in situ, utilizing permeabilised muscle fibres, isolated from skeletal muscle. This 
technique is advantageous over experiments using mechanical isolation of 
mitochondria as the mitochondrial remain intact and able to maintain their interactions 
with other subcellular compartments. No difference in oxidative damage in the VL 
muscle of CFS/ME subjects and HCs was confirmed through protein carbonyl, 4-HNE 
and 3-NT content. ROS regulatory proteins including superoxide dismutase (SOD) 
isoforms (SOD I and SOD II), catalase and PRXIII, nitric oxide synthase (NOS) 
isoenzymes and heat shock proteins were all similar between patients with CFS and 
HCs.  
 
7.3 General problems facing CFS research  
 
There has been a considerable amount of research undertaken in the field of CFS. 
Despite a wide coverage of investigations across various fields of science with regards 
to the pathology and pathophysiology of CFS, little progress has been made. The CFS 
population is highly heterogeneous and varied; which, combined with an absence of 
objective markers to formally diagnose patients and the presence of multiple 
diagnostic criteria (i.e. American Centre for Disease Control (CDC) 1994 definition 
(Fukuda et al., 1994), NICE guidelines (2007), the “Oxford Criteria” (1991) and the 
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“Canadian Guidelines”) and names (Chronic Fatigue Syndrome, Myalgic 
Encephalopathy, Myalgic Encephalitis, Post viral syndrome, Post-infectious Fatigue 
Syndrome, Effort Syndrome, and more recently Systemic Exertion Intolerance 
Disease). This has created confusion when defining patient cohorts and sometimes 
prevented direct comparison between studies. In turn this has made identifying 
potential differences to HCs very difficult and hindered progress in this area. 
The history of CFS has been plagued with scepticism from both health professionals 
and the general public, poor media coverage and inadequate quality of studies being 
undertaken/published across some areas of CFS research. This may potentially stem 
from the continual publication of negative data, low sample sizes and an often biased 
approach resulting in the creation of positive data based on tenuous associations. A 
resurgence in interest and funding in the 00’s from bodies such as the MRC (Medical 
Research Council) lead to the creation of the CFS Research Advisory Group (2003), a 
new collaborative workshop between the MRC and Action for ME (The UK’s leading 
charity for CSF/ME) and the formation of the MRC CFS Expert Group in 2008 in a 
bid to encourage and initiate “new high-quality research into CFS”.  
Recent advances in CFS research have seen the launch of the CFS Biobank which aims 
to encourage new collaborations between various field experts and CFS research. 
Studies have been recently published within the field of autonomic dysfunction, sleep, 
immune dysfunction (including cytokine levels) within CFS and genotyping of 
patients in the CFS wide genome database. A consistently low sample size across a 
large number of studies reduces the ability of data to be stratified and the potential 
identification of CFS subgroups. The need for sub-group analysis has been slowly 
progressed to the top of CFS priorities and a recognised entity (Jason et al., 2005, 
Twisk, 2014). 2016 sees the launch of the ME Association “Grand Challenge” which 
aims to collaboratively recruit ≥10,000 patients with CFS for detailed phenotyping and 
genetic analyses.  
Within many human studies, a large problem remains in the recruitment of a suitable   
appropriately matched control group taking into consideration study outcomes and 
confounding factors which may impact these. In the current study, a large number of 
markers were investigated. Controls were comparably matched for age and gender; 
two of the major factors which affect the scientific data/outcome.  
The stigma surrounding CFS has led to often a failing in the reporting of negative data, 
which is something that is endemic across all aspects of scientific research.  In contrast, 
the findings reported in this thesis are very important, and will aid future researchers 
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in focussing CFS research towards identifying the exact pathophysiology behind the 
condition and symptoms associated with it.  
 
7.4 Study strengths and limitations  
 
Resveratrol attenuates TNF-α induced cytokine release from C2C12 myotubes 
This study validated and expanded upon a pre-existing model of TNF-α induced 
cytokine release from C2C12 mytoubes (Lightfoot et al, 2015). As an in vitro study, 
there are the obvious limitations of applicability to in vivo. Using a muscle cell line 
allowed cytokine release to be assessed directly from muscle without any confounding 
cell types such as immune cells infiltrating. However, cells were observed outside of 
their normal environment and have reduced functional ability (lack of innervation and 
contractile function). The effects of polyphenols on TNF-α induced cytokine release 
from muscle cells in vitro has not been investigated before. The study used 
physiologically relevant doses of polyphenol treatments according to previous 
literature and demonstrated resveratrol as a potential therapy for patients with 
pathologically elevated cytokines levels.  
 
Patients with CFS as a model of Fatigue 
The overall design of this study is strong in comparison to a large amount of CFS 
research studies to date. The main body of the study included 95 patients with CFS 
and 95 HCs. This is one of the largest cross sectional studies to investigate cytokine 
levels in patients with CFS from one cohort. All subjects entered the study via the CFS 
service from the Royal Liverpool and Broadgreen University Hospitals NHS Trust. 
Accurate diagnosis/acceptance of referrals of CFS was left to the discretion of one unit 
of health care professions within the Royal Liverpool and Broadgreen University 
Hospitals NHS Trust, CFS services using the Oxford (1990) diagnostic criteria of CFS 
and recommended NICE guidelines (2007). Given the disparity between many health 
care professions, this study is strengthened by this aspect of uniformity across all 
patients entering the CFS services and therefore the possibility of entering the study. 
The study would have benefitted from a more rigorous, inclusion/exclusion criteria for 
CFS subjects in addition to the CFS diagnosis. No further investigation was undertaken 
to assess whether subjects had any co-existing morbidities or illnesses which may 
affect markers known to influence cytokines, ROS and oxidative stress. Logistical 
issues within study design meant the study team were not able to pursue these matters 
further during consent into the study.    
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The study was strengthened with the exclusion of smokers and individuals with a 
history of substance abuse (informed by subjects at their own discretion) as both these 
factors directly affect systemic cytokine levels and the production of RONS and 
subsequently increased oxidative stress (McCrea et al., 1994, Morrow et al., 1995). 
The study would have benefitted from a stronger exclusion criteria for HCs. Further 
control matching with regards to detailed analysis of habitual physical activity/ 
physical fitness would have been beneficial.  
There are fundamental issues regarding the recruitment of CFS patients into research 
studies given the lack of diagnostic markers, multiple diagnostic criteria, stigma from 
health care professionals and a lack of CFS specialist centres within the NHS. 
Inconsistencies in CFS have been largely attributed to the case definition utilised and 
the varying approaches to diagnosis (Christley et al., 2012).   
As previously mentioned, there are no biomarkers or tools to confirm CFS. Diagnosis 
is made using one of many case definitions and the exclusion of any other medical 
disorders associated with CFS symptoms which has subsequently created a poor, error 
prone, inefficient and slow diagnosis process. The current study utilised the Oxford 
Criteria (1990) and recommended NICE guidelines (2007) which are in accordance 
with the National Institute for Health and Clinical Excellence, UK (NHS) through 
which recruitment took place. These case definitions have both been extensively 
researched and tested (Sharpe et al., 1991, Baker et al., 2007). There is a lack of data 
regarding the validation of the NICE guidelines (2007) from external studies which 
may potentially be due to its relatively recent creation. The Oxford criteria/NICE 
guidelines are not as extensively used as other diagnostic criteria. This may limit 
potential comparisons between this study and those using an alternative criterion. The 
CDC-1994/Fukuda is reportedly the most frequently applied case definition (Brurberg 
et al., 2014).  
All complaints and ailments associated with CFS are subjective to the individual. The 
use of health questionnaires is common within diagnostic clinics and research 
however; the power of their applications is limited. There have been attempts to create 
objective diagnostic markers in CFS (Fletcher et al., 2010) however the lack of 
consistency between data from different studies has prevented this.  
Within the current study, a wide range of techniques were utilised to assess markers of 
i) systemic cytokine levels, ii) skeletal cytokine production iii) skeletal muscle 
function, iv) in vivo skeletal muscle mitochondrial respiration, v) skeletal muscle redox 
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homeostasis vi) in vivo skeletal muscle ROS generation. The experiments included 
sensitive, accurate, novel techniques.   
 
7.5 Future directions  
 
7.5.1 Mechanisms through which resveratrol attenuates TNF-α induced cytokine 
release.  
 
The current study identified resveratrol as a modulator of TNF-α induced cytokine 
release from C2C12 myotubes. Further work investigating this effect in additional cell 
lines such as a human muscle cell line or an immune cell line would be beneficial in 
assessing whether the effect of resveratrol can be translated to humans and whether it 
is specific to certain cell types. Additionally, the study of mechanisms by which 
resveratrol attenuated TNF-α induced cytokine release is warranted. Current data 
suggested that resveratrol acts through redox sensitive pathways including the 
activation of transcriptional factors SIRT1 and NRF2 with increased production of 
glutathione and an up regulation of antioxidant systems including the SODs and 
catalase (Li et al., 2016).  
 
7.5.2 Stratification of CFS patients  
CFS encompasses a wide range of individuals. Each case is unique with sufferers 
reporting their own particular set of symptoms, potential triggers and disease patterns. 
Many researchers have suggested CFS is a broad spectrum disorder or syndrome which 
encompasses many subgroups of diseases. Within many disease areas there are 
overlapping triggers/symptoms. The causes and mechanisms underpinning these 
symptom profiles are different. By grouping all patients with CFS together, potential 
differences to HCs may be masked. Improved phenotyping, stratification and 
subtyping of patients is essential in CFS in providing valuable new insights into the 
pathology of the disease and associated symptoms and enable the development of more 
effective, better targeted treatments. Subgrouping of patients will require the 
recruitment of a much larger number. A new collaborative approach which spans the 
potential disciplines of research which CFS may cover is essential (immunology, 
neurology/neurobiology, psychology, sociology, physiology etc.). The phenotyping of 
subjects needs to occur through objective measurements including triggers and 
symptoms (e.g. medical history – glandular fever, measures of cognitive function, 
sleep, inflammation, psychological profile, physical function, pain, etc.). There is a 
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large overlap between CFS and fibromyalgia (chronic widespread musculoskeletal 
pain). Evidence suggests that 43-70% of CFS patients also suffer from fibromyalgia 
(Bradley et al., 2000, Ciccone and Natelson, 2003, Goldenberg et al., 1990). More 
objective markers of differentiation between these two disorders are also needed to 
help stratify patients. The similarities between these two cohorts should be utilised  
Symptoms associated with CFS can be grouped under endocrine, cognitive, 
psychological, cardiovascular, immune, gastrointestinal, neurological and motor-
sensory to aid grouping. In order to stratify and subgroup patient cohorts whilst 
maintaining a large enough sample size, studies will require even greater total 
recruitment numbers. The new ME collaborative “Grande Challenge” aims to tackle 
these issues (recruiting >10,000 subjects). Recruiting a large enough population will 
also allow for subjects to be diagnosed across multiple diagnostic criteria removing a 
major source of heterogeneity.  
Findings within the current study including potentially raised levels of the cytokine 
IP-10 and CCL2 in muscle and altered mitochondrial ETC sensitivity to different 
substrates may be fully elucidated through the stratification of subjects. These 
differences may be specific to a cohort of individuals diagnosed with CFS and 
potentially masked in the current study.  
 
7.5.3 Determining the cause of reduced MVC in patients with CFS  
The current study revealed patients with CFS have reduced MVC in comparison to 
HCs. Additional experiments of percutaneous electromyostimulation did not reveal 
any differences in force generation between these two groups. The study did not find 
any peripheral impairments in the muscle function of patients with CFS with additional 
investigations into isolated single fibre force production revealing no difference. 
Patients with CFS displayed comparable redox homeostasis and mitochondrial 
function to HCs supporting the theory that peripheral muscle function is not altered. 
These data suggest a more central deficit in force production in patients with CFS. A 
natural progression of this work would include the use of transcranial magnetic 
stimulation to stimulate the motor cortex and/or direct stimulation of the peripheral 
motor nerve. This area of research is yet to be addressed in patients with CFS. 
 
 
7.5.4 Physical activity, skeletal muscle cytokine release and fatigue in patients 
with CFS 
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In the current study, cytokine responses to exercise and other stimuli were not 
assessed. Normal levels at rest do not rule out abnormal response patterns, however, a 
recent review did not find evidence of such abnormalities in CFS (Nijs et al.,2014). 
Despite these limitations the current results are generally in support of similar, 
physiological levels of plasma cytokines in patients with CFS and in HCs. 
Increased subjective fatigue and impaired physical function has generated a large 
interest in skeletal muscle function in patients with CFS. As presented in the current 
work, impaired central processes appear to be the major cause of decreased voluntary 
force production in a large proportion of CFS patients. The cause of post exertional 
malaise and extreme bouts of fatigue following physical or mental activity remains 
unclear in CFS. Further investigation is necessary to elucidate the cause of post 
exertional malaise also commonly known by patients as “payback” and whether 
changes in mitochondrial respiration, redox homeostasis or cytokine levels play a role 
in such changes. It has been suggested that CFS patients have altered cytokine levels 
in response to exercise in comparison to HCs (Nijs et al., 2014). This would include a 
similar set of experiments to those completed in the current study assessing 
mitochondrial function, ROS production (redox homesostasis) and local/systemic 
cytokine levels.  
Additionally, some evidence suggests that CFS individuals have elevated RONS and 
oxidative damage following physical exercise compared with HCs (Jammes et al., 
2005, Jammes et al., 2009). Given the post exertional malaise experienced by all 
patients with CFS and current understanding of exercise and elevated ROS production; 
there is plausible rational to hypothesis that patients with CFS may have elevated 
RONS production during increased physical exercise resulting in elevated oxidative 
damage and the symptoms of post-exercise malaise. This may explain potential 
differences in studies reporting redox homeostasis in CFS subjects as previous 
physical activity in the prior 24 hours to analysis is rarely reported.  
 
7.5.5 Interventions   
Despite a lack of understanding and knowledge surrounding the pathophysiology of 
CFS and its associated symptoms, there have been numerous intervention studies. 
These include nutritional, immunological, behavioural, pharmacological and 
complimentary therapies (such as homeopathy, osteopathy and massage therapy) 
(Hobday et al., 2008).  
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Non-pharmacological behavioural interventions/treatments have been a strong focus 
for CFS research proving promising results. The NHS, UK has enrolled cognitive 
behavioural therapy (CBT) as part of its treatment programme for CFS to relieve 
symptoms associated with the disease as well as graded exercise therapy (GET). CBT 
and GET have been shown to improve a wide range of psychological and physical 
markers in patients with CFS. Exercise as a therapeutic intervention has been widely 
described to be a very successful non-pharmacological means of treatment in several 
muscle pathologies, such as myositis (Lightfoot & Cooper, 2016). Specifically, 
periods of endurance training reduced disease status and induced long-term 
physiological improvements in patients with myositis (Alemo Munters et al., 2013, 
Munters et al., 2016, Schmidt and Wonneberger, 2014) 
A number of research groups have begun more extreme intervention studies in patients 
with CFS without sufficient evidence to support study rational. Recently, interventions 
studies in CFS have begun with Rituximab (a B-lymphocyte (B-cell) depleting 
monoclonal anti-CD20 antibody) (Pescovitz et al., 2009). Rituximab targets a protein 
called CD20, which is found on the surface of white blood cells called B-cells, 
however patients do not appear to experience a change in their symptoms/fatigue 
severity for several months. Phase three clinical trials are currently underway using 
Rituximab in patients with CFS. Early investigations included a double-blind, placebo-
controlled phase 2 study in which subjects received rituximab (500 mg/m2) or saline 
twice with two weeks apart, with follow-up for 12 months. Sixty-seven percent (10/15) 
of patients reported major or moderate responses with improvements in self-reported 
fatigue scores (Fluge et al., 2011). A second single-centre, open-label, one-armed 
phase 2 study with no randomization has recently been completed. Twenty-nine 
patients were exposed to rituximab (500 mg/m2) twice, two weeks apart, followed by 
maintenance rituximab infusions after 3, 6, 10 and 15 months and follow-up for 36 
months. The major limitation of this work was that it did not include a placebo group 
and the open-label design is flawed (Fluge et al., 2015).  Phase 3 trials are currently 
underway. The extreme effects of Rituximab should ensure health professionals act 
with caution. If CFS is a condition containing more than one sub-group of 
disease/disorders, the response of all CFS patients may not be uniform. Given the lack 
of objective markers to differentiate between patients with CFS, it may be hard to 
determine who will benefit from this drug.  
In summary, CFS research should focus its attention on determining the 
pathophysiology of CFS and CFS related symptoms by determining differences in 
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objective measures between CFS subjects and HCs. Intervention trials in patients with 
CFS should be carefully monitored and the potential existence of subgroups within the 
CFS cohort should be noted, as dissimilar groups may respond to interventions 
differently. The use of drugs such as Rituximab should be cautioned given the adverse 
effects these drugs may elicit.  
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Chapter Eight 
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8.1 Plasma levels of growth factor cytokines in patients with CFS and HCs 
 
 
Figure 8.1 Plasma levels of PDGF and VEGF in patients with CFS and HCs. Data are 
presented as mean ± standard error of the mean (SEM) (n=95). 
 
Figure 8.2 Box plots of PDGF and VEGF in patients with CFS and HCs. Data are 
presented as mean ± standard error of the mean (SEM) (n=95). 
 
 
Figure 8.3 Plasma levels of FGF-b (basic) in patients with CFS and HCs. Data are 
presented as mean ± standard error of the mean (SEM) and box plots (n=95). 
 
8.2 qPCR – Housekeeping gene analysis 
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Figure 8.4 Relative mRNA expression of housekeeping gene B-Actin from muscle 
biopsies. Data presented at mean ± SEM.  
 
Figure 8.5 Relative mRNA expression of housekeeping gene GAPDH from muscle 
biopsies. Data presented at mean ± SEM.  
 
252 
 
 
Figure 8.6 Relative mRNA expression of housekeeping gene B2M from muscle 
biopsies. Data presented at mean ± SEM.  
  
8.3 Maximal Voluntary Contraction (MVC) force vs. plasma cytokine levels in 
patients with CFS and HCs 
 
Interleukins  
 
Figure 8.7 Correlations analyses between the MVC force and plasma cytokine levels 
(IL-1β, IL-1ra, IL-4, IL-5) in patients with CFS in comparison with HCs.  
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Figure 8.8 Correlations analyses between the MVC force and plasma cytokine levels 
(IL-6, IL-7, IL-8, IL-9) in patients with CFS in comparison with HCs.  
 
 
Figure 8.9 Correlations analyses between the MVC force and plasma cytokine levels 
(IL-10, IL-12, IL-13, IL-17) in patients with CFS in comparison with HCs.  
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Figure 8.10 Correlations analyses between the MVC force and plasma cytokine levels 
(G-CSF) in patients with CFS in comparison with HCs. 
 
 
CC Chemokines 
 
Figure 8.11 Correlations analyses between the MVC force and plasma cytokine levels 
(Eotaxin/CCL11, RANTES/CCL5, MIP-1α/CCL3, MIP-1β/CCL4) in patients with 
CFS in comparison with HCs.  
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CXCL, TNF-α and Interferon Cytokines 
 
 
Figure 8.12 Correlations analyses between the MVC force and plasma cytokine levels 
(IP-10, TNF-α and IFN-γ) in Patients with CFS in comparison with HCs.  
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8.4 Percentage force reduction of the quadriceps during fatigue protocol vs. 
plasma cytokine levels in patients with CFS and HCs 
 
Figure 8.13 Correlations analyses between the % force loss and plasma cytokine levels 
(IL-1β, IL-1ra, IL-4, IL-5) in patients with CFS in comparison with HCs.  
Figure 8.14 Correlations analyses between the % force loss and plasma cytokine levels 
(IL-6, IL-7, IL-8, IL-9) in patients with CFS in comparison with HCs.  
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Figure 8.15 Correlations analyses between the % force loss and plasma cytokine levels 
(IL-10, IL-12, IL-13, IL-17) in patients with CFS in comparison with HCs.  
 
 
Figure 8.16 Correlations analyses between the % force loss and plasma cytokine levels 
(G-CSF) in patients with CFS in comparison with HCs.  
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Figure 8.17 Correlations analyses between the % force loss and plasma cytokine levels 
(Eotaxin/CCL11, RANTES/CCL5, MIP-1α/CCL3, MIP-1β/CCL4) in patients with 
CFS in comparison with HCs.  
 
 
Figure 8.18 Correlations analyses between the % force loss and plasma cytokine levels 
(IP-10, TNF-α and IFN-γ) in patients with CFS in comparison with HCs.  
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8.5 Health Questionnaires  
 
Figure 8.19 Chalder Fatigue Questionnaire.  
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Figure 8.20 Visual Analogue Pain Rating Scale.  
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Figure 8.21 Self Efficacy Scale. 
Not at all         Completely
confident  confident
1  2   3    4     5 6  7   8    9     10
 
 
 
 
 
Today's Date / /
 
We would like to know how confident you are in doing certain activities. For each of the following questions, please
choose the number that corresponds to how confidently you can do these tasks regularly at the present time.
Please cross only one box on each line
 
 
 
 
CFS/NHS/ - Specialist help for ME  
ID Code: Flag
1 - Pre 5 - 24 mth
2 - 6 wk 6 - Misc
3 - 6 mth 7 - D/C
4 - 12 mth
Self Efficacy Scale
1.1 How confident are you that you can keep the fatigue caused by
your disease from interfering with the things you want to do?
1.2 How confident are you that you can keep the physical discomfort or
pain of your disease from interfering with the things you want to do?
1.3 How confident are you that you can keep the emotional distress 
caused by your disease from interfering with the things you want to do?
1.4 How confident are you that you can keep any other symptoms or 
health problems from interfering with the things you want to do?
1.5 How confident are you that you can do the different tasks and
activities needed to manage your health condition so as to reduce
your need to see a doctor?
1.6 How confident are you that you can do things other than just taking 
medication to reduce how much your illness affects your everyday life?
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
1 2 3 4 5 6 7 8 9 10
 
Example
 
1214148461
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Figure 8.22 Hospital Anxiety and Depression Score Questionnaire (HADS).  
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Figure 8.23 Short Form Health Survey 36 (SF-36) – Physical Functioning. 
 
  
  
  
  
  
  
  
  Please cross only one box in each line 
SF-36 
  
ID Code: Flag: 1 
1 - Pre 5 - 24 mth 
2 - 6 wk 6 - Misc 
3 - 6 mth 7 - D/C 
4 - 12 mth 
CFS/NHS/ADULT - Specialist help for ME 
The following questions are about ACTIVITIES you might do during a 
typical day. Does your health now limit you in these activities?   If so, how much? 
1.1 Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports 
1.2 Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or playing golf 
1.3 Lifting or carrying groceries 
1.4 Climbing several flights of stairs 
1.5 Climbing one flight of stairs 
1.6 Bending, kneeling, or stooping 
1.7 Walking more than a mile 
1.8 Walking half a mile 
1.9 Walking one hundred yards 
1.10 Bathing or dressing yourself 
1 2 3 
Yes,       Yes,   No, not 
limited a lot    limited a little    limited at all 
1 2 3 
1 2 3 
1 2 3 
1 2 3 
1 2 3 
1 2 3 
1 2 3 
1 2 3 
1 2 3 
© RAND - All rights reserved.  
 
  
V2.0  
 
 
 36-Item Health Survey (Version 1.0) 
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Figure 8.24 European Quality of Life Questionnaire (EQ-5D).
 
  
  
  
  
  
  
  
  
  
EQ-5D™ 
  
Flag: 1 
1 - Pre 5 - 24 mth 
2 - 6 wk 6 - Misc 
3 - 6 mth 7 - D/C 
4 - 12 mth 
CFS/NHS/ADULT - Specialist help for ME 
By placing a tick in one box in each group below, please indicate which 
statements describe your own health state today 
 
1.1 Mobility 
1.2 Self-Care 
1.3 Usual Activities (e.g. work, studies, housework, families or leisure) 
1.4 Pain/Discomfort 
1.5 Anxiety/Depression 
  
1 
2 
3 
2 
3 
1 
1 
 EQ-5D™ is a trademark of the EuroQoL Group 
V2.0 
I have no problems in walking about 
I have some problems in walking about 
I am confined to bed  
I have no problems with self-care 1 
I have some problems with washing or dressing myself 
I am unable to wash and dress myself 
2 
3 
1 
2 
3 
2 
3 
I have no problems with performing my usual activities 
I have some problems with performing my usual activities 
I am unable to perform my usual activities 
I have no pain or discomfort 
I am not anxious or depressed 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
 
 
ID Code:  
 © 1990 EuroQoL Group 
265 
 
265 
 
 
Figure 8.25 Epworth Sleepiness Scale.  
 
  
  
  
  
  
  
Epworth Sleepiness Scale 
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